Genomics and Transcriptomics Approaches to Understanding Drug Resistance Mechanisms in the Malaria Parasite \u3cem\u3ePlasmodium falciparum\u3c/em\u3e by Gibbons, Justin Allan
University of South Florida 
Scholar Commons 
Graduate Theses and Dissertations Graduate School 
3-28-2019 
Genomics and Transcriptomics Approaches to Understanding 
Drug Resistance Mechanisms in the Malaria Parasite Plasmodium 
falciparum 
Justin Allan Gibbons 
University of South Florida, JustinGibbons.ms@gmail.com 
Follow this and additional works at: https://scholarcommons.usf.edu/etd 
 Part of the Bioinformatics Commons, and the Medicine and Health Sciences Commons 
Scholar Commons Citation 
Gibbons, Justin Allan, "Genomics and Transcriptomics Approaches to Understanding Drug Resistance 
Mechanisms in the Malaria Parasite Plasmodium falciparum" (2019). Graduate Theses and Dissertations. 
https://scholarcommons.usf.edu/etd/7794 
This Dissertation is brought to you for free and open access by the Graduate School at Scholar Commons. It has 
been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Scholar 
Commons. For more information, please contact scholarcommons@usf.edu. 
	
	
	
	
	
Genomics	and	Transcriptomics	Approaches	to	Understanding	Drug	
	
Resistance	Mechanisms	in	the	Malaria	Parasite	Plasmodium	falciparum	
	
	
by	
	
Justin	Allan	Gibbons	
	
A	dissertation	submitted	in	partial	fulfillment	of	the	requirements	of		
Doctor	of	Philosophy		
Department	of	Molecular	Medicine		
Morsani	College	of	Medicine		
University	of	South	Florida		
	
Major	Professor:	Rays	HY	Jiang,	Ph.D.	
Co-major	Professor:	Gloria	C.	Ferreira,	Ph.D.	
John	H.	Adams,	Ph.D.	
Vladimir	Uversky,	Ph.D.,	DSc.	
Yu	Chen,	Ph.D.	
	
Date	of	Approval	
November	13,	2018	
	
	
	
Keywords:	Malaria,	arteminsin,	drug	resistance,	K13,	atovaquone		
	
Copyright	© 2019,	Justin	Allan	Gibbons	
	
	 	
	
Acknowledgments	
	
The	beginning	is	usually	the	best	place	to	start	so	I	would	like	to	thank	my	parents	and	my	
family.	The	first	lab	I	was	ever	a	member	of	was	the	lab	of	Alexei	Evsikov	and	Caralina	
Marin	De	Evsikova,	thank	you.	It	is	a	very	true	statement	that	I	am	only	where	I	am	today	
because	I	ran	into	Amanda	Hott	at	a	happy	hour,	so	thank	you.	I	need	to	thank	Rays	for	
letting	me	join	her	lab	and	for	putting	up	with	me.		Thank	you	John	Adams	for	your	consul	
and	letting	me	join	your	lab	family.	I	would	not	have	made	it	through	my	first	few	months	
in	the	lab	without	my	first	lab	partner	Swamy	Rakesh.	I	would	not	have	succeeded	without	
assistance	from:	Maxwell	Pietsch,	Min	Zhang,	Xiangyun	Liao,	Chenqi	Wang,	Jenna	
Oberstaller,	Suzanne	Li,	Ali	Roth,	Richard	Thomson,	and	Ken	Udenze.	I	need	to	thank	
Samantha	Barnes	and	Katherine	Small	for	their	assistance	navigating	the	university	
administration.	Of	course,	I	need	to	thank	my	co-PI	Gloria	Ferreira	and	my	committee	
members:	John	Adams,	Yu	Chen,	and	Vladimir	Uversky	for	providing	their	time	and	
knowledge	to	help	guide	me.		This	manuscript	was	considerably	improved	thanks	to	
editing	suggestions	from	Thomas	Keller	and	Gloria	Ferreira.	Last,	but	most	definitely	not	
least	I	need	to	thank	the	many	wonderful	friends	I	have	made	in	Tampa.	It	is	not	a	lie	to	say	
I	would	not	have	made	it	through	my	dissertation	without	you.	In	no	particular	order,	and	
certainly	not	exhaustively	I	would	like	to	thank:	Gerald	Stinnett,	Amanda	K	Olexen,	Logan	
Michelle,	Teddy	Marcelo,	Rich	Brown,	Christopher	Witrak,	Ash	Mulholland,	Devin	Beverage,	
Sam	Demmi,	Jennica	Robe,	Jessikah	Stahl,		Helena	Hernandez-Cuervo,	and	Bryan	Hindert.		
	
	
	
i	
	
	
	
	
	
	
Table	of	Contents	
	
List	of	Tables	 v	
	
List	of	Figures	 vi	
	
List	of	Abbreviations	 viii	
	
Abstract	 x	
	
Chapter	1:	Introduction	 1	
	 Historical	overview	 	 	 	 	 	 	 	 	 											1	
	 	 Phylogenetics	 	 	 	 	 	 	 	 											1	
	 	 Human	history	 	 	 	 	 	 	 	 											2	
	 Plasmodium	life-cycle	and	distribution	 	 	 	 	 	 											4	
	 	 Plasmodium	in	the	mosquito	 	 	 	 	 	 											5	
	 	 Plasmodium	in	humans	 	 	 	 	 	 	 											6	
	 Malaria	infection	 	 	 	 	 	 	 	 	 											9	
	 	 Signs,	symptoms	and	diagnosis	 	 	 	 	 	 											9	
	 	 Treatment	of	uncomplicated	malaria	 	 	 	 	 								10	
	 	 Treatment	of	severe	malaria	 	 	 	 	 	 								11	
	 Treatment	and	control	strategies	 	 	 	 	 	 	 								11	
	 	 Vector	control	 	 	 	 	 	 	 	 								13	
	 	 Antimalarial	drugs	 	 	 	 	 	 	 	 								13	
	 	 	 Arylamino	alcohols	 	 	 	 	 	 	 								13	
	 	 	 	 Quinine	 	 	 	 	 	 	 								13	
	 	 	 	 Mefloquine	 	 	 	 	 	 	 								14	
	 	 	 	 Lumefantrine		 	 	 	 	 	 								15	
	 	 	 4-aminoquinolines	 	 	 	 	 	 	 								15	
	 	 	 	 Chloroquine	 	 	 	 	 	 	 								15	
	 	 	 	 Amodiaquine		 	 	 	 	 	 								17	
	 	 	 	 Piperaquine	 	 	 	 	 	 	 								17	
	 	 	 Mannich	bases	 	 	 	 	 	 	 								17	
	 	 	 	 Pyronaridine	 	 	 	 	 	 	 								17	
	 	 	 8-aminoquinolines	 	 	 	 	 	 	 								18	
	 	 	 	 Primaquine	 	 	 	 	 	 	 								18	
ii	
	
	 	 	 	 Tafenoquine	 	 	 	 	 	 	 								18	
	 	 	 Antifolates	 	 	 	 	 	 	 	 								18	
	 	 	 	 Proguanil	and	cycloguanil	 	 	 	 	 								18	
	 	 	 	 Pyrimethamine	and	sulfadoxine	 	 	 	 								19	
	 	 	 Antibiotics	 	 	 	 	 	 	 	 								20	
	 	 	 2-hydroxynaphtoquinones	 	 	 	 	 	 								21	
	 	 	 	 Atovaquone	 	 	 	 	 	 	 								21	
	 	 	 Sesquiterpene	lactone	endoperoxides	 	 	 	 								23	
	 	 	 	 Artemisinins	 	 	 	 	 	 	 								23		
	
	 Prophylaxis	 	 	 	 	 	 	 	 	 	 								24	
	 Vaccines	 	 	 	 	 	 	 	 	 	 								27	
	 	 Transmission	blocking	vaccines	 	 	 	 		 	 								27	
	 	 Pre-erythrocytic	vaccines	 	 	 	 	 	 	 								28	
	 Antimalarial	discovery	efforts	 	 	 	 	 	 	 								32	
	 	 Drugs	in	phase	I	clinical	development	 	 	 	 	 								34	
	 	 Drugs	in	phase	II	clinical	development	 	 	 	 	 								34	
	 	 Drugs	in	phase	III	clinical	development	 	 	 	 	 								36	
	 Plasmodium	genome		 	 	 	 	 	 	 	 								37	
	 Plasmodium	gene	regulation	 	 	 	 	 	 	 								38	
	 Plasmodium	mitochondria	 	 	 	 	 	 	 	 								41	
	 	 Mitochondrial	structure	 	 	 	 	 	 	 								41	
	 	 Mitochondrial	genome	 	 	 	 	 	 	 								42	
	 	 Mitochondrial	inheritance	and	replication		 																																																	42	
	 	 Mitochondrial	metabolism	 	 	 	 	 	 	 								43	
	 Methods	to	study	drug	resistance	 	 	 	 	 	 	 								43	
	 	 Goals	 	 	 	 	 	 	 	 	 	 								43	
	 	 Relevant	data		 	 	 	 	 	 	 	 								44	
	 	 Efficacy	studies	 	 	 	 	 	 	 	 								44	
	 Identification	of	molecular	markers	 	 	 	 	 								46	
	 	 The	study	of	artemisinin	resistance	 	 	 	 	 								48	
	 Computational	methods	to	study	malaria	 	 	 	 	 	 								49	
	 	 Gene	identification	 	 	 	 	 	 	 	 								49	
	 	 Gene	annotation	 	 	 	 	 	 	 	 								50	
	 	 Obtaining	data	with	Illumina	next	generation	sequencing	 	 								53	
	 	 Genomic	analysis	 	 	 	 	 	 	 	 								54	
	 	 Transcriptomics	 	 	 	 	 	 	 	 								57	
	 	 Forward	genetics	 	 	 	 	 	 	 	 								59	
	 Focus	of	study	 	 	 	 	 	 	 	 	 								61	
	
	
	
Chapter	2:	Developing	and	validating	a	dephaser	identifier	(DI)	algorithm		
to	search	for	genes	involved	in	life-cycle	shifts	(Aim1)	 	 	 	 								62	
	 Rationale	of	Study	 	 	 	 	 	 	 	 	 								62	
	 Materials	and	Methods	 	 	 	 	 	 	 	 								67	
iii	
	
	 	 Parasite	culturing	and	sequencing	 	 	 	 																																			67	
	 	 Obtaining	expression	data	 	 	 	 	 	 	 								69	
	 	 Sample	outlier	identification	 	 	 	 	 																						70	
	 	 Individual	gene	differential	expression	analysis	 	 	 	 								70	
	 	 Life-cycle	correlation	clustering	 	 	 	 	 	 								71	
	 	 Description	of	the	dephaser	identifier	algorithm	 	 	 	 								71	
	 	 Assessment	of	the	biological	consistency	of	the	DI	algorithm	 	 								72	
	 	 Assessment	of	consistent	changes	in	expression	of		
the	dephasing	set									 	 	 	 	 	 																						72	
	 	 Assessment	of	consistent	changes	in	relative	rank		
of	the	dephasing	set	 	 	 	 	 	 	 								74	
	 Results	 	 	 	 	 	 	 	 	 	 								74	
	 	 DI	algorithm	can	make	curves	with	a	periodic	structure		
as	similar	as	required		 	 	 	 	 	 																						74	
DI	algorithm	identifies	biologically	consistent	groups	of	genes	 	 								76	
DI	algorithm	consistently	improves	the	correlations		
between	samples		 	 	 	 	 	 																						77	
DI	algorithm	shows	no	bias	by	gene	expression	level	 	 	 								78	
Genes	identified	by	the	DI	algorithm	have		
changes	in	gene	expression	 	 	 	 	 	 								79	
	 Discussion	 	 	 	 	 	 	 	 	 	 								83	
	
Chapter	3:	Elucidating	the	biological	function	of	artemisinin	resistance		
gene	k13	by	analyzing	transcriptome	differences	(Aim	2)		 	 	 																						88	
	 Rationale	of	Study	 	 	 	 	 	 	 	 	 								88	
	 Materials	and	Methods	 	 	 	 	 	 	 	 								89	
	 	 Parasite	culturing	and	sequencing	 	 	 	 	 	 								87	
	 	 Analysis	of	transcriptome	differences	identified		
by	the	DI	algorithm	 	 	 	 	 	 	 								87	
	 	 Linking	dephasing	genes	to	a	transcription	factor		 	 	 								90	
	 	 Linking	K13	to	replication	factor	C	 	 	 	 	 	 								90	
	 Results	 	 	 	 	 	 	 	 	 	 								89	
	 	 K13	dysregulation	is	specific	 	 	 	 	 	 								91	
	 	 Analysis	of	affected	pathways	 	 	 	 	 	 								92	
	 	 Confirmation	of	the	specificity	of	DNA	replication	and		
repair	dysregulation	 	 	 	 	 	 	 								92	
Dephasing	genes	are	regulated	by	a	transcription	factor		
predicted	to	regulated	DNA	replication	 	 	 	 								96	
Linking	K13	to	replication	factor	C	 	 	 	 	 	 								96	
	 Discussion	 	 	 	 	 	 	 	 	 	 								97	
	
	
Chapter	4:	Perform	whole	genome	sequencing	to	understand	the		
genotypic	changes	associated	with	Atovaquone	resistance	(Aim	3)	 	 						104	
	 Rationale	of	Study	 	 	 	 	 	 	 	 	 						104	
	 Materials	and	Methods	 	 	 	 	 	 	 	 						104	
iv	
	
	 	 In	vitro	evolution	of	an	atovaquone	resistant	strain	 	 	 						104	
	 	 DNA	extraction	and	sequencing	protocols	 	 	 	 																			105	
	 	 Sequence	alignment	 	 	 	 	 	 	 	 						106	
	 	 Identification	of	SNPs	and	Indels	 	 	 	 	 	 						106	
	 	 Detection	of	copy	number	variants		 	 	 	 	 						108	
	 Results	 	 	 	 	 	 	 	 	 	 						109	
	 	 SNPs	 	 	 	 	 	 	 	 	 	 						106	
	 	 Indels	 	 	 	 	 	 	 	 	 	 						112	
	 	 Copy	number	variation	 	 	 	 	 	 	 						113	
	 Discussion	 	 	 	 	 	 	 	 	 	 						115	
Chapter	5:	Summary		 	 	 	 	 	 	 	 	 						119	
Chapter	6:	List	of	References	 	 	 	 	 	 	 	 						124	
Appendix	A:	Housekeeping	pathway	genes	 	 	 	 	 	 						143	
Appendix	B:	Contingency	tables	 	 	 	 	 	 	 	 						158	
Appendix	C:	Supporting	microarray	data	from	the	Ferdig	lab	 	 	 	 						160	
Appendix	D:	Justification	for	combining	DNA	replication	and	repair	pathways		 						161	
Appendix	E:	Custom	code	for	SNP	and	indel	identification	 	 	 	 						162	
Appendix	F:	Custom	code	for	CNV	detection	 	 	 	 	 	 						177	
Appendix	G:	Consent	to	use	copyrighted	material		 	 	 	 																			182	
	 	
v	
	
	
	
	
	
	
List	of	Tables	
Table	3.1:	 	KEGG	pathways	over-represented	amongst	the	dephasing	genes	 	 								92	
Table	4.1:	 	The	4	ways	the	parent	and	drug	treated	strains	can	differ		
from	reference	genome	 	 	 	 	 	 	 	 																			108	
Table	4.2:	 	SNP	changes	that	occurred	in	all	5	atovaquone	treated	replicates	 	 						109	
Table	4.3:	 Indel	changes	that	occurred	in	all	5	atovaquone	treated	replicates	 	 						112	
	
	 	
vi	
	
	
	
	
	
	
List	of	Figures	
Figure	1.1:	 Life	cycle	of	the	human	malarias	 	 	 	 	 	 											4	
Figure	1.2:		 Stability	of	malaria	transmission	rates	 	 	 	 	 											5	
Figure	2.1:		 K13	mutant	piggyBac	insertion	site	and	effect	on	transcription	 	 								63	
Figure	2.2:		 Global	overview	of	K13	mutant	and	wild-type	transcriptomes	 	 								64	
Figure	2.3:		 Sequencing	quality,	sample	variation,	transposon	effect,		
differential	expression		 	 	 	 	 	 	 								66	
	 	 	 	 	 	 	
Figure	2.4:	 Dephaser	identifier	algorithm	can	make	correlation	curves		
arbitrarily	precise								 	 	 	 	 	 	 								75	
	 	
Figure	2.5:		 Biological	coherence	of	dephasing	genes	 	 	 	 	 								76	
Figure	2.6:		 DI	algorithm	consistently	improves	correlations		
							between	datasets		 	 	 	 	 	 																						78	
	 	 	 	 	 	 	
Figure	2.7:		 DI	algorithm	not	biased	by	expression	level		 	 	 	 								79	
Figure	2.8:	 	DI	algorithm	identifies	genes	with	consistent	changes		
	 	 in	expression	 									 	 	 	 	 	 	 								81	
Figure	2.9:		 DI	algorithm	identifies	genes	with	consistent	changes	in		
	 	 									relative	rank	 									 	 	 	 	 	 	 								83	
Figure	3.1:		 K13	mutant	piggyBac	insertion	site	and	effect	on	transcription	 	 								89	
Figure	3.2:		 DNA	replication	and	repair	and	house-keeping		
	 	 										pathway	expression	 									 	 	 	 	 	 								93	
Figure	3.3:	 DNA	replication	and	repair	expression	at	6	and	24	hours		 	 								95	
Figure	3.4:		 Replication	factor	C	expression		 	 	 	 	 	 								97		
Figure	3.5:		 Model	of	K13	function	 	 	 	 	 	 	 								99	
Figure	4.1:		 Plasmepsin	II	and	III	copy	number	variation	 	 	 	 						114															
vii	
	
Figure	4.2:	 	Plasmepsin	family	fold	change	distribution		 	 	 																			115	
	 	 																										
	
	 	
viii	
	
	
Abbreviations	
	
ACT:	Artemisinin-based	combination	therapy	
AT:	Adenine-Thymine	
CNV:	Copy	number	variation	
DHA:	Dihydroartemisinin		
DHODH:	Dihydroorotate	dehydrogenase	
DTP:	Diphtheria,	pertussis,	tetanus		
eQTLs:	Expression	quantitative	trait	loci	
FDR:	False	discovery	rate	
FPIX:	Ferriprotoporphyrin	IX	
FPKM:	Fragments	per	kilobase	per	million	mapped	reads	
G6PD:	Glucose-6-phosphate	dehydrogenase	
IC50:	Half-maximal	inhibitory	concentration	
IDC:	Intraerythrocytic	development	cycle	
MMV:	Medicines	for	Malaria	Venture	
pfcrt:	Plasmodium	falciparum	chloroquine	resistance	transporter	
PfCSP:	Circumsporozoite	protein	
PfDHODH:	Plasmodium	falciparum	dihydroorotate	dehydrogenase	
PfDHPS:	Plasmodium	falciparum	dihydropteroate	synthetase			
PfDHR:	Plasmodium	falciparum	dihydrofolate	reductase	
pfmdr1:	Plasmodium	falciparum	multidrug	resistance	protein	1	
pfmdr2:	Plasmodium	falciparum	multidrug	resistance	protein	2	
pfnhe:	Plasmodium	falciparum	sodium/hydrogen	exchanger,	Na+,	H+	antiporter	
ix	
	
QTL:	Quantitative	trait	loci	
SNP:	Single	nucleotide	polymorphism	
TMHMM:	Transmembrane	hidden	Markov	model	
TMM:	Trimmed	mean	of	M-values	
VQSR:	Variant	Quality	Score	Recalibration	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
x	
	
	
	
Abstract		
	
The	malaria	parasite	Plasmodium	falciparum	is	responsible	for	about	500,000	deaths	a	year	
and	is	evolving	resistance	to	the	front-line	treatment	of	artemisinin-based	combination	
therapy.	Resistance	is	currently	confined	to	South	East	Asia,	however	millions	of	lives	will	
be	at	risk	if	resistance	spreads	to	Africa.		Understanding	the	mechanism	of	resistance	to	
artemisinins	would	aid	containment	strategies	to	prevent	the	spread	of	artemisinin	
resistance.	There	is	also	an	urgent	need	to	accelerate	drug	discovery	since	drug	resistance	
has	already	been	documented	to	all	existing	antimalarials.	Here,	I	report	on	our	efforts	to	
understand	the	function	of	the	gene	k13,	the	gene	with	the	strongest	association	with	
artemisinin	resistance,	and	the	potential	genetic	mechanisms	associated	with	resistance	to	
atovaquone,	another	widely	used	antimalarial.		
	
To	precisely	study	the	transcriptome	characteristics	of	an	isogenic	k13	dysregulation	
mutant	and	wild	type	strain,	I	developed	a	new	computational	algorithm	called	Dephasing	
Identifier	(DI)	that	is	capable	of	identifying	the	genes	dysregulated	in	cell	cycle	shifts.	DI	is	
designed	to	solve	the	problem	of	pinpointing	important	patterns	in	complex	genomics	data	
with	temporal	sequences	that	cannot	be	resolved	by	standard	pair-wise	comparison	
methods,	by	using	an	innovative	method	that	leverages	external	reference	data	for	
systematic	comparisons.		In	the	k13	study,	I	demonstrated	that	the	algorithm	identifies	co-
regulated	gene	sets	that	have	consistent	annotated	functions.	The	DI	algorithm	successfully	
identified	aberrantly	early	DNA	replication	as	the	driving	process	of	transcriptome	changes	
in	the	mutant.		
xi	
	
	
To	understand	genome-wide	changes	that	occurred	in	a	set	of	atovaquone	resistance	
stains,	I	analyzed	whole	genome	sequencing	data	previously	generated	for	a	P.	falciparum	
strain	that	underwent	in	vitro	atovaquone	selection	to	create	atovaquone	resistant	strains.	
I	systematically	analyzed	the	genomes	of	these	strains	to	search	for	significant	genetic	
changes	associated	with	atovaquone	resistance.	Towards	this	end,	I	used	stringent	criteria	
to	identify	genes	involved	in	regulating	transcription	and	protein	modifications	as	
acquiring	non-synonymous	mutations.	Additionally,	copy	number	variations	in	plasmepsin	
genes,	a	family	known	to	be	involved	in	resistance,	were	found	in	the	resistant	strains.	
	
In	summary,	genomics	and	transcriptomics	technologies	can	be	used	to	rapidly	identify	
resistance	mechanisms	allowing	for	faster	adjustment	of	current	containment	strategies.	
Future	research	on	the	critical	targets	identified	in	this	study	can	aid	new	drug	discovery	
efforts	and	novel	control	strategies.	
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Chapter	1	
	
Introduction	
	
Historical	Overview	
	
Phylogenetics		
	
Today	malaria	parasites	are	responsible	for	about	500,000	deaths	a	year,	mostly	children	
under	the	age	of	5	in	sub-Saharan	Africa	[1].	Malaria	is	a	modern	problem	with	ancient	
roots	[2].	The	malaria	parasites	are	part	of	the	phylum	Apicomplexa,	which	is	a	large	
parasitic	group	with	around	5,000	named	species;	all	Apicomplexa	have	an	“apical	
complex”	and	their	origin	is	closely	aligned	with	the	evolution	of	multicellularity	[2].	There	
is	much	controversy	among	phylogeneticists	about	what	constitutes	a	“malaria	parasite”	
[3].	For	the	purposes	of	this	manuscript,	the	World	Health	Organization	classification	of	
malaria	parasites	as	members	of	the	genus	Plasmodium	will	be	followed	[3,	4].		The	genus	
Plasmodium	is	estimated	to	have	begun	radiating	around	129	million	years	ago	[2].		
	
Malaria	infections	have	long	been	a	part	of	human	evolutionary	history	[2],	with	the	
current	genetic	evidence	suggests	that	Plasmodium		infections	of	humans	arose	multiple	
times	on	several	independent	occasions	[2].	The	species	that	currently	infect	humans	are	P.	
falciparum,	P.	vivax,	P.	ovale,	and	P.	malariae.	Recent	evidence	suggests	that	the	monkey	
malaria	species	P.	knowlesi	has	the	potential	to	emerge	as	a	human	parasite	[5].		
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P.	falciparum	and	P.	vivax	are	the	most	prevalent	parasites	of	the	human	malarias	with	P.	
falciparum	being	responsible	for	the	most	deaths	due	to	its	higher	virulence.	The	higher	
virulence	of	P.	falciparum	led	to	speculation	that	it	started	infecting	humans	relatively	
recently	[6].	The	less	virulent	P.	vivax	likely	evolved	earlier	with	the	evidence	suggesting	a	
split	from	the	monkey	malaria	P.	knowlesi	15	to	46	million	years	ago	[7].	However,	the	bulk	
of	the	evidence	suggests	that	the	origin	of	P.	falciparum	dates	to	around	the	time	of	the	
human-chimpanzee	differentiation	[7,	8].		Therefore,	it	is	unlikely	that	P.	falciparum’s	
deadlier	nature	results	from	a	recent	introduction	into	humans.			
	
The	ancient	origin	of	the	disease	is	evidenced	in	the	human	genome.		Populations	in	
malaria	endemic	regions	have	long-standing	genetic	adaptations	that	aid	malaria	infection	
survival	such	as	sickle	cell	trait	and	thalassemias	[9].		
	
Human	history	
Malaria	was	originally	thought	to	be	the	work	of	demons	or	gods	[10].	To	our	knowledge	
the	first	person	to	note	the	connection	between	malaria	and	marshes	was	Hippocrates	[10].	
The	Romans	understood	that	there	was	a	connection	between	marshes	and	malaria	but	
thought	that	the	disease	was	caused	by	swamp	fumes	[10].	Indeed,	it	is	believed	that	the	
word	malaria	originates	from	Italian	for	“bad	air”	[10].	Some	cultures	correctly	surmised	
that	malaria	was	transmitted	by	mosquitos	as	evidenced	by	the	Sanskrit	text	Susruta	and	
the	stories	of	the	tribes	of	the	Usambara	mountains	and	Somalia	[10].		
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However,	it	was	not	until	1897	that	Ronald	Ross	discovered	that	the	avian	malaria	parasite	
P.	relictum	was	transmitted	by	culicine	mosquitos,	and	in	1898	Bignami	and	Grassi	proved	
that	human	malaria	was	transmitted	by	Anopheles	mosquitoes	[11].	Prior	to	these	
discoveries,	in	1880,	Laveran	identified	malaria	parasites	under	the	microscope	in	the	
blood	of	patients,	establishing	that	malaria	was	caused	by	a	parasite	and	not	miasma	or	
bacteria	[11].		Between	1898	and	1900,	Bignami	and	Grassi	characterized	the	stages	of	
development	in	the	blood	for	P.	vivax,	P.	falciparum,	and	P.	malariae	[11].	In	1898,	Ross	
identified	the	development	of	P.	vivax,	P.	falciparum,	and	P.	malariae	in	anopheline	
mosquitoes	[8].	Thus,	the	life-cycle	of	malarial	parasites	was	almost	worked	out	by	1900.		
	
However,	two	mysteries	remained.	The	parasites	disappeared	for	approximately	10	days	
before	they	could	be	detected	in	the	blood.	It	was	not	until	1948	that	Shortt	and	Garnham	
[11],	along	with	some	very	brave	and	unselfish	volunteers,	discovered	P.	vivax	in	the	
human	liver,	followed	shortly	by	the	identification	of	P.	falciparum	in	the	liver	in	1949	[11].		
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Plasmodium	life-cycle	and	distribution	
	
	
Figure	1.1	The	definitive	host	of	the	human	malarias	are	Anopheles	mosquitos.	The	malaria	
parasites	perform	sexual	reproduction	in	a	female	Anopheles	mosquito.	When	a	malaria	
infected	mosquito	takes	a	blood	meal	the	sporozoite	stage,	of	the	malaria	parasite,	is	
injected	into	the	dermis	of	the	human	host.	The	sporozoites	travel	from	the	dermis	to	the	
liver	where	they	undergo	a	replicative	phase.	After	completing	the	liver	replicative	phase	
the	parasites	burst	out	of	the	liver	and	infect	red	blood	cells.	After	invading	a	red	blood	cell	
a	parasite	undergoes	another	replicative	phase	followed	by	re-infection	of	red	blood	cells.	
Some	of	these	parasites	will	develop	into	gametocytes	that	can	be	taken	up	by	mosquitos	
via	a	blood	meal	to	begin	the	life-cycle	again.	Figure	obtained	from	
https://www.cdc.gov/malaria/about/biology/index.html.		
	
Malaria	infection	in	a	human	begins	with	the	bite	of	an	infected	female	Anopheles	mosquito.	
The	stage	of	the	malaria	parasite	injected	by	the	mosquito	is	referred	to	as	a	sporozoite.	
The	sporozoites	travel	from	the	dermis	to	the	liver	where	they	undergo	an	asexual	
replicative	phase	[12].	The	parasites	that	burst	from	the	infected	liver	cells	are	called	
merozoites	and	these	invade	erythrocytes	where	they	undergo	another	asexual	replicative	
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phase	that	involves	the	production	of	more	merozoites	that	infect	more	erythrocytes;	this	
is	the	stage	of	infection	associated	with	morbidity	[12].	Some	of	these	merozoites	will	
develop	into	gametocytes	that	can	be	taken	up	by	females	Anopheles	mosquitos	where	they	
will	undergo	sexual	reproduction	and	start	the	life-cycle	over	again	[12].		
	
Plasmodium	in	the	mosquito	
The	definitive	host	of	Plasmodium	parasites	are	Anopheles	mosquitos.	There	are	465	
formally	recognized	species	of	Anopheles	and	50	species	complexes,	out	of	which	
approximately	70	species	are	capable	of	transmitting	human	malaria	parasites	and	among	
these	only	41	are	considered	dominate	vector	species	[13].		
	
Figure	1.2	The	stability	index	or	the	stability	of	malaria	transmission	rates	as	estimated	by	
Kiszewski	et	al	2004	[14].	Transmission	potential	is	highest	in	tropical	regions	and	lower	in	
more	temperate	regions.	This	stability	of	transmission	estimate	incorporated	information	
on	the	number	of	blood	meals	taken	by	a	regions	dominant	malaria	vector,	the	survival	rate	
of	the	vector,	the	length	of	the	transmission	season	and	the	extrinsic	incubation.	
	
6	
	
The	highest	transmission	rates	are	in	sub-Saharan	Africa	(Figure	1.2)	[14].		Transmission	of	
malaria	is	not	stable	in	the	temperate	regions	of	the	world	[14],	which	likely	explains	why	
these	once	endemic	regions	have	had	an	easier	time	eliminating	malaria	transmissions.	
Only	two	mosquito	species	are	responsible	for	most	malaria	transmissions	in	Africa,	i.e.,	An.	
gambiae	and	An.	funestus	[13,	15].		
	
Female	Anopheles	mosquitos	require	a	blood	meal	as	a	source	of	protein	for	egg	
development	[15].	A	female	Anopheles	mosquito	may	become	infected	with	a	malaria	
parasite	if	they	take	a	blood	meal	from	a	malaria	parasite	infected	human.	Development	of	
malaria	in	the	mosquito	is	known	as	the	sporogonic	or	“extrinsic”	cycle	and	lasts	between	
10	and	18	days,	with	the	length	of	the	cycle	being	heavily	dependent	on	the	ambient	
temperature	and	humidity	[15].	A	gametocyte	ingested	by	a	mosquito	develops	into	either	
a	female	macrogamete	or	up	to	eight	male	microgametes	[16].	Fusion	of	the	gametes	occurs	
in	the	midgut	of	the	mosquito	to	form	a	zygote	that	develops	into	a	motile	form	called	an	
ookinete	which	then	penetrates	the	midgut	wall	to	form	an	oocyst	[16,	17].	The	sporozoites	
develop	in	the	oocyst	and	eventually	burst	the	oocyst	and	migrate	to	the	mosquito	salivary	
gland	where	they	can	be	injected	to	a	human	[16,	17].	
	
Plasmodium	in	humans	
A	human	malaria	infection	begins	when	an	infected	female	Anopheles	mosquito	bites	a	
person.	This	bite	results	in	about	100	sporozoites	being	injected	into	the	dermis	[18].	Using	
a	motility	mechanism	known	as	gliding	motility	the	sporozoites	forge	an	apparently	
random	path	out	of	the	dermis	[18,	19].	In	order	to	infect	the	liver,	a	sporozoite	must	cross	
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the	dermal	fibroblasts,	the	endothelial	cells	of	blood	vessels,	and	the	phagocytes	in	the	
dermal	and	liver	sinusoidal	layers	by	actively	entering	and	exiting	host	cells	using	a	
transversal	process	that	damages	the	host	cells	[18,	19].	Once	in	the	liver,	each	liver	stage	
form	is	capable	of	producing	up	to	90,000	merozoites	capable	of	infecting	erythrocytes	
[20].	These	merozoites	burst	out	of	the	liver	cells	and	enter	the	blood	stream.	
	
Invasion	of	an	erythrocyte	starts	with	a	reversible	attachment	to	the	erythrocyte	followed	
by	the	formation	of	a	tight	junction	the	parasite	uses	to	enter	the	cell	[18].	Once	inside	the	
erythrocyte	the	parasite	extensively	remodels	the	host	cell	by	exporting	proteins	to	change	
the	cells	morphology,	physiology,	and	function.	Up	to	8%	of	the	parasites	gene	products	are	
dedicated	to	this	process	[21].	Most	of	these	exported	proteins	contain	a	Plasmodium	
export	element	(PEXEL)	motif	which	is	cleaved	in	the	endoplasmic	reticulum	by	
plasmepsin	V	and	sent	to	an	ATP-powered	translocon	that	actively	transports	the	proteins	
into	the	host	cell	cytoplasm	[22].		
	
The	best	studied	and	possibly	most	clinically	relevant	of	these	exported	proteins	is	P.	
falciparum	erythrocyte	membrane-1	(PfEMP1).	The	gene	encoding	this	protein	is	part	of	a	
paralogous	family	of	var	genes.	A	single	parasite	has	approximately	60	var	genes,	but	only	a	
single	one	is	expressed	at	a	time	[22].	The	PfEMP1	proteins	(encoded	by	var	genes)	are	
involved	in	adhesion	to	host	endothelial	cells	via	binding	to	ICAM-1,	CD31,	CD36,	CSA	and	
glycosaminoglycans	[22].		This	cytoadherence	helps	the	parasite	avoid	splenic	clearance	
[21].	The	resulting	adherence	to	microvasculature	[23]	results	in	the	sequestration	of	
parasites	in	different	organs.	Sequestration	in	the	placenta	or	brain	can	cause	life-
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threatening	complications	[21].	There	are	a	few	other	apparent	variant	surface	antigen	
protein	families	(rifin,	stevor,	PfMC-2TM,	and	surfin),	but	the	PfEMP1	proteins	appear	to	be	
the	immunodominant	form	[23].	The	var	family	members	are	very	diverse	with	very	little	
encoded	protein	sequence	similarity	between	strains	[23].	This	diversity	coupled	with	the	
fact	that	only	a	single	var	gene	is	ever	expressed	in	a	single	parasite	is	thought	to	aid	the	
parasites	in	evading	the	host	immune	response.		
	
Like	many	other	rapidly	dividing	cells,	such	as	cancer	cells,	Plasmodium	during	the	blood	
stage	relies	on	glycolysis	for	most	of	its	energy	production	[22].	The	parasite	digests	
hemoglobin	from	the	erythrocyte	as	a	source	of	amino	acids	[24].	This	digestion	occurs	in	
an	acidic	digestive	vacuole.	Aspartic	proteases	called	plasmepsins	and	cysteine	proteases	
called	falcipains	are	involved	in	hemoglobin	degradation	inside	the	digestive	vacuole	[24].	
The	toxic	free	heme	that	results	from	this	digestion	is	detoxified	by	conversion	to	hemozoin	
crystals	[22].		
	
The	replication	of	Plasmodium	in	the	erythrocyte	is	described	using	a	Plasmodium	specific	
nomenclature	that	roughly	corresponds	to	the	different	stages	of	the	traditional	eukaryotic	
cell	cycle.	The	ring	and	early	trophozoite	stages	correspond	to	G0,	late	trophozoites	prepare	
for	chromosome	replication	(G1)	and	begin	DNA	synthesis	around	24	hours	(S	phase).	The	
schizont	stage	is	a	series	of	M	phases	with	the	first	nuclear	division	reported	to	occur	
between	26	and	28	hours	after	the	invasion	of	the	erythrocyte	[25].		However,	between	26	
and	28	hours	post-invasion	is	still	considered	the	trophozoite	stage	because	traditional	
staining	methods	do	not	detect	the	commencement	of	M	phase	in	the	parasites.	
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Most	of	the	merozoites	that	result	from	this	replication	will	infect	new	erythrocytes	and	
continue	the	cycle	detailed	above.	However,	some	of	the	merozoites	will	develop	into	
gametocytes.	The	early	stages	of	gametocyte	development	(I-IV)	occur	in	the	bone	marrow	
and	it	is	only	the	mature	gametocytes	that	are	present	in	the	peripheral	blood	where	they	
can	be	taken	up	by	a	female	Anopheles	mosquito.	The	parasites	undergo	sexual	
reproduction	in	the	mosquito	midgut	to	restart	the	Plasmodium	life-cycle	[16].	
		
	
	
Malaria	infection	
Signs,	symptoms	and	diagnosis	
The	hallmark	of	malaria	infection	is	periodic	fevers.	The	two	most	common	forms	of	
malaria	P.	falciparum	and	P.	vivax	are	characterized	by	periodic	fevers	that	reoccur	
approximately	every	48	hours	[26].	Other	species	have	different	cycle	lengths	but	they	are	
all	multiples	of	24	hours	[26].	The	fevers	result	from	rupturing	schizonts	stimulating	the	
release	of	pyrogenic	cytokines	from	macrophages	and	other	cells.	The	fevers	occur	
periodically	because	the	erythrocytic	phase	of	the	life-cycle	always	takes	about	the	same	
amount	of	time	and	the	parasites	replicate	simultaneously	inside	the	host	[27].	The	reason	
for	this	synchrony	is	unclear,	but	the	fact	that	the	parasites	lose	synchrony	in	vitro	suggests	
that	host	factors	are	involved	[27].		Synchrony	can	be	achieved	in	vitro	by	subjecting	the	
parasites	to	febrile	temperatures	suggesting	that	the	fever	response	is	involved	in	
maintaining	synchrony	[27].	
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Clinically	the	initial	symptoms	(before	the	periodic	fevers)	of	malaria	infection	are	
nonspecific	and	similar	to	those	caused	by	a	minor	systemic	viral	illness	[28].	These	early	
symptoms	include:	headache,	lassitude,	fatigue,	abdominal	discomfort,	muscle	and	joint	
aches,	often	followed	by	fever,	chills,	perspiration,	anorexia,	vomiting,	and	worsening	
malaise	[28].	Malaria	in	young	children	is	associated	with	lethargy,	poor	feeding	and	cough	
[28].	If	the	infection	is	caught	and	promptly	treated	at	the	early	stages	of	infection	a	full	
recovery	is	expected	[28].	Severe	malaria	is	associated	with	one	or	more	of	the	following:	
coma,	metabolic	acidosis,	severe	anemia,	hypoglycemia,	acute	renal	failure	or	acute	
pulmonary	edema,	and	if	left	untreated	is	usually	fatal.	In	endemic	areas	with	high	levels	of	
transmission	clinical	disease	mostly	occurs	in	young	children	and	pregnant	women,	whose	
immunity	has	been	reduced.	In	areas	of	unstable	transmission	all	humans	are	at	risk	of	
developing	severe	malaria	[28].	Diagnosis	of	malaria	is	based	on	microscopic	identification	
of	the	parasites	or	an	immunochromatographic	diagnostic	test	[28].		
	
Treatment	of	uncomplicated	malaria	
Uncomplicated	malaria	is	defined	as	the	presence	of	malaria	symptoms	and	a	positive	
parasitological	test,	but	without	the	features	of	severe	malaria	[28].	Uncomplicated	malaria	
is	treated	with	an	artemisinin-based	combination	therapy	(ACT)	[28].	The	therapeutic	
objective	when	treating	uncomplicated	malaria	is	to	prevent	progression	to	severe	disease,	
prevent	transmission	of	malaria	to	others	and	to	prevent	the	evolution	of	drug	resistance	
to	antimalarial	drugs	[28].	
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Treatment	of	severe	malaria	
Individuals	experiencing	severe	malaria	cannot	tolerate	oral	medication	and	should	be	
given	intravenous	or	intramuscular	artesunate	for	at	least	24	hours	and	until	the	use	of	an	
oral	ACT	is	possible	[28].	The	primary	objective	when	treating	severe	malaria	is	preventing	
patient	death	[28].		
	
Treatment	and	control	strategies	
The	elucidation	of	the	Plasmodium	life-cycle	allowed	the	rationale	design	of	control	efforts.	
One	of	the	first	attempts	to	control	malaria	using	the	knowledge	of	its	life-cycle	was	
reported	by	Ronald	Ross	in	Prevention	of	Malaria	in	Mauritius	[29].	In	this	work,	Ross	states	
that	the	key	factors	to	consider	when	trying	to	reduce	malaria	transmission	are:	the	
number	of	infected	mosquitos,	how	likely	an	infected	mosquito	is	to	infect	a	person,	how	
likely	a	person	is	to	infect	a	mosquito	and	how	far	an	infected	mosquito	can	travel	[29].	
While	the	current	modeling	of	malaria	transmission	to	understand	optimal	control	
measures	has	gotten	more	complex,	they	are	all	rooted	in	these	factors	first	described	by	
Ross	[30,	31].	Using	the	Ross	model	of	malaria	transmission,	the	first	efforts	to	control	
malaria	focused	on	reducing	mosquito	populations	and	preventing	humans	from	getting	
bitten	by	mosquitos	[29].		Drugs	became	a	part	of	containment	strategies	following	the	
discovery	of	drugs	capable	of	blocking	transmission	to	mosquitos	[32].			
	
Vector	control	
Vector	control	is	traditionally	the	most	effective	control	strategy	for	malaria	[15].	The	
original	vector	control	methods	involved	reducing	the	larval	population	by	treating	
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breeding	sites	with	petroleum	derivatives	or	Paris	Green	[33].		Attempts	were	also	made	to	
reduce	the	number	of	potential	breeding	sites	where	larva	develop	[33-35].	Successful	use	
of	larval	control	methods	required	the	identification	of	the	major	vectors	in	a	region	and	
their	breeding	sites	[33-35].	The	mosquito	vectors	targeted	was	determined	by	the	species	
competence	as	a	malaria	vector.	The	competence	of	a	mosquito	as	a	malaria	vector	is	
effected	by	its	susceptibility	to	Plasmodium	infection,	the	type	of	host	it	prefers	to	take	
blood	meals	from,	and	how	long	the	mosquito	lives	[15].		
	
The	first	control	measures	aimed	at	the	adult	female	Anopheles	mosquitos	was	mosquito	
proofing	houses	[34,	36].			When	using	insecticides	as	part	of	a	malaria	control	effort	the	
species	susceptibility	to	insecticides	and	where	the	adult	female	Anopheles	mosquitos	
prefer	to	feed	and	rest	must	be	taken	into	account	[15].	Large	scale	targeting	of	adult	
female	Anopheles	mosquitos	started	with	DDT	in	1944	in	Italy	using	indoor	residual	
spraying	[33].	Indoor	residual	spraying	is	spraying	the	walls	and	ceilings	of	houses	with	an	
insecticide	to	kill	mosquitos	which	reduces	transmission	by	decreasing	the	life	expectancy	
of	the	female	mosquitoes	[36].	This	is	an	effective	strategy	because	many	of	the	most	
important	malaria	vector	mosquitos	prefer	to	bite	humans	inside	homes	[37,	38].		Since	
indoor	residual	spraying	does	not	prevent	mosquito	biting,	this	is	a	population	level	
intervention	that	usually	requires	>85%	of	the	homes	in	a	vicinity	to	be	covered	to	reduce	
transmission	[36].	Indoor	residual	spraying	is	more	effective	than	efforts	that	involve	
draining	water	near	humans’	homes	or	adding	screens	to	homes	[38].	
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Another	form	of	spraying	similar	to	indoor	residual	spraying	is	space	spraying.	Space	
spraying	is	used	to	halt	epidemics	and	involves	heating	the	insecticide	to	form	fine	droplets	
that	resemble	fog	[37].	This	technique	rapidly	reduces	the	mosquito	population	but	
provides	no	residual	protection	[37].		
	
The	other	common	vector	control	intervention	used	today	is	long-lasting	insecticidal	nets.	
Insecticide-treated	nets	are	used	to	create	a	physical	barrier	between	mosquitos	and	a	
person	[37].	All	bed	nets	provide	some	level	of	protection	against	malaria	but	insecticide	
treated	nets	provide	up	to	twice	as	much	protection	as	untreated	nets	[39].	Long-lasting	
insecticide	nets	provide	population	level	protection	when	extensively	used	in	communities	
[36].	Bed	nets	usages	were	attributed	to	a	35%	decline	in	mortality	among	children	less	
than	5	years	old	in	Tanzania	between	2000	and	2004	[37].		
	
Antimalarial	drugs	
Arylamino	alcohols	
Quinine	was	the	first	antimalarial	drug.	Quinine’s	mechanism	of	action	is	not	well	
understood	but	is	thought	to	be	related	to	heme	degradation	in	the	digestive	vacuole	[40].	
Compliance	with	quinine	treatment	is	low	because	the	side	effects	can	be	severe	and	
include:	nausea,	headache,	tinnitus,	hearing	impairment,	and	dysphoria	[40].	These	side	
effects	are	usually	temporary,	but	more	detrimental	side	effects	such	as	arrhythmia	and	
hypoglycemia	do	occur	[40,	41].		
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Resistance	to	quinine	was	first	reported	in	1907	in	Brazil	and	resistance	in	Europe	became	
apparent	during	World	War	I	[42].	However,	because	it	was	not	widely	used	after	the	
discovery	of	chloroquine,	quinine	remained	largely	effective	for	a	long	time	and	was	the	
recommended	treatment	for	severe	malaria	and	still	is	if	an	artemisinin	is	not	available	
[40].	However,	large	spikes	in	the	quinine	IC50s	(half-maximal	inhibitory	concentration)	
were	observed	in	Vietnam	in	1989	and	in	Thailand	in	1990	[43],	indicating	the	emergence	
of	resistance.		By	1994	the	cure	rates	for	quinine	were	down	to	32%	in	Africa	[44].		
	
The	main	mechanism	of	quinine	resistance	is	increased	copy	number	of	pfmdr1	[40].	Other	
genes	contributing	to	the	modulation	of	resistance	include	pfcrt,	pfnhe,	and	pfmdr2	[45,	46].	
	
Mefloquine	came	into	use	because	it	was	active	against	chloroquine	resistant	strains	[47].	
Similar	to	its	structural	analog	quinine,	the	mechanism	of	action	is	unknown	[48].	Though	it	
is	known	to	cause	morphological	changes	to	the	digestive	vacuole	[48],	and	it	has	been	
proposed	that	mefloquine	and	quinine	work	by	binding	to	phospholipid	targets	resulting	in	
the	inhibition	of	vesicular	docking	to	the	digestive	vacuole	[48].		Mefloquine	is	well	
tolerated	by	most	humans	but	prophylactic	use	has	been	linked	to	insomnia,	depression,	
and	panic	attacks	in	5-29%	of	individuals	[40].		
	
There	was	a	steady	decline	in	mefloquine	sensitivity	among	P.	falciparum	isolates	from	
southeastern	Thailand	between	1984	and	1989	with	the	trend	accelerating	in	1990	[49].	
By	2003,	the	efficacy	of	mefloquine	in	some	areas	of	Thailand	was	only	62%	[40].	Increased	
copy	number	of	pfmdr1	is	associated	with	decreased	sensitivity	to	mefloquine	[50,	51].	Due	
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to	this	resistance	and	the	relatively	common	side	effects,	today	mefloquine	is	only	used	as	
part	of	ACT.	
	
Lumefantrine	is	used	in	combination	with	the	artemisinin	artemether.	Chloroquine-
resistant	parasites	show	a	slight	increase	in	susceptibility	to	lumefantrine	[40].	There	is	
large	variation	in	the	bioavailability	of	lumefantrine	[52].	The	bioavailability	is	improved	
by	co-administration	with	a	fatty	meal	[52].	
	
	
	
4-aminoquinolines	
Chloroquine’s	exact	mechanism	is	debated,	but	there	is	a	general	consensus	that	it	
interferes	with	the	parasites	ability	to	digest	hemoglobin.	The	digestion	of	hemoglobin	
results	in	the	production	of	ferriprotoporphyrin	IX	(FPIX)		[40]	which	is	toxic	to	the	
parasite,	probably	due	to	increased	oxidative	stress.	FPIX	is	disposed	via	the	formation	of	
an	insoluble	polymer	called	hemozoin.	Chloroquine	accumulates	in	the	digestive	vacuole	
and	binds	FPIX	preventing	its	polymerization	into	hemozoin	[40].		
	
Long-term	use	of	chloroquine	(as	a	prophylactic)	rarely	results	in	serious	and	irreversible	
side	effects	which	include:	neuromyopathy,	retinopathy,	erythema	multiform,	and	bone-
marrow	toxicity	[40].	
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By	1994,	the	chloroquine	cure	rates	in	Africa	were	down	to	9%	[44].	Chloroquine	
resistance	evolved	independently	in	4	different	regions	[40].	Mutations	in	pfcrt	are	
associated	with	removal	of	chloroquine	from	the	digestive	vacuole	and	increased	
acidification	of	the	digestive	vacuole	[53].	It	is	thought	that	the	K76T	mutation	allows	
chloroquine	to	be	exported	from	the	digestive	vacuole	by	replacement	of	the	positive	
charge	on	lysine	with	the	neutral	threonine.	An	additional	14	more	amino	acid	changes	
must	occur	in	pfcrt	to	make	the	K76T	mutation	viable.	This	resistance	mechanism	appears	
to	have	a	fitness	cost	with	patients	infected	with	parasites	containing	the	pfcrt	resistance	
allele	having	lower	parasite	densities	[54].	However,	the	resistance	allele	is	also	associated	
with	increased	gametocyte	production,	suggesting	that	resistant	parasites	may	have	higher	
transmission	rates	[54].		
	
A	N86Y	mutation	in	pfmdr1	modulates	the	level	of	chloroquine	resistance	and	increases	
sensitivity	to	mefloquine,	halofantrine,	lumefantrine,	and	dihydroartemisinin[40].		
Parasites	with	the	same	pfmdr1	and	pfcrt	alleles	have	different	levels	of	sensitivity	to	
chloroquine,	suggesting	that	other	genes	are	involved	in	the	response.	Experimental	
evidence	suggested	that	other	transporter	proteins	are	involved	in	modulating	the	
response	to	chloroquine	[46].	Interestingly,	there	is	an	inverse	correlation	between	
resistance	to	chloroquine	and	resistance	to	arylamino	alcohol	and	endoperoxide	drugs	
[55].	In	particular,	increased	copy	numbers	of	pfmdr1	is	associated	with	increased	
sensitivity	to	chloroquine,	but	decreased	sensitivity	to	mefloquine	[55].		
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Chloroquine	sensitivity	appears	to	return	in	the	absence	of	chloroquine	drug	pressure.	The	
resistant	pfcrt	allele	frequency	decreases	in	the	population	during	the	dry	season	when	
mostly	asymptomatic	infections	occur	[54]	and	studies	of	isolates	from	Africa	and	Thailand	
also	show	chloroquine	sensitivity	rising	in	the	population	[43,	56].			
	
It	is	possible	that	chloroquine	could	once	again	be	used	as	an	antimalarial	agent,	as	double	
dosing	with	Chloroquine	has	been	shown	to	kill	resistant	parasites	[54].	
	
Amodiaquine	was	originally	used	as	a	stand-alone	treatment	for	malaria	but	is	now	paired	
with	artesunate	[28].	When	used	as	a	prophylactic	amodiaquine	is	associated	with	
neutropenia	and	hepatitis	[41].		The	chloroquine	resistance	allele	K76T	in	pfcrt	and	the	
N86Y	allele	of	pfmdr1	are	associated	with	resistance	to	amodiaquine	[57].	
	 	
Piperaquine	is	used	in	combination	with	the	artemisinin	dihydroartemisinin	(DHA).	
Piperaquine	makes	for	a	good	partner	drug	with	DHA	because	its	half-life	of	3-4	weeks	is	
much	longer	than	the	2-hour	half-life	of	DHAs	[58,	59].	Piperaquine	was	previously	used	as	
a	monotherapy	to	treat	malaria	in	China,	but	resistance	emerged	in	the	1980s	[58].	
Resistance	to	Piperaquine	is	associated	with	amplification	of	the	genes	plasmepsin	2	and	3	
[60].		
	
Mannich	bases	
Pyronaridine	is	too	toxic	to	neutrophils	to	be	used	as	a	standalone	treatment	but	has	been	
proven	useful	as	a	partner	drug	with	the	artemisinin	artesunate	[40].	
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8-aminoquinolines	
Primaquine	is	active	against	the	liver	and	sexual	blood	stages,	but	activity	against	the	
asexual	blood	stages	is	too	low	to	use	therapeutically	[40].	Primaquine	is	used	to	eliminate	
P.	vivax	or	P.	ovale	hypnozoites	in	the	liver,	which	can	cause	relapses	months	after	the	
initial	infection	[40].	The	short	half-life	of	primaquine	necessitates	administration	of	doses	
for	14	days	[40].	The	mode	of	action	against	malaria	is	unknown,	but	causes	life-
threatening	hemolysis	in	humans	deficient	in	G6PD	[40]	which	is	extremely	unfortunate	
because	this	enzyme	deficiency	is	common	in	areas	with	P.	vivax	malaria	[61].		
	
Tafenoquine	is	also	active	against	the	liver	and	gametocyte	stages.	It	shows	higher	activity	
against	blood	stage	and	sporontocidal	activity	than	primaquine;	and	is	better	tolerated	by	
humans	with	G6PD	deficiency	than	primaquine	[40].	Tafenoquine	was	approved	for	use	in	
patients	in	2018	to	prevent	relapsing	malaria	form	P.	vivax	or	P.	ovale	infections	[62].		
	
Antifolates	
Proguanil	and	cycloguanil:	Proguanil	is	used	in	combination	with	atovaquone	where	it	
acts	synergistically	by	enhancing	the	collapse	of	the	mitochondrial	membrane	potential	
[63,	64].	Proguanil	was	thought	to	exert	its	antimalarial	activity	after	conversion	via	P450	
isoenzymes	to	the	metabolite	cycloguanil,	which	targets	dihydrofolate	reductase	[65-67].	
However,	cycloguanil	does	not	enhance	mitochondrial	membrane	potential	collapse	and	
the	dihydrofolate	reductase	inhibitor	pyrimethamine	does	not	have	synergy	with	
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atovaquone,	suggesting	that	proguanil	is	the	active	agent	when	paired	with	atovaquone	and	
acts	via	a	mechanism	distinct	from	proguanil	[63,	66].		
	
Pyrimethamine	and	sulfadoxine:	Plasmodium	lacks	the	pyrimidine	salvage	pathway	and	
therefore	must	synthesize	all	pyrimidines	de	novo.	Two	key	enzymes	in	this	process	are	
PfDHR	and	PfDHPS	which	are	present	on	separate	domains	on	a	single	protein	[40].	
Because	there	is	synergy	in	inhibiting	both	PfDHR	and	PfDHPS	the	PfDHR	inhibitor	
pyrimethamine	and	the	PfDHPS	inhibitor	sulfadoxine	were	combined	into	the	anti-malarial	
Fansidar	[40].		Treatment	with	pyrimethamine	and	sulfadoxine	could	be	administered	in	a	
single	dose	which	ensured	compliance	[68].	This	formulation	is	well	tolerated	when	used	
intermittently	but	when	used	prophylactically	can	cause	toxic	epidermal	necrolysis	and	
Steven	Johnson	syndrome	[41].		
	
Resistance	to	pyrimethamine	and	sulfadoxine	results	from	changes	to	the	binding	sites	of	
their	respective	targets.	In	both	cases	resistance	evolved	as	a	series	of	sequential	mutations	
that	resulted	in	a	stepwise	decline	in	sensitivity	[40].			
	
The	evolution	of	pyrimethamine	resistance	was	initiated	with	a	S108N	mutation	in	PfDHR	
that	created	a	steric	clash	in	the	binding	site	between	the	arginine	side	chain	and	the	chloro	
on	pyrimethamine.	The	S108N	mutation	results	in	a	10-fold	decrease	in	sensitivity	and	was	
followed	by	2	different	series	of	mutations,	creating	2	haplotypes.	The	
S108N/N51I/C59R/I164L	is	500	fold	less	sensitive	and	S108N/N51I/C59R	is	100	fold	less	
sensitive	to	pyrimethamine	[40].	These	subsequent	mutations	helped	restore	catalytic	
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activity	and	further	decreased	inhibitor	binding	affinity	by	causing	a	change	in	the	
localization	of	the	amino	acids	lining	the	binding	pocket	[40].		
	
The	evolution	of	resistance	to	sulfadoxine	followed	a	similar	route	with	a	S346A	mutation	
in	pfdhps	that	prevented	the	formation	of	hydrogen	bonds	with	the	drug	or	a	S346F	
mutation	causing	steric	blockage.	A437G,	K540E,	A581G	and	A613S	mutations	followed	
that	caused	changes	in	the	active	site	topology	that	allows	more	rotational	freedom	for	the	
inhibitor	in	the	binding	site	leading	to	decreased	binding	affinity	[40].		
	 	
Antibiotics	
Malaria	parasites	have	two	organelles	of	bacterial	origin:	the	apicoplast	and	the	
mitochondria	which	have	bacterial	genes	for	replication,	transcription	and	translation	[40].	
Antibiotics	used	to	treat	malaria	are	thought	to	act	via	the	apicoplast	targets	[40].	When	
used	as	antimalarials	antibiotics	are	only	used	prophylactically	or	with	a	partner	drug	
because	they	show	no	effect	during	the	first	cycle	and	are	only	active	after	the	invasion	of	
new	cells	and	therefore	cannot	be	used	for	rapid	symptom	relief	[40].	This	delayed	effect	
can	be	fatal	in	a	patient	without	pre-existing	immunity	[40].		
	
Doxycycline	binds	to	the	16S	RNA	of	the	30S	ribosomal	subunit	at	the	aminoacyl	(A)	site	
and	inhibits	GTP	hydrolysis	by	elongation	factor	2.	Doxycycline	and	quinine	used	to	be	
used	to	treat	severe	malaria,	but	today	doxycycline	is	only	used	as	a	prophylactic	[40].	
Unfortunately,	doxycycline	cannot	be	used	during	pregnancy	or	in	children	under	the	age	
of	8	due	to	side	effects	and	can	cause	phototoxicity	upon	skin	exposure	to	sunlight	[40].		
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2-hydroxynaphtoquinones	
Atovaquone	is	a	lipophilic	analog	of	ubiquinone	(also	known	as	coenzyme	Q)	which	is	part	
of	the	mitochondrial	electron	transport	chain	and	targets	the	cytochrome	bc1	complex	
(Complex	III)	of	the	electron	transport	chain	causing	the	loss	of	the	mitochondrial	
membrane	potential	[69,	70].	The	bc1	complex	at	first	seems	like	a	surprising	target	for	an	
anti-malarial	because	humans	are	dependent	upon	this	protein	for	energy	production,	but	
this	drug	has	low	toxicity	in	humans	with	homology	modeling	suggesting	that	atovaquone	
experiences	steric	clashes	in	the	bc1	binding	pocket	of	humans	[71].	Atovaquone	is	active	
against	malaria,	toxoplasmosis	and	Pneumocystis	pneumonia	[72].	When	used	as	an	
antimalarial	it	is	active	against	the	liver	stage,	gametocytes,	and	the	entire	blood	stage	[73-
75].		
	
Atovaquone	appears	to	kill	malaria	parasites	not	by	preventing	the	production	of	energy,	
as	would	be	expected,	but	by	causing	the	collapse	of	the	mitochondrial	membrane	potential	
and	potentially	by	inhibiting	the	synthesis	of	pyrimidines.	Blood	stage	P.	falciparum	
parasites	get	most	of	their	energy	from	glycolysis,	leading	to	the	hypothesis	that	they	only	
maintain	the	mitochondrial	electron	transport	chain	to	regenerate	ubiquinone	to	be	an	
electron	acceptor	for	dihydroorotate	dehydrogenase.		Dihydroorotate	dehydrogenase	is	
required	for	pyrimidine	biosynthesis	[70,	76]	and	treatment	with	atovaquone	inhibits	de-
novo	pyrimidine	synthesis	[76].	Parasites	resistant	to	dihydroorotate	dehydrogenase	
inhibitors	are	also	resistant	to	atovaquone	[77,	78]	and	replacing	the	P.	falciparum	
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dihydroorotate	dehydrogenase	with	one	that	does	not	require	ubiquinone	to	be	an	electron	
acceptor	are	resistant	to	mitochondrial	electron	transport	inhibitors	but	are	not	resistant	
to	mitochondrial	membrane	potential	collapse	[76].		
	
Use	of	atovaquone	as	a	single	therapy	results	in	initial	clinical	improvement,	but	the	overall	
cure	rate	is	only	67%	[64].	Atovaquone	is	an	effective	antimalarial	when	it	is	paired	with	
proguanil.	Proguanil	has	no	effect	on	atovaquone’s	inhibition	of	mitochondrial	respiration	
but	does	enhance	the	collapse	of	the	mitochondrial	membrane	potential	creating	a	
synergistic	effect	[63,	79].	When	recrudescence	occurs	after	treatment	with	atovaquone	
and	proguanil	the	isolates	are	not	resistant	to	atovaquone	in	vitro	[79]	suggesting	that	the	
evolution	of	resistance	is	not	a	factor	in	the	treatment	failure.		
	
Resistance	to	atovaquone	in	the	field	is	associated	with	mutations	in	the	PEWY	region	of	
the	Qo	pocket	of	cytochrome	b1.	The	most	common	mutation	is	Y268S	[80].	The	Y268S	
mutation	results	in	decreased	catalytic	activity	and	is	associated	with	probable	
compensatory	changes	including	higher	expression	levels	of	cytochrome	bc1	and	
cytochrome	c	oxidase	genes	[80].	One	study	estimated	the	fitness	costs	associated	with	
resistance	to	be	between	5	and	9%,	but	these	calculations	were	based	on	mutations	not	
common	in	the	field	[81].	The	mutations	associated	with	resistance	change	the	
hydrophobicity	and	volume	of	the	amino	acids	in	the	binding	pocket	[72].	Homology	
modeling	of	the	potential	atovaquone	binding	sites	in	P.	falciparum	suggests	that	mutations	
occur	in	residues	that	make	contact	with	atovaquone	[82].	In	vitro	additional	mutations	
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occur	in	non-contact	residues	[82].	Mutations	in	pfmrp1	and	pfmrp2	have	been	linked	to	
atovaquone	resistance	[83,	84].	
	
Sesquiterpene	lactone	endoperoxides		
Artemisinins:	Artemisinin-based	combination	therapy	(ACT)	is	the	current	WHO	
recommended	treatment	for	uncomplicated	P.	falciparum	infection	[28].	With	ACT	a	drug	
based	on	the	artemisinin	molecule	is	paired	with	a	partner	drug.	The	current	
recommended	combinations	are	artemether-lumefantrine,	artesunate-amodiaquine,	
dihydroartemisinin-piperaquine	and	artesunate-sulfadoxine-pyrimethamine	[28].	
	
Artemisinins	are	converted	into	free	radicals	via	interaction	with	free	heme	[85,	86]	which	
then	go	on	to	oxidatively	damage	proteins.	However,	there	is	no	consensus	on	any	
particular	target	[87,	88].	There	is	evidence	that	an	increase	in	unfolded	proteins	
overwhelms	the	proteasome	leading	to	the	activation	of	the	endoplasmic	reticulum	stress	
response,	ultimately	leading	to	parasite	death	[89].		
	
Resistant	strains	have	been	reported	in	Thailand,	Laos,	and	Vietnam	[90,	91].	In	the	Pursat	
province	of	Cambodia	the	treatment	failure	rate	was	reported	to	be	46%	[92].	Resistance	is	
associated	with	entry	into	a	dormant	state	during	the	ring	stage	[85,	93-96].	Since	the	
resistance	mechanism	involves	entry	into	a	dormant	state	traditional,	in	vitro	screens	of	
drug	resistance	do	not	work,	and	an	alternative	mechanism	that	takes	the	dormancy	
mechanism	into	account	was	devised	[97,	98].	Transcriptional	profiling	of	resistant	
mutants	has	implicated	in	the	resistance	mechanism	up-regulation	of	the	unfolded	protein	
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response	and	oxidative	stress	genes,	down-regulation	of	DNA	replication	and	repair,	and	
altered	expression	in	protein	damage	and	cell	cycle	pathways	[99,	100].		
	
The	gene	with	the	strongest	link	to	resistance	is	k13	[101-104].	K13	is	a	homolog	of	the	
human	oxidative	stress	response	regulator	Keap1	[105].	Keap1	functions	as	an	E3	ubiquitin	
substrate	ligase	adapter	that	regulates	the	transcription	factor	Nrf2	[106].	Given	the	
homology	to	Keap1,	it	is	hypothesized	K13	mediates	resistance	to	artemisinins	by	
regulation	of	transcription.	The	gene	pfmdr1	has	also	been	shown	to	mediate	the	level	of	
artemisinin	resistance	[50].	
	
Prophylaxis		
The	use	of	antimalarials	prophylactically	is	recommended	in	non-immune	individuals	
traveling	to	malaria	endemic	areas.	The	type	of	drug	used	depends	upon	the	age	and	health	
of	the	individual.	The	travel	region	is	also	an	important	consideration	since	some	drugs	are	
more	effective	in	certain	areas	than	others.	The	Centers	for	Disease	Control	cautions	that	
the	use	of	a	prophylactic	drug	should	not	be	used	as	an	excuse	to	not	follow	other	personal	
protective	measures	such	as:	using	insect	repellent,	wearing	long	sleeves	and	long	pants,	
sleeping	in	a	mosquito-free	setting	or	using	an	insecticide-treated	bed	net.		
There	are	currently	5	drugs	recommended	for	anti-malarial	prophylactic	use	[107].		
1. Malarone	is	a	combination	of	atovaquone	and	proguanil	[107].	Malarone	rarely	
causes	side-effects	and	can	be	started	only	1-2	days	before	traveling	[107].	
However,	it	must	be	taken	for	7	days	after	leaving	a	malaria	endemic	area	and	
must	be	taken	daily	[107].	It	cannot	be	used	by	women	who	are	pregnant,	when	
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breast-feeding	a	child	that	weighs	less	than	5	kg,	or	with	humans	that	have	renal	
impairment	[107].	Malarone	is	one	of	the	more	expensive	options,	making	it	cost	
prohibitive	for	long	trips	[107].	
2. Chloroquine	only	requires	weekly	dosing	and	can	be	used	during	pregnancy	
[107].	However,	it	cannot	be	used	in	areas	with	chloroquine	or	mefloquine	
resistance	[107].	Chloroquine	has	been	reported	to	exacerbate	psoriasis	and	
requires	additional	dosing	for	4	weeks	after	travel	[107].	
3. Doxycycline	must	be	taken	daily,	but	can	be	started	1-2	days	before	travel	[107].	
It	is	usually	the	least	expensive	option	for	travelers	and	can	be	used	as	a	
prophylactic	for	other	infections	common	upon	travels	such	as	Rickettsia	and	
leptospirosis	[107].	Doxycycline	cannot	be	used	by	pregnant	women	or	children	
under	8	years	old	[107].	Dosing	of	doxycycline	must	continue	for	4	weeks	after	
travel.	Side	effects	include	increased	risk	of	vaginal	yeast	infection,	phototoxicity	
and	upset	stomach	[107].		
4. Mefloquine	is	taken	weekly	and	can	be	used	while	pregnant.	The	efficacy	of	
mefloquine	is	limited	by	the	spread	of	resistant	parasites	as	well	as	series	side	
effects	that	exclude	humans	with	certain	psychiatric	conditions,	seizure	
disorders,	or	with	cardiac	conduction	abnormalities	[107].	Dosing	with	
mefloquine	needs	to	start	2	weeks	prior	to	travel	and	continue	for	4	weeks	after	
travel	[107].	
5. Primaquine	is	the	most	effective	medicine	against	P.	vivax	malaria	[107].	Dosing	
with	primaquine	can	start	1-2	days	before	travel,	must	occur	daily	and	must	be	
taken	for	7	days	after	returning	[107].	Primaquine	cannot	be	used	in	humans	
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with	glucose-6-phosphate	dehydrogenase	(G6PD)	deficiency	or	in	patients	who	
have	not	been	tested	for	G6PD	deficiency	[107].	Women	who	are	pregnant	or	
breast-feeding	cannot	take	primaquine	unless	the	infant	has	been	tested	for	
G6PD	deficiency.	Primaquine	sometimes	causes	gastrointestinal	(GI)	track	
irritation	[107].		
	
Chemical	prophylaxis	is	recommended	under	certain	conditions	for	humans	living	in	
malaria	endemic	areas	[28].	Pregnant	women,	infants,	and	humans	in	areas	with	seasonal	
transmission	of	malaria	have	been	shown	to	benefit	from	prophylactic	treatment	[28].		
	
Pregnant	women	and	their	children	have	been	found	to	benefit	from	intermittent	
preventative	treatment	with	sulfadoxine-pyrimethamine	[28].	It	is	recommended	to	begin	
treatment	in	the	second	trimester	with	doses	one	month	apart;	at	least	3	doses	should	be	
completed	[28].	This	regimen	increases	birth	weight	an	average	56	g,	reduces	low	birth	
weight	by	about	20%,	reduces	placental	parasitemia	by	about	60%	and	reduces	maternal	
parasitemia	by	about	33%.	This	treatment	remains	effective	even	in	areas	with	high	levels	
of	sulfadoxine-pyrimethamine	resistance	[28].		
	
Prophylactic	treatment	of	infants	with	sulfadoxine-pyrimethamine	in	areas	where	
sulfadoxine-pyrimethamine	is	still	effective	is	recommended	in	infants	less	than	12	months	
of	age	[28].	The	treatments	occur	at	the	time	of	the	2nd	and	3rd	vaccinations	against	DTP	
and	measles	[28].	This	treatment	has	been	shown	to	provide	protective	efficacies	of	30.3%	
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against	clinical	malaria,	21.3%	against	anemia,	38.1%	against	hospital	admissions	
associated	with	malaria	parasitemia	and	all	cause	hospital	admissions	of	22.9%	[28].		
	
Seasonal	malaria	chemoprevention	is	performed	in	areas	with	seasonal	malaria	
transmission	in	the	sub-Sahel	region	of	Africa	[28].	Children	less	than	6	years	old	get	
amodiaquine	paired	with	sulfadoxine-pyrimethamine	monthly	during	transmission	season	
[28].	This	prevents	up	to	75%	of	malaria	cases	and	up	to	75%	of	severe	malaria	cases	[28].	
	
	
	
	
Vaccines	
	Development	of	malaria	vaccines	is	challenging	because	even	a	naturally	acquired	
infection	does	not	produce	sterilizing	immunity.	Given	this	challenge,	the	main	focus	is	not	
on	completely	preventing	infection	but	on	decreasing	morbidity,	mortality	and	
transmission	[108].	The	Malaria	Vaccine	Technology	Roadmap	to	2030	states	its	goal	is	to	
have	a	vaccine	with	75%	efficacy	for	over	2	years	against	P.	falciparum	or	P.	vivax	[108].	
There	are	3	categories	of	malaria	vaccines:	transmission	blocking,	pre-erythrocytic,	and	
blood	stage.	
	
Transmission	blocking	vaccines:	Transmission	blocking	vaccines	target	the	sexual	stages	
of	the	parasite	that	occur	in	the	mosquito	[109].	As	the	name	implies	transmission	blocking	
vaccines	are	not	designed	to	protect	humans	directly.	Instead	the	goal	is	to	reduce	infection	
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rates	by	either	decreasing	the	number	of	infected	mosquitos	or	at	least	decreasing	the	
infectiousness	of	an	infected	mosquito.	A	phase	one	trial	was	recently	completed	on	a	
vaccine	that	used	the	Pfs25	protein	conjugated	to	Pseudomonas	aeruginosa	ExoProtein	A	
(EPA),	which	created	transmission	reducing	antibodies	in	malaria-naïve	volunteers	[110].	
The	Pfs25-EPA	vaccine	has	a	good	safety	profile	but	antibody	titers	returned	to	baseline	
within	a	year	[110].			
	
A	clinical	trial	of	a	different	vaccine	candidate,	Pfs-25H-EPA/Alhydrogel	in	Malian	adults	
was	able	to	detect	transmission	blocking	via	the	standard	membrane	feeding	assay,	but	the	
antibodies	did	not	work	when	the	mosquitos	fed	directly	on	humans	[111].	Efficacy	in	the	
standard	membrane	feeding	assay	required	4	doses	of	the	vaccine	[111].	The	antibody	
titers	decreased	rapidly	after	vaccination,	with	a	half-life	of	42	days	for	anti-Pfs25H	
antibodies.	The	Pfs-25H-EPA/Alhydrogel	vaccine	did	have	a	good	safety	profile	[111]	and	a	
nanoparticle	formulation	that	encapsulated	the	antigen	in	poly(lactic-co-glycolic	acid)-
based	synthetic	particles	increased	Pfs25	antibody	titers,	Pfs25-specific	plasmablasts,	
circulating	memory	B	cells,	and	plasma	cells	in	the	bone	marrow	[112].	Other	transmission	
antigens	currently	being	tested	are	Pfs48/45,	PfHAP2	and	AnAPN1	[113].		
	
Pre-erythrocytic	vaccines:	The	goal	of	pre-erythrocytic	vaccines	is	to	generate	a	
protective	immune	response	against	the	pre-erythrocytic	stages.	The	pre-erythrocytic	
stages	targeted	are	the	liver	stage	and	the	merozoites	that	infect	the	erythrocytes.	The	pre-
erythrocytic	stages	are	promising	targets	because	the	parasites	experience	population	
bottlenecks	at	these	stages	of	infection.	There	are	four	types	of	pre-erythrocytic	vaccines:	
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sporozoite	subunit	vaccines,	whole	sporozoite	vaccines,	wild-type	sporozoites	treated	with	
drugs,	and	liver-stage	subunit	vaccines.		
	
To	date	the	most	effective	sporozoite	subunit	vaccine	is	RTS,S/AS01	which	induces	an	
immune	response	to	circumsporozoite	protein	(PfCSP),	which	covers	the	surface	of	the	
sporozoite.	The	vaccine	is	PfCSP	fused	to	hepatitis	B	virus	surface	antigen	and	formulated	
with	the	liposomal	adjuvant	system	AS01	from	GlaxoSmithKline	[108].	A	phase	III	clinical	
trial	demonstrated	that	3	doses	given	1	month	apart	reduced	clinical	malaria	by	51%	in	
children	5-17	months	old	in	the	first	year	and	after	2	years	efficacy	was	26%	and	if	a	4th	
dose	is	given	efficacy	at	20	months	was	39%	[110-114].	The	initial	half-life	of	the	
antibodies	was	found	to	be	about	40	days	followed	by	a	rate	of	slower	decline	with	a	half-
life	of	~600	days	[115].	A	larger	long-term	follow-up	study	is	expected	to	start	in	2018	to	
follow	up	on	concerns	about	increased	risk	of	meningitis	and	cerebral	malaria	[108].		
	
Whole	sporozoite	vaccines	use	live-attenuated	sporozoites	that	stop	developing	before	
they	reach	the	erythrocytic	stage	or	the	use	of	drugs	to	kill	the	parasites	when	they	reach	
the	erythrocytic	stage.	Attenuation	either	involves	radiation-attenuated	sporozoites	which	
stop	maturing	at	random	points	of	early	liver	stage	development	or	targeted	gene	deletion	
[108].		Protection	seems	to	be	conferred	by	cytotoxic	CD8+	T	cells	[116]	with	rodent	studies	
showing	that	the	killing	of	infected	hepatocytes	requires	a	large	number	of	specialized	
liver-resident	memory	T	cells	[117,	118].	
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PfSPZ	is	the	first	purified,	aseptic	and	cryopreserved	radiation-attenuated	sporozoite	
vaccine	[108].	Giving	PfSPZ	intravenously	creates	a	strong	immune	response	in	humans.	
The	PfSPZ-specific	antibody	and	T	cell	responses	are	dose	dependent	[119].	Studies	in	non-
human	primates	show	a	PfSPZ-specific	CD8+	T	cell	responses	in	the	liver	[120].	
Unfortunately,	PfSPZ	does	not	elicit	a	sufficiently	strong	immune	response	when	injected	
subcutaneously	[120],	which	would	complicate	the	logistics	of	a	mass	immunization	
campaign.		
	
The	first	genetically	attenuated	pre-erythrocytic	vaccine	tested	was	a	p52-/p36-	knockout.	
In	one	of	the	5	volunteers	parasitemia	reached	detectable	levels	in	the	erythrocytes	
suggesting	insufficient	attenuation.	The	vaccine	did	induce	a	detectable	immune	response	
with	CPS	antibodies	detected	as	well	as	IFN-gamma,	multiple	antigenic	responses,	and	CD4	
and	CD8	cell	cytokine	production	detected	[121].	In	response	to	breakthrough	infections	
with	the	p52-	/p36-	vaccine	a	P52-/p36-/sap1−	is	being	developed.	The	P52-/p36-/sap1−	
stops	growth	during	liver-stage	development	and	a	study	with	10	volunteers	found	the	
vaccine	to	be	safe	but	efficacy	data	is	not	yet	available	[122].		Work	in	rodent	models	has	
found	that	halting	development	in	the	later	stages	of	liver	development	leads	to	a	more	
potent	and	diverse	immune	response	[123].	Work	replicating	this	in	humans	is	underway	
with	plasmei2	and	lisp2	P.	falciparum	knockouts	[124].		
	
The	use	of	wild-type	sporozoites	treated	with	chloroquine	has	also	been	tried	as	a	vaccine	
strategy.	This	allows	the	liver	stage	to	complete	but	kills	the	parasites	before	they	reach	
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symptomatic	levels	in	the	blood	[108].	This	strategy	results	in	strong	protection	against	a	
particular	strain	but	only	limited	protection	against	multiple	strains	[125-127].	
	
Liver-stage	subunit	vaccines	present	a	liver-stage	antigen	to	the	host	immune	system.	The	
most	well	tested	liver-stage	subunit	vaccine	uses	a	thrombospondin-related	adhesion	
protein	insert	into	ChAd63-MVA,	a	replication-deficient	viral	vector	vaccine	boosted	with	a	
modified	vaccinia	virus	[108].	A	controlled	human	malaria	infection	study	found	this	
vaccine	induced	sterile	immunity	21%	of	the	time	and	that	this	was	associated	with	a	
peripheral	CD8+	T	cell	response	[128].	A	study	on	adults	in	Kenya	found	that	it	reduced	the	
risk	of	infection	by	67%	for	a	short	period	of	time,	but	no	efficacy	was	found	in	a	study	in	
Senegal	[129,	130].		
	
Blood	stage	vaccines	have	mainly	focused	on	blocking	merozoite	invasion	and	have	not	
been	successful	because	they	have	not	been	able	to	produce	strain	transcending	antibody	
responses	[108].	Part	of	the	problem	may	be	that	merozoites	take	less	than	1	minute	to	
invade	with	some	invasion	antigens	being	exposed	for	just	a	fraction	of	that	time	because	
they	are	stored	in	organelles	[131].		
	
A	subunit	vaccine	that	uses	3	different	recombinant	variants	of	PfAMA1	has	been	shown	to	
produce	antibodies	in	human	volunteers	that	were	active	against	different	strains	[132].		A	
vaccine	with	PfAMA1	in	complex	with	its	protein	ligand	PfRON2	led	to	better	in	vivo	
protection	in	Aotus	monkeys	than	PfAMA1	on	its	own	in	humans	[133].	
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	Another	subunit	vaccine	in	development	uses	PfRH5,	a	highly	conserved	protein	essential	
for	invasion	[134].	This	vaccine	inhibits	invasion	in	vitro	and	in	Aotus	monkeys	[135].		The	
PfRH5	vaccine’s	protection	is	correlated	with	IgG	concentration	and	functional	activity	
[135].			
	
Studies	are	underway	to	develop	a	subunit	vaccine	capable	of	preventing	placental	malaria	
using	VAR2CS	[136].	Controlled	infections	with	drug	sensitive	strains	have	been	tried	in	
rodent	models	and	shown	to	be	protective	[137].	
	
Antimalarial	discovery	efforts	
Since	1999	the	paradigm	for	anti-malarial	drug	discovery	has	been	product	development	
partnerships.	Product	development	partnerships	are	collaborations	between	the	
pharmaceutical	industry	and	academic	researchers.	This	strategy	was	initiated	with	the	
creation	of	Medicines	for	Malaria	Venture	(MMV)	[138].	MMV	donates	compounds	with	
known	antimalarial	activity,	as	well	as	compounds	with	known	activity	against	other	
neglected	tropical	diseases.	MMV	requires	that	all	of	the	data	generated	about	the	
compounds	be	shared	openly	[139,	140].		
	
The	antimalarials	that	MMV	donates	were	screened	and	donated	by	GlaxoSmithKline,	
Novartis,	and	Saint	Jude.		These	three	entities	identified	20,441	compounds	with	anti-
malarial	activity	providing	a	broad	chemical	space	to	find	all	of	the	possible	ways	to	kill	
malarial	parasites	with	drugs	[139].	MMV	has	chosen	a	chemically	diverse	subset	of	these	
compounds	to	donate	for	academic	research	[139].		MMV-supported	research	has	led	to	the	
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identification	of	new	potential	antimalarial	compounds	such	as	translational	inhibitors	
[141]	and	a	compound	that	inhibits	thioredoxin	3	[142].		Most	of	the	inhibitors	now	in	
clinical	development	resulted	from	projects	supported	by	MMV.	MMV	compounds	
currently	in	phase	II	clinical	trials	are:	MMV	390048,	DSM265,	KAF156,	artefenomel,	and	
cipargamin.	The	MMV	compound	M57171	has	entered	phase	I	clinical	trials.		
	
Historically,	phenotypic	screening	is	the	most	common	way	to	identify	inhibitors	of	malaria	
growth,	which	leads	to	a	bias	towards	anti-blood	stage	drugs	[143].	This	is	a	problem	
because	while	case	management	is	important,	drugs	are	also	needed	to	block	transmission	
and	prevent	relapses	[144,	145].	Reducing	the	blood	stage	bias	by	improving	drug	assays	
against	the	other	stages	of	the	malarial	parasite	life-cycle	is	an	active	area	of	research	
[143].		
	
Target-based	approaches	are	another	way	to	identify	antimalarials	that	is	becoming	
increasingly	more	common	[146,	147].	What	separates	this	from	phenotypic	screens	is	that	
a	putative	target	is	identified.	Gene	knockout	studies	are	an	increasingly	common	way	of	
identifying	drug	targetable	genes	that	are	required	for	growth	[146,	147].	The	advent	of	
whole	genome	sequencing	allows	the	use	of	drug	pressure	to	identify	how	the	parasites	
evolve	in	response	to	a	drug.	Whole	genome	sequencing	provides	information	on	probable	
targets	and	resistance	mechanisms	[84].	Screens	using	enzyme	assays	are	also	used	once	a	
possible	drug	target	has	been	identified	[148].		
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Drugs	in	phase	I	clinical	development		
P218	is	a	DHFR	inhibitor	active	against	the	blood	stage	[149]	and	shows	good	activity	
against	quadruple	mutant	strains	(those	with	the	highest	resistance	to	the	DHFR	inhibitor	
pyrimethamine)	[148].		
	
CDRI	97/98	is	a	trioxane	with	activity	against	the	blood	stage	[138].	A	safety	study	with	50	
adult	volunteers	found	no	major	adverse	events	and	the	adverse	events	reported	showed	
no	dose	relationship	[150].	
	
M5717	inhibits	peptide	elongation	factor	2.	This	compound	is	active	against	the	blood,	pre-
erythrocytic	and	gametocyte	stages	[151].		
	
	
Drugs	in	phase	II	clinical	development	
Artefenomel	is	a	synthetic	endoperoxide	and	the	exact	mechanism	of	action	is	unknown	
[152].	This	drug	is	active	against	the	blood	stages	of	P.	falciparum	and	P.	vivax	with	a	
minimum	inhibitory	concentration	against	P.	falciparum	of	4.1	ng/mL	[153].	However,	
efficacy	was	only	78.6%	when	paired	with	piperaquine	and	failure	was	linked	to	the	K13	
resistance	mutation	[154].		
	
KAF156	is	an	imidazolopiperazine	with	an	unknown	mode	of	action	that	is	active	against	
blood	stage,	liver	stage,	and	gametocytes	[155,	156].	A	study	with	21	patients	reported	that	
KAF156	had	a	cure	rate	of	67%	and	caused	vomiting	[157].	Other	adverse	events	reported	
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include:	asymptomatic	bradycardia	and	mild	post-treatment	transaminitis	[157].	KAF156	
is	currently	being	tested	in	combination	with	lumefantrine	[138].	
	
Cipargamin	inhibits	PfATP4	[158]	and	causes	disruptions	to	Na+	homeostasis	[159].	
Cipargamin	shows	activity	against	P.	falciparum	and	P.	vivax	blood	stage	as	well	as	the	P.	
falciparum	sexual	stages	[160].	The	minimum	inhibitory	concentration	against	P.	
falciparum	is	0.126	ng/ml	[161].	Dose-related	gastrointestinal	and	genitourinary	adverse	
events	have	been	reported	[162].		
	
Fosmidomycin	inhibits	1-deoxy-D-xyulose	5-phosphate	reductoisomerase	in	the	
isoprenoid	biosynthesis	pathway.	This	drug	is	active	against	the	P.	falciparum	blood	stage	
[138].	In	a	study	with	9	human	volunteers	the	cure	rate	was	89%	[163].	When	paired	with	
piperaquine,	83	out	of	83	patients	were	cured	and	the	adverse	events	were	mild	to	
moderate	gastrointestinal	and	respiratory	track	symptoms	[164].		
	
DSM265	inhibits	PfDHODH	which	is	essential	for	pyrimidine	biosynthesis	[165].	DSM265	
has	an	elimination	half-life	of	86-118	hours	[166]	and	is	active	against	the	blood	and	liver	
stages	[165].		In	vitro	studies	suggest	evolution	against	DSM265	is	easy	(it	has	the	same	
resistance	rate	as	atovaquone)	[165].	
	
AQ-13	is	a	modified	4-aminoquinoline	that	is	active	against	blood	stage	P.	falciparum	and	P.	
vivax	[138].	Estimated	to	have	a	cure	rate	of	84.8%	[167].	Adverse	events	reported	for	this	
drug	are:	headache,	lightheadedness/dizziness	and	gastrointestinal	tract	symptoms	[168].		
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Methylene	Blue	inhibits	P.	falciparum	glutathione	reductase	preventing	heme	
polymerization	[138].	This	drug	is	active	against	P.	falciparum	blood	stage	and	gametocytes	
[169].	When	used	as	a	monotherapy,	it	has	a	16%	early	treatment	failure	rate	[170].	When	
paired	with	artesunate,	methylene	blue	has	a	62%	cure	rate,	and	when	paired	with	
amodiaquine	it	has	a	82%	cure	rate	[171].	There	is	ongoing	research	into	combining	
methylene	blue	with	artesunate-amodiaquine	to	create	a	triple	combination	therapy.	
Combining	methylene	blue	with	artesunate-amodiaquine	causes	vomiting	in	some	patients	
[169].		
	
Sevuparin	is	an	anti-adhesive	polysaccharide	that	blocks	merozoite	invasion	and	
sequestration	[172].	It	is	well	tolerated	with	no	adverse	events	reported	so	far	in	phase	I/II	
clinical	trials	[172].	Sevuparin	has	been	shown	to	decrease	rosetting	and	cytoadherence	to	
endothelial	cells	[173].		
	
MMV	390048	is	a	P.	falciparum	PI4K	inhibitor	that	kills	blood	stages	and	inhibits	
gametocytogenesis	and	oocyst	formation	[174].		
	
Drugs	in	phase	III	clinical	development		
Tafenoquine	was	in	phase	III	clinical	development	until	July	2018	when	it	was	approved	by	
the	Federal	Food	and	Drug	Administration	(FDA)	as	a	malaria	prophylactic	and	radical	cure	
for	P.	vivax	infection	[62].	It	should	not	be	used	by	humans	with	G6PD	deficiency	and	is	not	
recommended	for	humans	with	psychotic	disorders	[62].	Tafenoquine	has	a	half-life	of	2	
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weeks	[62].	This	long	half-life	makes	tafenoquine	a	good	prophylactic	drug.	When	used	
prophylactically	it	is	taken	3	days	prior	to	travel	and	then	weekly	and	once	more	after	
returning	[62].	The	long	half-life	also	allows	it	to	cure	an	infection	with	one	dose.	Side	
effects	include:	dizziness,	nausea,	vomiting,	headache,	and	clinically	insignificant	decreases	
in	hemoglobin	[62].		
	
	
Plasmodium	genome	
Sequencing	of	the	P.	falciparum	genome	commenced	in	1996	and	was	completed	in	2002	
[175].	The	genome	consists	of	14	chromosomes	and	as	of	September	2018	is	predicted	to	
code	for	5,712	genes.	Approximately	40%	of	the	predicted	genes	are	unannotated	due	to	
insufficient	sequence	similarity	to	annotated	sequences.		The	genome	is	approximately	22.8	
megabases	in	size	with	an	unusually	high	gene	density	at	greater	than	1	gene	per	4,338	bp	
[175].	The	genome	is	80.6%	ATs,	with	the	AT	content	in	non-coding	regions	reaching	87%	
and	in	the	coding	regions	reaching	70%.	This	skewed	AT	distribution	leads	to	uneven	
genome	coverage	during	sequencing	with	higher	coverage	in	the	coding	regions	and	lower	
coverage	of	the	highly	polymorphic	regions	containing	the	var,	rifin,	and	stevor	genes	
[176].	It	is	predicted	that	~10%	of	the	genome	is	targeted	to	the	apicoplast	[175].	
Consistent	with	its	parasitic	life-style,	the	genome	has	a	high	proportion	of	genes	for	
proteins	involved	in	immune	evasion	(3.9%)	and	encodes	a	low	number	of	enzymes	(14%)	
[175].		
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Comparative	analysis	of	multiple	Plasmodium	genomes	revealed	that	77%	of	genes	are	
orthologous	between	P.	falciparum,	P.	knowlesi,	P.	vivax,	and	P.	yoelii	yoelii	[177].	The	
synonymous	to	nonsynonymous	ratio	is	~2:1	in	P.	falciparum	which	is	a	lower	rate	than	
found	in	humans	(~3:1)	[178].	However,	85.5%	of	genes	in	P.	falciparum	contain	only	one	
or	two	SNPs	[178].	Proteins	that	are	extracellular,	and	hence	more	likely	to	come	into	
contact	with	the	host	immune	system,	are	encoded	by	genes	that	evolve	at	a	faster	rate	
than	genes	encoding	proteins	that	remain	intracellular	[177].		
	
Plasmodium	gene	regulation	
Four	different	gene	regulation	strategies	have	been	described	for	Plasmodium	[179]:	
1. Housekeeping:	genes	that	are	detectable	in	most	stages.	
2. Host-related	expression:	genes	that	change	expression	in	response	to	host	
environment.	
3. Strategy-specific	expression:	gene	expression	is	based	upon	the	type	of	activity.	
being	engaged	in	(the	same	activity	but	at	different	stages	or	different	hosts).	
4. Stage-specific	expression:	gene	expressed	during	only	one	developmental	stage.	
	
The	predominant	mechanism	for	gene	regulation	in	P.	falciparum	is	controversial.	
Preliminary	analysis	of	the	genome	suggested	that	regulation	of	transcription	was	not	the	
primary	mechanism	to	regulate	gene	expression.	The	genome	of	P.	falciparum	contains	just	
1/3	the	number	of	transcription	associated	proteins	typical	of	a	free	living	eukaryote	with	
enrichment	of	CCH-type	zinc	finger	protein	genes	which	are	commonly	involved	in	
regulating	mRNA	decay	and	translation	rates	[180].	One	study	found	a	weak	correlation	
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between	mRNA	and	protein	abundance	[181]	and	other	studies	have	found	delays	between	
transcription	and	translation	[182,	183].			
	
The	transcriptional	program	appears	to	be	largely	fixed	with	differences	in	life-cycle	
transcription	between	strains	appearing	to	be	limited	to	surface	antigen	genes	[184]	and	
the	parasites	do	not	seem	to	respond	transcriptionally	to	drug	pressure	[185].	However,	
for	most	genes	expression	seems	to	be	induced	“just-in-time”	for	when	the	protein	product	
is	needed	[186].	Further,	another	study	of	translational	efficiency	found	that	less	than	10%	
of	P.	falciparum	genes	display	a	disconnect	between	transcript	levels	and	translation	rates	
and	found	that	merozoite	egress	genes	were	over-represented	amongst	genes	with	a	
mismatch	between	timing	of	transcription	and	translation	[187].		Another	study	estimated	
that	~18%	of	genes	are	regulated	by	eQTLs	(expression	quantitative	trait	loci)	[188].		
	
	
	There	is	growing	evidence	that	chromatin	organization	associated	with	regulatory	
sequences	plays	a	role	in	regulating	transcription.	One	of	the	earliest	reports	of	a	
regulatory	sequence	affecting	gene	expression	was	the	discovery	of	a	motif	linked	to	the	
expression	of	heat	shock	proteins	[189].	While	P.	falciparum	has	an	unusually	small	
number	of	transcription	factors	for	its	genome	size,	transcription	factor-binding	
specificities	are	correlated	with	functional	annotations	[190].	These	regulatory	sequences	
are	likely	linked	to	the	types	of	chromatin.	The	heterochromatin	marker	H3K9me3	appears	
to	play	a	role	in	regulating	antigenic	variation	genes	and	is	only	found	in	the	subtelomeric	
regions	(where	the	antigenic	variation	genes	tend	to	cluster)	and	in	discrete	patches	
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intrachromasomally	associated	with	antigenic	variation	genes	[191,	192].		The	var	
antigenic	variation	genes	in	particular	are	also	enriched	for	heterochromatin	marker	HP1,	
which	is	also	found	in	the	subtelomeric	non-coding	regions	[193].		
	
Most	genes	have	been	found	to	be	enriched	for	H3K4me	and	H3K9ac	with	highly	active	
genes	enriched	for	H3K4me3	and	H3K9ac	on	the	5’	end	[191].	H3K9ac	is	correlated	with	
transcription	levels	and	H3K4me3	is	linked	to	stage-specific	gene	expression	but	is	not	
correlated	with	expression	level	[194].	These	histones	are	packaged	into	nucleosomes,	
which	tend	to	be	located	around	the	transcription	start	site	as	well	as	splice	acceptor	and	
donor	sites	with	the	organization	not	correlated	with	transcription.	However,	the	upstream	
region	of	active	transcription	start	sites	tend	not	to	be	in	nucleosomes	[195,	196].		The	
nucleosome	occupancy	of	genomic	sequences	changes	throughout	the	intraerythrocytic	
cycle	[197]	suggesting	that	the	accessibility	of	the	sequence	upstream	of	the	transcription	
start	site	regulates	transcription	rates.		
	
The	histone	H2A.Z	seems	to	be	the	marker	that	denotes	the	intergenic	regions	[194].	H2A.Z	
as	well	as	the	histone	H2B.Z	are	enriched	in	promoter	regions	[194].	The	preferred	
localization	of	H2A.Z	to	the	intergenic	regions	may	result	from	the	extreme	AT	richness	of	
the	intergenic	regions	compared	to	the	intragenic	regions	(87%	vs.	70%)	[194].			
	
The	3-dimensional	organization	of	the	genome	plays	a	role	in	regulating	gene	expression	
and	is	likely	a	by-product	of	the	chromatin	organization.	There	is	no	correlation	between	
gene	expression	and	the	linear	organization	of	the	chromosomes	[186].	However,	genes	
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that	cluster	together	in	3-dimensional	space	do	have	correlated	gene	expression	and	the	3-
dimensional	organization	of	the	genome	changes	throughout	the	intraerythrocytic	life-
cycle	[198].		Suppression	of	gene	expression	is	associated	with	co-localization	with	the	
subtelomeric	centers	[198].	
	
Plasmodium	mitochondria	
During	the	asexual	stages,	93%	of	the	parasites’	ATP	comes	from	aerobic	glycolysis	[199].	
Despite	the	inefficiency	of	aerobic	glycolysis,	this	is	the	primary	means	of	ATP	production	
for	rapidly	dividing	cells	such	as	in	cancer	and	malarial	parasites	during	the	asexual	stages	
[200].	While	some	strains	are	more	dependent	upon	a	working	mitochondrial	electron	
transport	chain	than	others	[201],	ATP	synthase	is	nonessential	during	the	asexual	stages.	
This	indicates	that	oxidative	phosphorylation	is	not	necessary	to	meet	the	energy	
requirements	of	the	asexual	stage.	A	functioning	mitochondrial	electron	transport	chain	is	
essential	in	the	gametocyte	stages	likely	reflecting	the	lower	glucose	availability	in	the	
mosquito	host	[202].		
	
Mitochondrial	structure	
The	different	energy	requirements	between	the	asexual	and	sexual	stages	are	evident	by	
changes	in	mitochondrial	copy	number	and	structure.	During	the	asexual	stage	there	is	just	
a	single	mitochondrion,	while	during	the	gametocyte	stage	there	is	between	4	and	8	
mitochondria	[203].	During	the	gametocyte	stage	there	are	also	more	electron-dense	
cristae,	which	are	associated	with	the	presence	of	ATP	synthase	[203].		
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Mitochondrial	genome	
The	mitochondrial	genomes	of	Plasmodium	are	~6kb,	making	them	the	smallest	known	
mitochondrial	genomes	[204].	The	mitochondrial	genome	contains	tandemly	repeated	
linear	elements	[205]	and	only	encodes	3	genes:	cox1,	cox3,	and	cytochrome	b	[204,	206].	
The	ordering	of	the	genes	and	the	repeats	on	the	chromosome	are	identical	in	all	
Plasmodium	with	90%	sequence	identify	between	P.	falciparum,	P.	vivax,	P.	yoelli,	and	P.	
gallinaceum	[204,	207].	The	mitochondrial	proteins	coded	by	the	nuclear	genome	are	
targeted	to	the	mitochondria	using	a	presequence	or	transmembrane	domains	[206].	
Nuclear	encoded	mitochondrial	proteins	are	imported	into	the	mitochondria	using	TOM	
and	TIM	complexes	[206].		
	
Mitochondrial	inheritance	and	replication	
The	mitochondrial	genome	of	P.	falciparum	is	inherited	uniparentally	through	the	maternal	
line	[208,	209].	During	the	schizont	stage	the	mitochondria	forms	a	branched	structure	that	
segments	into	multiple	mitochondria	during	cytokinesis	[206].	There	are	~20	copies	of	the	
mitochondrial	genome	per	cell	with	most	of	them	being	linear,	but	a	few	circular	copies	are	
present	as	a	result	of	recombination	[210].	There	is	evidence	that	not	all	of	these	copies	are	
identical,	resulting	in	mitochondrial	heteroplasmy	within	individual	parasites	[211,	212].	
Replication	of	the	mitochondrial	genome	occurs	at	the	same	time	as	nuclear	DNA	
replication	and	is	thought	to	occur	using	a	recombination	dependent	process	that	could	
allow	beneficial	mutations	to	rapidly	spread	in	a	population	despite	the	uniparental	
inheritance	[210].		
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Mitochondrial	metabolism		
The	primary	role	of	the	mitochondria	during	the	asexual	stage	is	the	regeneration	of	
ubiquinone	and	the	maintenance	of	the	membrane	potential,	so	that	DHODH	can	synthesize	
pyrimidine	precursors	since	Plasmodium	lack	a	pyrimidine	salvage	pathway	[76].	DHODH	
is	thought	to	localize	to	the	inner	membrane	of	the	mitochondria	[206],	where	it	performs	
the	rate	limiting	step	of	pyrimidine	synthesis	of	converting	dihydroorotate	to	orotate,	
which	requires	ubiquinone	to	be	an	electron	acceptor	[213].	The	drug	atovaquone	inhibits	
the	production	of	pyrimidines	by	preventing	cytochrome	b	from	oxidizing	ubiquinol	to	
ubiquinone,	which	prevents	cytochrome	b	from	acting	as	an	electron	sink	for	DHODH.	The	
experimental	drug	DSM265	directly	inhibits	DHODH	[165].			
	
Methods	to	study	resistance	
Goals	
Problems	associated	with	resistance	include:	early	treatment	failure,	recurrent	malaria,	
anemia,	increased	transmission	and	mortality	and	increased	healthcare	expenditure	[214].	
Identifying	when	resistance	is	spreading	allows	the	changing	of	treatment	strategies	or	
drugs	before	there	are	increases	in	mortality	[215].	Surveillance	efforts	also	identify	
treatment	failures	or	delayed	clearance	due	to	factors	other	than	resistance	that	need	to	be	
addressed	such	as	inadequate	dosing	or	poor	quality	drugs	[216].	Understanding	the	
mechanisms	of	drug	resistance	helps	determine	the	optimal	combinations	to	use	
(especially	since	some	drugs	have	incompatible	resistance	mechanisms)	[216],	reveal	
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cross-resistance	mechanisms,	predict	how	resistance	will	evolve	to	new	drugs,	and	identify	
new	targets	[216].	
	
Relevant	data	
There	are	4	categories	of	data	relevant	to	monitoring	drug	resistance	[214]:	
1. Clinical	efficacy:	measuring	how	effective	the	drug	is	at	relieving	symptoms	and	
reducing	parasitemia.	
2. In	vitro	sensitivity:	measuring	the	response	of	parasites	isolated	from	patients	in	
vitro.	Making	in	vitro	studies	comparable	requires	the	use	of	standard:	culture	
conditions,	time	of	incubation,	starting	parasite	density	and	hematocrit.	
3. Pharmacological	responses:	identifying	treatment	failures	or	delayed	clearance	
caused	by	poor	quality	drugs	or	dosing	problems.	Identifying	poor	quality	drugs	or	
dosing	problems	is	important	since	treatment	failures	may	result	from	drug	
concentrations	not	reaching	therapeutic	levels.	This	monitoring	is	also	critical	
because	when	antimalarial	drugs	are	first	used	in	the	population	there	are	often	not	
adequate	measures	of	absorption,	distribution,	metabolism	or	excretion	in	high	risk	
groups	such	as	infants,	pregnant	women,	the	malnourished	or	HIV	positive	humans.	
4. Molecular	markers	of	resistance:	identification	of	SNP	or	copy	number	changes	
associated	with	resistance.	When	good	molecular	markers	are	known,	this	approach	
is	faster	and	cheaper	than	clinical	efficacy	studies	[217,	218].	
Efficacy	studies	
The	primary	outcomes	of	in	vivo	efficacy	studies	in	humans	are	how	quickly	the	parasite	
population	declines	and	the	prevention	of	fever	from	recurrent	infection.	The	treatment	is	
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considered	successful	as	long	as	fever	does	not	return,	even	if	there	is	persistent	or	
recurrent	parasitemia	[219].		Even	if	the	treatment	is	successful,	a	trend	towards	delayed	
clearance	suggests	the	evolution	of	resistance.		
	
The	interpretation	of	results	from	in	vivo	human	studies	can	be	complicated	by:	poor	
patient	compliance,	variation	in	how	the	drug	is	absorbed,	secreted,	and	metabolized	by	
patients,	the	overall	health	and	nutritional	status	of	patients,	the	local	re-infection	rate,	the	
complexity	of	the	resistance	phenotype,	pre-existing	immunity,	and	the	initial	parasitemia	
at	the	time	of	treatment	[219,	220].	In	vitro	drug	screens	of	patient	isolates	overcome	these	
difficulties	[219,	220].	
	
In	vitro	studies	allow	for	measuring	the	level	of	resistance	to	the	individual	drugs	in	a	
combination	therapy	and	also	allows	for	the	identification	of	small	differences	in	
susceptibility;	since	there	are	fewer	variables	in	vitro	compared	to	studies	in	patients	
[214].		
	
Despite	the	advantages	of	in	vitro	studies	there	are	a	number	of	limitations.	This	method	
requires	a	cold-chain	to	cryopreserve	parasites	during	transport	from	the	field	site	to	the	
lab	[220].	The	presence	of	mixed	genotypes	in	patients	can	complicate	the	interpretation	of	
in	vitro	efficacy	studies	[220].	It	is	also	possible	to	select	out	or	lose	the	resistant	strain	
during	adaptation	to	culture	[219,	220].	The	sample	collection	process	is	biased	towards	
adults	with	high	parasitemia	[220].	It	is	difficult	to	link	in	vitro	IC50	values	to	treatment	
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failure	due	to	the	large	number	of	confounding	variables	associated	with	treatment	of	
patients	[220].		
	 	
Identification	of	molecular	markers	
The	in	vitro	evolution	approach	exposes	parasite	cultures	to	drug	pressure	to	see	how	the	
parasite	evolves	resistance.	This	approach	has	been	successfully	used	to	identify	resistance	
mechanisms	as	well	as	drug	targets	[84].	The	strain	used	in	these	studies	is	important	since	
different	strains	show	different	propensities	to	evolve	resistance	[221].	The	same	gene	
involved	in	resistance	in	the	field	maybe	identified	but	with	a	different	mutation.	Since	
there	is	less	selective	pressure	in	the	lab	the	mutation	most	beneficial	in	the	lab	may	not	be	
the	optimal	mutation	in	the	field	[222].	
	
The	use	of	in	vivo	models	to	study	the	evolution	of	drug	resistance	typically	uses	a	rodent	
malaria	(P.	yoelii,	P.	chabaudi,	P.	vinckei,	or	P.	berghei)	[218].	The	mouse	models	sometimes	
diverge	in	resistance	mechanisms	such	as	the	of	response	P.	chabaudi	to	chloroquine	[223].	
The	rodent	malaria	response	to	arteminsins	also	appears	to	differ	[224,	225].	Rodent	
malaria	models	have	faithfully	recapitulated	the	P.	falciparum	response	to	atovaquone,	
mefloquine,	and	pyrimethamine	[218].	
	
The	candidate	gene	approach	involves	looking	for	association	between	genes	that	have	
either	homology,	or	other	information	suggesting	involvement	in	resistance.	If	the	gene	
target	is	known	it	can	be	directly	tested	for	polymorphisms	or	amplifications	[226,	227],	or	
in	the	case	of	mdr1	is	known	to	mediate	drug	resistance	in	other	organisms	[228].	
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Genetic	crossing	involves	crossing	resistant	and	sensitive	clones	and	linking	changes	in	the	
genome	to	the	drug	response.	Combining	genetic	crosses	with	linkage	mapping	was	used	to	
identify	the	mechanism	of	chloroquine	and	pyrimethamine	resistance	[53,	229,	230].	
Genetic	crosses	can	also	be	used	to	identify	quantitative	trait	loci	(QTL)	involved	in	drug	
resistance	[220,	231].	Identifying	genes	involved	in	resistance	with	this	method	can	be	
difficult	and	time	consuming	because	the	identified	regions	are	often	large	and	contain	
many	genes.	
	
Genomic	epidemiology	is	similar	to	genetic	cross	analysis	but	involves	looking	for	genetic	
associations	with	drug	resistance	from	parasites	taken	from	patients.		In	this	approach	
conserved	polymorphisms	are	sequenced	to	identify	haplotype	blocks	which	are	a	
collection	of	polymorphisms	that	tend	to	segregate	together	during	recombination	[218].	
Once	a	region	of	interest	has	been	identified	a	more	targeted	sequencing	approach	is	used	
to	identify	the	specific	genes	involved.	The	same	variables	that	can	confound	in	vivo	efficacy	
studies,	are	also	potential	confounders	of	genomic	epidemiology	studies	to	identify	
resistance	markers.	
	
Methods	to	confirm	a	gene’s	involvement	in	drug	resistance	include	ecological	studies,	
clinical	trials	and	allelic	exchange.	Ecological	studies	determine	if	putative	resistance	alleles	
become	more	common	in	a	population	experiencing	drug	pressure	[232-234].	Clinical	trial	
confirmation	evaluates	the	effect	of	the	putative	resistance	mutation	on	treatment	
response	[101,	235-238].			Allelic	exchange	replaces	a	sensitive	allele	with	a	putative	
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resistance	allele	to	examine	if	the	putative	resistance	allele	increases	resistance	to	the	drug.	
This	approach	has	traditionally	been	difficult	to	apply	in	malaria	research	because	genomic	
integration	is	not	efficient	in	P.	falciparum	[218].	To	overcome	this	limitation,	episomes	
have	been	used	[218].	More	recently	CRISPR	and	zinc	finger	editing	have	been	successfully	
employed	to	confirm	the	role	of	resistance	alleles	[103,	104].	
	
The	study	of	artemisinin	resistance		
The	first	hint	of	artemisinin	resistance	came	from	delayed	clearance	in	patients	in	western	
Cambodia,	but	it	was	not	clear	that	this	delayed	clearance	was	due	to	heritable	resistance	
since	the	phenotype	could	not	be	confirmed	using	the	traditional	48	hour	in	vitro	assay	
[239].	Analysis	of	polymorphisms	confirmed	that	the	delayed	clearance	was	heritable	
[240].	Clinical	trial	data	revealed	that	the	clearance	half-life	of	infections	in	western	
Cambodia	steadily	increased	between	2001	and	2010	with	the	percent	of	the	clearance	
half-life	attributable	to	parasite	genetics	increasing	from	30%	to	66%	[241].	Genomic	
epidemiology	studies	on	parasites	collected	from	patients	identified	a	region	on	
chromosome	13	associated	with	delayed	clearance	and	evidence	of	a	recent	selective	
sweep	[101,	237,	242].	In	2014	an	in	vitro	drug	selection	study	identified	changes	in	K13	
associated	with	resistance	and	confirmed	that	specific	K13	alleles	in	the	propeller	and	
BTB/POZ	domains	are	significantly	associated	with	increased	clearance	half-life	and	that	
these	alleles	increased	in	western	and	southeastern	Cambodia	between	2001	and	2012	
[101,	102,	237,	238,	242,	243].	Allelic	exchange	experiments	confirmed	in	vitro	that	K13	
confers	resistance	to	arteminsins	[103,	104].	By	2016	treatment	failure	rates	in	the	Pursat	
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region	of	Cambodia	reached	46%	and	there	were	reports	that	resistant	strains	were	
present	in	Thailand,	Laos,	and	Vietnam	[90,	91].		
	
The	arteminsin	resistance	mechanism	is	associated	with	halting	parasite	development	at	
the	ring	stage	in	response	to	treatment	[85,	93,	244].	The	ring	stage	is	less	susceptible	to	
artemisinin	[85,	93,	244].	Treatment	with	artesunate	is	reported	to	cause	an	entry	into	a	
latent	developmental	state	via	PK4	phosphorylation	of	eIF2alpha	[245].	A	transcriptome	
study	of	clinical	isolates	with	delayed	clearance	shows	an	up-regulation	of	the	protein	
folding	response,	down-regulation	of	the	DNA	replication	machinery	and	delayed	
progression	out	of	the	ring	stage	[99].	A	in	vitro	drug	selection	study	showed	resistant	
parasites	with	altered	gene	expression	in	oxidative	stress,	protein	damage,	and	cell	cycle	
pathways,	but	without	a	change	in	the	k13	allele	[100].	In	vivo	selection	studies	using	a	
rodent	malaria	produced	resistant	strains	but	with	an	unclear	connection	to	the	drug	
resistance	mechanism	to	the	P.	falciparum	resistance	mechanism	[224,	225].		
	
Computational	methods	to	study	malaria	
Gene	identification	
The	first	step	of	genome	annotation	is	identifying	the	length	and	structure	of	genes.	There	
are	many	programs	available	for	gene	identification.	The	annotation	of	the	P.	falciparum	
genome	relied	upon	several	programs	[175]	which	used	an	ab	initio	approach	to		gene	
identification.	The	basic	methodology	of	ab	initio	gene	identification	is	to	use	
experimentally	verified	genes	to	train	a	scoring	algorithm,	usually	a	variation	of	a	hidden	
Markov	model	or	neural	network	to	compute	a	score	reflective	of	the	probability	of	a	
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nucleotide	being	part	of	an	intergenic	region,	an	exon,	or	an	intron.	The	score	for	a	
nucleotide	is	based	on	the	nucleotide	composition	and	sequence	upstream	of	the	
nucleotide.	The	output	of	the	scoring	algorithm	is	fed	into	a	dynamic	programming	
algorithm	to	find	the	highest	scoring	gene	models	(combinations	of	exons,	introns,	and	
intergenic	regions)	for	the	input	sequence	(typically	a	chromosome)	[246-251].	Newer	
approaches,	developed	since	the	publication	of	the	P.	falciparum	genome	allow	the	
identification	of	genes	via	the	alignment	of	transcripts	from	an	RNA-seq	experiment	or	by	
projecting	the	annotations	of	a	closely	related	species	onto	the	genome	[252].	
	
Gene	Annotation	
Gene	annotations	are	assigned	based	on	the	predicted	protein	sequence.	There	are	
different	types	of	annotations,	but	all	of	them	follow	from	the	protein	sequence.	Domains	
are	conserved	sequences	that	fold	independently	of	the	rest	of	the	protein	and	perform	a	
specific	function.	The	same	domain	can	be	found	in	different	proteins	and	in	different	
species	and	provides	clues	about	a	proteins	function.	Standardized	enzyme	commission	
numbers	can	be	assigned	to	an	enzyme.	If	a	protein	is	an	enzyme	the	enzyme	commission	
number	indicates	the	function	of	the	enzyme	with	varying	levels	of	specificity	depending	
upon	how	much	is	known	about	the	protein	function	[253].	The	metabolic	pathways	in	
which	a	protein	participates	can	also	be	assigned	via	a	KEGG	accession	number	[254].	The	
most	comprehensive	annotation	a	gene	can	be	assigned	is	in	gene	ontology	terms.	Gene	
ontology	is	a	set	of	annotations	that	encompass	all	of	the	3	previous	annotations.	There	are	
3	gene	ontology	categories:	
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1. Biological	process	“is	a	collection	of	molecular	events	with	a	defined	beginning	
and	end”	[255].	
2. Molecular	function	is	how	the	gene	contributes	towards	a	biological	process.	For	
example,	the	gene	product	may	be	an	enzyme	or	a	structural	component.	
3. Cellular	location	is	where	the	gene	product	is	performing	its	molecular	function.	
Being	able	to	identify	or	predict	the	location	of	a	protein	provides	important	
clues	about	its	function.	
	
The	terms	used	to	define	gene	ontologies	are	rigorously	defined	and	applicable	across	
species.	They	are	organized	in	an	acyclic	graph	structure	so	that	terms	can	have	sub-terms	
[256].	For	example,	a	set	of	genes	may	be	annotated	with	very	specific	terms	involved	in	
DNA	replication	and	because	of	the	graph	structure	these	genes	can	be	computationally	
linked	together	as	being	related	to	one	another	using	a	program	that	was	designed	to	read	
the	gene	ontology	graph	structure.	This	allows	the	identification	of	processes,	functions,	or	
cellular	locations	that	show	consistent	changes	in	an	experiment	form	a	long	list	of	genes.		
	
Assigning	the	above	annotations	to	genes	requires	the	use	of	different	computational	tools,	
depending	upon	the	annotation.	Protein	domains	are	typically	identified	using	a	tool	like	
InterProScan,	which	integrates	information	from	different	sources	on	protein	families,	
domains	and	functional	sites	[257-259].		
	
Protein	sequences	may	contain	localization	sequences	that	help	target	the	protein	to	a	
particular	location	such	as	the	ER,	mitochondria,	or	other	organelles.	These	localization	
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sequences	are	not	well	conserved	but	are	located	on	the	N-terminal	and	have	
compositional	biases	that	allow	for	localization	predictions	[260].	There	are	2	general	
methodologies	for	predicting	protein	localization:	
1. Ab	initio	methods	only	take	the	protein	sequences	as	input.	Within	this	group	of	
methods	there	are	2	approaches.	One	makes	the	prediction	based	only	on	the	
sorting	signal	sequence	on	the	N-terminal	end	and	the	other	makes	the	
prediction	by	analyzing	the	whole	protein	sequence	[260].	
2. The	other	group	of	methods	considers	information	other	than	the	sequence	or	
combines	the	sequence	information	with	other	information.	Other	sources	of	
information	that	have	been	used	to	predict	protein	localization	include:	
expression	levels,	phylogenetic	profiles,	keywords	used	to	describe	proteins	in	
databases,	and	gene	ontology	annotation	[260].	
	
Two	programs	were	used	to	annotate	protein	localization	for	the	initial	annotation	of	the	P.	
falciparum	genome.	Transmembrane	Hidden	Markov	Model	(TMHMM)	was	used	to	identify	
transmembrane	proteins.	TMHMM	uses	a	hidden	Markov	model	to	predict	whether	or	not	a	
protein	is	a	transmembrane	protein	[261].	The	other	program	used	was	SignalP,	which	
uses	a	neural	network	and	hidden	Markov	model	to	predict	secreted	proteins	[262].		Later,	
an	algorithm	was	developed	to	predict	protein	targeting	to	the	apicoplast	organelle	[263].	
	
The	best	way	to	assign	annotations	is	by	identifying	orthologs	in	other	species	that	are	
already	well	annotated.	The	simplest	way	to	do	this	is	by	performing	BLAST	and	FASTA	
sequence	searches,	which	is	the	approach	initially	taken	to	annotate	the	P.	falciparum	
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genome.		Additional	annotations	were	predicted	using	a	more	sophisticated	ortholog	
detection	tool	named	OrthoMCL.	OrthoMCL	is	based	on	reciprocal	BLAST	hits,	but	uses	a	
Markov	clustering	algorithm,	which	simulates	a	random	walk	in	a	similarity	network,	to	
integrate	information	from	more	than	2	species	at	a	time.	This	increases	the	probability	of	
linking	a	gene	of	unknown	function	with	an	annotated	gene	in	another	species	while	also	
decreasing	the	probability	of	spuriously	linking	genes	based	upon	the	presence	of	
promiscuous	domains	[264-266].	
	
Obtaining	data	with	Illumina	next	generation	sequencing	
Next	generation	sequencing	is	a	methodology	to	obtain	large	numbers	of	either	genomic	or	
transcriptomic	reads	relatively	cheaply	[265].	The	Illumina	methodology	requires	
sequences	to	be	randomly	broken	up	and	then	immobilized	onto	a	solid	surface.	These	
template	sequences	are	then	amplified	to	form	clusters	using	a	PCR	reaction.	The	reverse	
strand	is	removed	and	re-sequenced	using	nucleotides	with	fluorescent	dyes	on	their	3’	
ends.	After	the	fluorescence	for	a	cluster	is	recorded	the	fluorescent	dye	is	cleaved	off	and	
washed	away	and	a	new	round	of	nucleotide	incorporation	occurs.	This	continues	until	the	
library	is	the	required	size.	The	library	size	is	restricted,	because	errors	start	to	accumulate	
through	bases	not	being	incorporated	during	a	cycle,	multiple	bases	being	incorporated,	or	
a	base	being	incorporated	without	dye	[267].		
	
In	the	original	methodology	only	the	forward	strand	was	sequenced	[267,	268].	This	
method	is	still	the	best	method	for	sequencing	small	RNAs	but	has	been	largely	supplanted	
by	paired-end	sequencing	[267,	268].	In	paired-end	sequencing	both	ends	of	the	DNA	
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fragment	are	sequenced	[267,	268].	This	works	by	sequencing	the	reverse	strand	after	
sequencing	of	the	forward	strand	is	completed.	Paired-end	sequencing	allows	for	more	
accurate	alignments	and	the	detection	of	indels	[267,	268].	PCR	duplicates	can	be	detected	
by	identifying	differential	read-pair	spacing	[267,	268].	The	paired-end	method	also	results	
in	twice	the	amount	of	data	for	the	same	amount	of	lab	work	[267,	268].		
	
Genomic	analysis	
Having	a	sequenced	genome	provides	the	gene	repertoire	of	an	organism,	which	greatly	
aids	in	the	identification	of	possible	drug	and	vaccine	targets.	By	allowing	comparative	
genome	comparisons	pathogen-specific	genes	can	be	identified	that	can	be	targeted	by	
drugs	with	low	risk	of	toxicity	to	the	host.	Knowing	the	gene	repertoire	allows	the	
computational	prediction	of	the	metabolic	pathways	of	an	organism	to	identify	potential	
weak	points	in	the	parasites	metabolism	that	can	be	exploited	[269,	270].			
	
Having	a	reference	genome	aids	genome	sequencing	efforts.	An	assembled	genome	can	
provide	a	reference	for	new	genomes	greatly	reducing	the	computational	cost	of	
assembling,	storing	and	analyzing	the	new	genomes.	This	has	allowed	the	identification	of	
conserved	polymorphisms	that	can	be	used	in	genomic	epidemiological	studies	to	trace	the	
origins	and	spread	of	drug	resistance	via	linkage	disequilibrium	analysis	[101,	102,	237,	
238,	242,	243,	271].	By	making	it	easier	to	assemble	and	analyze	the	whole	genome	
sequencing	of	other	strains	the	diversity	of	potential	vaccine	targets	can	be	assessed	[272].		
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The	analysis	of	genomes	typically	involves	identifying	differences	from	a	reference.	The	
GATK	tool	HaplotypeCaller	is	used	to	identify	possible	SNPs	and	indels	with	respect	to	a	
reference.	HaplotypeCaller	does	not	have	a	very	stringent	cutoff	for	filtering,	but	provides	a	
variety	of	measures	to	filter	on	[273]:	
• ReadPosRankSum	is	a	measure	of	position	bias	in	the	reads	supporting	an	alternate	
allele.	This	is	important	to	consider	since	sequencing	quality	tends	to	decline	
towards	the	end	of	a	sequence.	
• QUAL	is	a	measure	of	the	confidence	that	there	is	variation	at	a	site.	This	measure	
has	a	tendency	to	be	biased	by	sequencing	depth	and	so	is	normalized	by	
sequencing	depth	to	produce	the	QualitybyDepth	score.	
• MappingQualityRankSum	is	a	measure	of	the	bias	in	mapping	quality	between	reads	
supporting	the	reference	and	alternate	alleles.	
• FilteredDepth	is	the	number	of	reads	covering	a	site	that	passed	the	internal	quality	
control	metrics	of	HaplotypeCaller.	
	
After	the	potential	variants	have	been	identified	the	SNPs	and	indels	need	to	be	separated	
since	they	will	have	different	filtering	criteria.	There	are	two	general	approaches	to	
filtering	[274].	The	first	is	hard-filtering	which	involves	applying	the	same	set	of	standards	
to	each	potential	variant	in	all	of	the	samples.	A	modeling	based	approach	called	Variant	
Quality	Score	Recalibration	(VQSR)	can	also	be	used.	The	modeling	approach	should	be	
used	when	possible	because	the	metrics	of	a	good	call	vary	between	datasets	and	alleles.	
The	VQSR	approach	uses	machine	learning	algorithms	to	predict	high	quality	measures	by	
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using	known	polymorphisms	as	a	training	set.	These	predictions	are	used	to	set	the	
filtering	cut-off	criteria	[273].		
	
Once	the	datasets	have	been	filtered,	they	can	be	run	through	a	variation	identification	
program	such	as	SnpEff	[275]	to	make	predictions	about	the	effect	of	the	observed	change.	
The	annotations	are	based	on	the	location	of	the	change	(intronic,	untranslated	region,	
upstream,	downstream,	splice	site,	and	intergenic	regions).	If	protein	sequences	are	
provided,	SnpEff	can	report	the	effect	on	the	protein	sequence.		
	
The	identification	of	copy	number	variation	is	also	frequently	required	when	analyzing	
genomes.	There	are	5	general	strategies	to	identify	copy	number	variations	(CNVs)	from	
next	generation	sequencing	data	[276]:	
1. The	paired-end	mapping	approach	identifies	break	points	by	looking	for	regions	
where	there	are	large	distances	between	the	mapping	locations	on	the	reference	
genome	of	paired-reads.	This	approach	does	not	work	if	the	insertion	size	is	
larger	than	the	average	insert	size	and	cannot	detect	CNVs	in	low-complexity	
regions.		
2. The	split	read	approach	identifies	break	points	by	finding	paired	reads	where	
one	read	aligns	to	the	reference	and	the	other	either	does	not	align	or	aligns	
poorly.	This	approach	only	works	if	unique	segments	of	the	genome	are	involved	
in	the	CNV.		
3. The	read	depth	approach	analyzes	the	read	counts	mapped	to	a	location	with	the	
assumption	that	the	depth	of	coverage	is	correlated	with	the	CNV	number.	This	
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approach	does	not	identify	break	points	and	does	not	work	well	on	CNVs	less	
than	1	kb.	
4. The	de	novo	assembly	approach	involves	assembling	the	raw	reads	into	contigs,	
which	are	overlapping	DNA	segments	that	represent	a	region	of	genomic	DNA.	
These	contigs	are	checked	for	inconsistencies	with	the	reference.	This	approach	
is	computationally	expensive	and	does	not	handle	repeats	or	duplicated	regions	
well.	
5. Combination	approaches	use	some	combination	of	the	above	4	approaches.	
	
Due	to	the	low	sequence	diversity	of	the	P.	falciparum	genome	read	depth	based	
computations	are	used	to	detect	CNVs	[84].	
	
Genome	changes	of	interest	should	at	least	be	verified	by	manually	examining	the	raw	
reads	at	the	locations	of	interest	using	a	genome	browser	and	possibly	by	PCR	verification	
as	well.		
	
	
Transcriptomics		
The	field	of	transcriptomics	utilizes	the	transcript	level	measurements	of	a	sample.	The	
foundational	work	of	understanding	malaria	transcriptomes	was	performed	using	
microarrays	[184,	186].	Studies	of	malarial	transcriptomes	contributed	to	our	
understanding	of	drug	resistance	mechanisms	and	have	helped	identify	new	potential	drug	
and	vaccine	targets	[277-279].		
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The	study	of	the	malarial	transcriptome	is	shifting	towards	using	RNA-seq.	RNA-seq	has	
several	benefits	over	microarrays	such	as	the	identification	of	novel	isoforms	and	
alternative	splicing	and	digital	transcript	expression	measurements	allows	for	a	finer	
resolution	picture	of	expression	levels	and	a	greater	ability	to	detect	differential	expression	
which	has	proven	difficult	in	P.	falciparum.	
	
Obtaining	transcript	expression	level	measurements	using	next	generation	sequencing	
follows	the	general	next	generation	sequencing	workflow	outline	described	above	with	the	
exception	that	the	starting	material	is	RNA	and	ribosome	depletion	must	be	performed.		
Isolation	or	enrichment	steps	can	be	performed	to	obtain	either	mRNA,	small	RNA,	
noncoding	RNA	or	microRNA.	Following	isolation	the	RNA	is	converted	to	cDNA	and	the	
general	Illumina	sequencing	steps	are	followed	[267].			
	
If	a	reference	genome	is	present,	the	obtained	transcripts	are	aligned	to	the	genome	using	a	
tool	such	as	HISAT2,	which	can	handle	alternative	splicing	[280].		After	the	reads	have	been	
aligned	to	the	genome,	they	are	assembled	into	transcripts	using	either	Cufflinks	or	
StringTie	[281,	282].	Then	the	quantification	levels	of	the	transcripts	are	estimated,	
typically	at	the	gene	level	but	the	expression	levels	of	individual	isoforms	can	also	be	
estimated.	Programs	that	can	perform	expression	level	quantification	include	
FeatureCounts	and	Cuffquant	[281,	283].	The	two	variables	that	affect	abundance	
estimation	of	a	transcript	are	the	length	of	the	transcript	and	the	number	of	reads	
sequenced.	Therefore	abundance	levels	need	to	be	normalized	to	account	for	the	transcript	
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length	and	the	number	of	reads	sequenced	in	the	experiment.	The	TMM	normalization	
procedure	also	corrects	for	changes	in	the	RNA	population	composition	[284,	285].		
	
The	most	common	analysis	of	an	RNA-seq	dataset	is	the	identification	of	differentially	
expressed	genes.	There	are	two	approaches	to	the	analysis	of	differentially	expressed	
genes.	The	first	is	individual	gene	analysis,	which	performs	a	statistical	test	for	each	gene.	
The	advantage	of	individual	gene	analysis	is	that	it	is	not	restricted	by	current	knowledge,	
because	it	assumes	no	knowledge	about	the	roles	or	regulations	of	genes.	The	disadvantage	
of	individual	gene	analysis	is	that	it	is	biased	towards	highly	expressed	genes	that	have	
undergone	large	fold	changes	[286].		
	
The	second	approach	to	differentially	expressed	gene	analysis	is	gene	set	analysis,	which	
measures	changes	in	expression	of	a	defined	group	of	genes.	The	grouping	of	genes	is	
typically	based	on	a	gene	ontology	term,	biological	pathway,	or	shared	regulatory	
sequence.	The	advantages	of	gene	set	analysis	are	that	it	gives	more	consistent	results	
across	studies,	is	not	biased	towards	large	changes	in	expression,	and	the	results	are	often	
easier	to	interpret	since	it	uses	prior	knowledge.	The	disadvantages	of	gene	set	analysis	are	
that	it	does	not	work	well	with	small	datasets	and	is	unlikely	to	find	novel	relationships	
between	genes	because	it	is	based	on	prior	knowledge	[287].		
	
Factors	that	affect	the	ability	to	detect	differential	expression	include	sequencing	depth,	
gene	expression	level,	differences	in	library	construction	protocols	and	the	real	differences	
in	transcript	expression	[284].	
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Forward	genetics	
Nearly	40%	of	P.	falciparum	genes	have	no	informative	annotations.	The	major	reason	for	
this	is	that	there	is	insufficient	sequence	similarity	between	malarial	proteins	and	other	
model	organism	proteins	to	allow	the	transfer	of	annotations.	This	problem	is	further	
compounded	by	malaria	parasites	being	difficult	to	study	using	molecular	genetics.	
Conditionally	knocking	down	genes	in	Plasmodium	is	difficult	because	they	lack	RNA-
mediated	interference	genes	[288].	The	use	of	targeted	endonuclease	methods	is	also	
hampered	by	Plasmodium	lacking	nonhomologous	end	joining	genes	[289]	combined	with	
recombination	rates	in	general	being	low	in	Plasmodium	[288].	These	problems	are	
compounded	by	the	extreme	AT-richness	of	the	genome	which	makes	the	creation	of	site-
specific	guide	RNA	challenging	[289].		
	
The	AT-richness	of	P.	falciparum	makes	it	very	tractable	to	use	the	piggyBac	transposon	in	
forward	genetic	studies.	The	piggyBac	transposon	inserts	into	TTAA	sites	and	can	
theoretically	disrupt	every	gene	in	the	P.	falciparum	genome	[290].	In	the	P.	falciparum	
genome	there	are	an	average	of	more	than	20	piggyBac	transposon		insertion	sites	per	gene	
[290].	This	allows	for	high-throughput	and	unbiased	creation	of	Plasmodium	mutants.	
piggyBac	mutants	have	been	used	to	identify	genes	required	for	gametocytogenesis	[291]	
and	to	identify	genes	involved	in	response	to	febrile	temperatures	[292].	The	piggyBac	
system	has	been	extended	into	P.	berghei	where	it	was	used	to	identify	promoter	regions	
[293].	
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The	piggyBac	system	was	recently	used	to	identify	the	essential	genome	of	P.	falciparum.	
Zhang	et	al	generated	more	than	38,000	piggyBac	mutants,	which	is	enough	to	theoretically	
disrupt	every	gene	over	500	bp	long	in	the	genome	[289].	Based	upon	disruptability	it	is	
estimated	that	there	are	2,680	blood	stage	essential	genes.	Core	metabolic	processes	tend	
to	be	essential,	and	genes	belonging	to	multi-gene	families	involved	in	host-parasite	
interactions	tend	to	be	dispensable	[289].	A	separate	forward	genetic	screen	that	covered	
>50%	of	the	P.	berghei	genome	using	bar-coded	insertions	found	the	same	result	[146].		
	
The	ability	to	create	such	as	large	number	of	mutants	creates	exciting	opportunities	to	
uncover	the	functions	of	the	large	numbers	of	unannotated	Plasmodium	genes.	
Chemogenomics	is	one	promising	approach	to	both	drug	discovery	and	gene	annotation.	
Chemogenomics	began	as	an	approach	for	the	prediction	of	drug	mechanism	of	action	by	
measuring	activity	against	cell	lines	[294],	but	has	been	extended	into	making	predictions	
about	drug	resistance	mechanisms	and	gene	function	[277,	295,	296].	A	chemogenomic	
screen	of	piggyBac	mutants	identified	7	mutants	with	increased	susceptibility	to	
arteminsins	[277].	Co-expression	analysis	of	these	genes	predicted	interaction	with	DNA	
replication	and	repair	genes	which	is	consistent	with	what	is	known	about	transcriptional	
changes	in	resistant	strains	[99,	100].			
	
Focus	of	study	
The	focus	of	this	study	was	to	understand	the	genomic	and	transcriptomic	changes	
underlying	the	mechanisms	of	resistance	to	arteminsins	and	atovaquone.	
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Chapter	2	
	
Developing	and	validating	a	dephaser	identifier	(DI)	algorithm	to	search	for	genes	
involved	in	life-cycle	shifts	
(Aim	1)	
	
Rationale	of	study	
	
The	P.	falciparum	transcriptome	has	a	well-established	temporal	sequence	linked	to	its	
progression	through	the	intraerythrocytic	development	cycle	(IDC).	Unlike	other	species	
such	as	yeast	the	P.	falciparum	transcriptome	is	well	conserved	across	strains	and	even	
shows	remarkable	recalcitrance	to	perturbation	with	drugs	[184,	185,	297].	Despite	this	
conservation,	alterations	to	the	life-cycle	are	known	to	occur	that	allow	the	parasites	to	
survive	drug	pressure	[94-96,	298-302].	Understanding	the	transcriptome	changes	
underlying	these	life-cycle	alterations	is	important	to	untangle	the	drug	survival	
mechanisms	employed	by	the	parasite.		
	
This	study	focuses	on	an	isogenic	k13	dysregulation	mutant	(PB58).		K13	is	the	gene	with	
the	strongest	link	to	ACT	treatment	failure	in	the	field.	This	k13	dysregulation	mutant	is	
more	sensitive	to	both	arteminsins	and	proteasome	inhibitors	compared	to	the	parent	
strain	[277].		In	this	mutant	K13	is	transcriptionally	dysregulated	at	6	and	24	hours	(Fig.	
2.1).	We	discovered	that	the	mutant	undergoes	transcriptome	shifts	associated	with	the	
transcript	expression	levels	of	K13.	This	transcriptome	shift	was	not	immediately	apparent.	
In	fact,	the	transcriptomes	of	the	mutant	and	the	wild-type	are	very	well	correlated	(Fig.	
2.2A).	The	alterations	became	more	apparent	when	the	correlations	of	the	samples	with	a	
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reference	transcriptome	were	clustered	in	a	heatmap	(Fig.	2.2B),	with	the	mutant	6-hour	
samples	showing	increased	similarity	to	later	reference	time	points,	and	the	mutant	24	
hour	samples	showing	increased	similarity	to	earlier	reference	time	points.	These	shifts	are	
associated	with	the	sample	time	points	where	K13	transcript	expression	levels	are	
dysregulated.	However,	progression	through	the	cell	cycle	is	still	evident	in	the	heatmap	
and	the	aforementioned	differences	are	not	particularly	striking.		
	
	
	
Figure	2.1		(a)	Insertion	of	a	PiggyBac	Transposon	in	the	5’	upstream	region	the	gene	k13	
(b)	results	in	the	gene	being	aberrantly	down-regulated	at	the	6	hour	time	point	and	up-
regulated	at	the	24	hour	time	point.	The	expression	of	the	genes	on	either	side	of	k13	on	
the	same	DNA	strand	are	unaffected	by	the	insertion.	The	changes	in	K13	expression	are	
consistent	with	the	known	regulation	of	the	calmodulin	promoter	in	P.	falciparum.	The	
transcript	expression	is	measured	in	fragments	per	kilobase	per	million	mapped	reads	
(FPKM).	The	abbreviations	for	the	piggybac	transposon	are:	inverted	terminal	repeat	1	
(ITR1),	histidine-rich	protein-2	(hrp2),	human	dihydrofolate	reductase	(hdhfr),	regulatory	
elements	of	calmodulin	(cam),	and	inverted	terminal	repeat	2	(ITR2).	The	insertion	occurs	
1034	nucleotides	up-stream	of	k13.	Originally	published	in	Gibbons	et	al	[303].	
	
That	major	alterations	occur	in	the	mutant	is	not	apparent	until	the	correlations	are	plotted	
out	as	line	graphs	(Fig.	2.2C).	Normally	when	the	correlation	of	a	transcription	profile	of	a	
P.	falciparum	sample	time	point	with	the	reference	transcriptome	of	3D7	is	plotted	there	
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will	be	an	increase	in	the	correlation	coefficient	as	the	sample	time	point	approaches	the	
corresponding	reference	sample	time	point,	followed	by	a	steady	decline	in	the	correlation	
coefficient	as	the	sample	time	point	becomes	more	distant	to	the	reference	sample	time	
point	until	a	new	inflection	point	is	reached.	If	the	transcription	profile	of	the	mutant	line	is	
out	of	synch	with	normal	IDC	patterns	this	curve	will	not	be	smooth	[303].		All	of	the	
correlation	cell-cycle	curves	are	smooth	with	the	exception	of	the	mutant	6-hour	
transcriptome	which	flattens	out	at	later	time	points,	reflecting	an	increased	similarity	of	
the	6	hour	samples	to	later	time	points.		The	mutant	24-hour	samples	maintain	their	
sinusoidal	shape	but	show	a	shift	towards	earlier	time	points.		
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Figure	2.2	(A)	Comparing	wild-type	and	K13	mutant	sample	transcript	expression	at	their	
respective	time	points	shows	that	the	two	strains	are	very	similar.	Grey	dots	represent	
absolute	fold	changes	greater	than	2.5.	(B)	Clustering	all	of	the	sample	time-points	based	
on	their	similarity	to	the	3D7	reference	transcriptome	from	Derisi	[186]	shows	that	from	a	
global	perspective	the	two	strains	are	very	similar.	The	sample	time	points	have	their	
highest	similarities	to	the	expected	reference	sample	time-points	and	progression	through	
the	erythrocytic	cycle	is	visible	in	the	heatmap.	However,	at	the	6	hour	time-point	the	
mutant	strain	shows	a	stronger	similarity	to	trophozoite	time-points	compared	to	the	wild-
type	strain	and	at	24	hours	the	mutant	shows	a	less	dramatic	shift	towards	similarity	with	
earlier	time	points.	(C)	Plotting	the	sample	correlations	with	the	3D7	reference	
transcriptome	from	Derisi	makes	the	disruption	to	the	mutant	6	hour	transcriptome	more	
evident.	With	the	exception	of	the	mutant	6	hours	they	all	show	that	there	is	a	gradual	
increasing	in	similarity	as	the	sample	time	point	approaches	the	equivalent	3D7	sample	
time	point	and	then	a	gradual	decrease	in	similarity	as	it	moves	away	from	that	time	point.	
This	periodic	structure	is	disrupted	in	the	mutant	at	6	hours.	Originally	published	in	
Gibbons	et	al	[303].	
		
Frequently,	disruptions	to	the	cell-cycle	correlation	curves	such	as	those	seen	for	the	
mutant	6	hour	samples	are	attributable	to	poor	sequencing	quality,	but	the	sequencing	
quality	for	the	mutant	6	hour	samples	is	high	with	all	of	the	base-calls	having	a	probability	
of	error	of	less	than	1	in	1000.			This	is	also	true	of	the	wild-type	6-hour	samples	(Fig.	2.3A).	
The	6-hour	samples	also	do	not	have	higher	variation	than	the	samples	from	the	other	time	
points	suggesting	that	the	disruption	cannot	be	attributed	to	some	of	the	samples	
experiencing	nonstandard	culture	conditions	or	handling	(Fig.	2.3B).		This	disruption	also	
does	not	occur	in	other	mutants	with	the	same	transposon	inserted	indicating	that	the	
disruption	is	not	a	transposon	specific	effect	(Fig.	2.3C).	Finally,	a	differential	gene	
expression	test	suggests	that	the	6	hour	samples	should	be	the	most	similar	(Fig	2.3D).		
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Figure	2.3		Transcriptome	differences	do	not	result	from	differences	in	sequencing	
quality,	increased	sample	variation,	transposon	specific	effects,	or	large	numbers	of	
differentially	expressed	genes.	(A)	Transcriptome	differences	at	6	hours	cannot	be	
attributed	to	differences	in	sequencing	quality	since	the	sequencing	quality	is	high	and	
equivalent	between	the	wild-type	and	K13	mutant	strains.	(B)	Transcriptome	differences	
at	6	hours	cannot	be	attributed	to	increased	sample	variation	at	6	hours.	(C).	The	
transcriptome	shift	is	not	a	piggyBac	transposon	specific	effect.	The	transcriptome	shifts	
occur	in	the	K13	piggyBac	mutant	but	not	another	piggyBac	mutant	(note:	A	transcriptome	
shift	also	occurs	at	12	hours	in	the	K13	mutant,	but	is	not	discussed	further	since	there	
were	not	enough	replicates	to	perform	the	subsequent	validation	steps).	(D)	Despite	the	
major	transcriptome	differences,	the	6-hour	samples	have	the	fewest	number	of	detectable	
differentially	expressed	genes	suggesting	that	small	but	consistent	changes	are	occurring	in	
stage	specific	pathways.	Originally	published	in	Gibbons	et	al	[303].	
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The	fact	that	the	transcriptome	showed	radical	changes	by	one	methodology	but	not	by	
several	other	methodologies	suggests	that	small	but	consistent	changes	occur	in	pathways	
with	stage-specific	expression,	but	traditional	methodologies	do	not	provide	approaches	to	
determine	which	genes	are	involved	in	this	change.	The	inability	to	detect	differential	gene	
expression	in	P.	falciparum	is	a	common	problem	that	stems	from	the	fact	that	genes	with	
altered	expression	show	small	fold	changes	and	there	are	a	large	number	of	antigenic	
variation	genes	that	undergo	large,	seemingly	random,	fluctuations	causing	the	family-wise	
error	rate	to	become	inflated.	This	problem	has	led	to	the	use	of	unconventional	statistical	
methodologies	[100,	304]	to	detect	differential	gene	expression	that	are	rarely	used	
outside	of	the	malaria	field.	
	
Gene	set	analysis	is	one	way	around	this	problem	[286,	287,	305],	but	has	its	drawbacks.	
The	researcher	must	first	define	the	gene	sets.	This	method	is	unlikely	to	find	novel	
relationships	between	genes	and	testing	large	numbers	of	sets	will	also	inflate	the	family-
wise	error	rate.	In	the	case	were	a	cell-cycle	shift	has	occurred	it	is	not	possible	to	directly	
link	the	gene	set	analysis	results	to	the	cell-cycle	shift.	Therefore	there	is	a	need	for	a	novel	
methodology	that	can	directly	identify	the	transcriptome	differences	underlying	cell-cycle	
shifts.		
		
Materials	and	methods	
Parasite	culturing	and	sequencing		
The	wild-type	and	mutant	strains	were	maintained	in	identical	culture	conditions	and	
synchronized	by	3	rounds	of	sorbitol	synchronization	[306].	The	samples	collected	after	
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time	zero	were:	6	hours	(n=3),	12	hours	(n=2),	24	hours	(n=5),	38	hours	(n=3)	and	48	
hours	(n=3	for	wild-type	and	n=2	for	mutant)	with	time	zero	defined	as	when	the	culture	is	
half	schizonts	and	half	early	rings.	
	
Aliquots	were	taken	from	the	samples	at	the	specified	time	points	and	the	parasites	
separated	from	the	erythrocytes	using	0.015%	saponin	at	room	temperature	for	5	minutes	
[307].	The	parasites	were	then	pelleted	and	washed	3	times	in	10	mL	of	room	temperature	
PBS	and	the	samples	stored	at	-80oC	in	1	mL	TRIzol	reagent	(Fisher	Scientific,	Hampton,	
NH)	until	total	RNA	extraction	[307].	
	
RNA	was	extracted	from	the	samples	by	adding	200	μl	of	chloroform	to	the	samples	and	
vortexing	vigorously	for	15	seconds	followed	by	incubation	at	room	temperature	for	up	to	
5	minutes.	The	samples	were	then	spun	down	at	12000xg	(10800	rpm)	at	4oC	for	10	
minutes	and	the	supernatant	discarded.	1	mL	of	75%	ethanol	was	then	added	and	the	
samples	spun	down	at	10000xg	(9800	rpm)	for	5	minutes.	The	supernatant	was	discarded	
and	the	pellet	briefly	allowed	to	dry	and	then	dissolved	in	20-50	μl	of	DEPC-treated	water	
while	being	incubated	at	55	oC	for	10-15	minutes.	
	
Preparation	of	the	Illumina	library	was	performed	by	standard	protocol	[267].	A	total	of	
0.5-1.0	μg	of	RNA	per	sample	was	used	to	prepare	Illumina	libraries	using	the	TrueSeq	
Stranded	mRNA	Kit	(Illumina).	Library	quantification	was	measured	by	qPCR	and	
TapeStation	(Agilent	Technologies).	The	sequencing	was	done	on	an	Illumina	MiSeq	using	
300-cycle	V2	MiSeq	reagent	kit	(Illumina).		
69	
	
	
A	complementary	experiment	was	performed	that	measured	transcript	expression	using	
microarrays	(Buttons	and	Ferdig,	unpublished	data).	The	microarray	measurements	were	
obtained	as	described	in	Turnbull	et	al	2017	[308].	Briefly,	the	RNA	was	extracted	using	
TriZol	reagent	(Invitrogen,	Carlsbad,	CA),	and	the	quantity	determined	by	NanoDrop	
(NanoDrop	Technologies).	300	μg	of	RNA	was	used	for	cDNA	synthesis	using	the	Sigma	
WTA2	transcriptome	amplification	kit.	1	μg	of	cDNA	was	labeled	with	Cy3	dye	and	
hybridized	to	a	custom	Agilent	array	for	17	hours	prior	to	washing	[308].	The	microarray	
image	was	recorded	using	a	2	μM	scanner	and	the	probe	intensities	normalized	using	the	
robust	multichip	average	(RMA)	method	[308].	The	samples	were	collected	at	the	following	
time	points:	6	hours	(n=3),	24	hours	(n=3),	and	38	hours	(n=3).	
	
Ethical	approval	for	the	use	of	human	blood	was	obtained	from	the	institutional	review	
boards	of	the	University	of	South	Florida	and	the	University	of	Notre	Dame.	All	of	the	blood	
was	obtained	from	healthy	adult	volunteers	and	was	drawn	by	trained	personal	from	the	
Interstate	Blood	Bank.	
	
Obtaining	expression	data	
The	reads	obtained	from	RNA-seq	were	aligned	to	the	3D7	P.	falciparum	reference	genome	
27	using	HISAT2	version	2.0.4	[280].	The	gene	counts	were	calculated	using	FeatureCounts	
version	1.5.0-p3	[283].	Transcripts	were	assembled	using	Cufflinks	version	2.2.1	and	FPKM	
(fragments	per	kilobase	per	million	mapped	reads)	values	calculated	using	Cuffnorm	
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version	2.2.1	using	the	classic-fpkm	setting	and	sample	normalization	performed	by	strain	
and	time	point	[281].	
	
Since	lowly	expressed	genes	are	prone	to	stochastic	fluctuations	in	transcript	level	
measurement,	mitochondrial	and	apicoplastic	genes	and	genes	with	less	than	3	reads	for	
every	million	reads	sequenced	in	more	than	half	the	samples	were	removed	from	further	
consideration.	
	
Sample	outlier	identification		
TMM	(trimmed	mean	of	M-values)	normalized	[284]	count	data		were	used	to	calculate	the	
Pearson	correlation	between	all	replicates.	Samples	with	a	correlation	of	less	than	0.7	with	
more	than	2	other	samples	were	removed	as	outliers.	Using	these	criteria	4	out	of	the	35	
samples	were	removed	as	outliers.	
	
	
Individual	gene	differential	expression	analysis	
Identification	of	differentially	expressed	genes	was	performed	using	EdgeR	version	3.18.1	
[285].	The	count	data	obtained	using	FeatureCounts	version	1.50.0-p3	was	normalized	
using	TMM	normalization	and	differential	expression	tested	between	strains	at	each	time	
point.	
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Life-cycle	correlation	clustering	
The	samples	were	clustered	based	on	their	similarity	profile	to	the	Derisi	3D7	reference	
transcriptome	obtained	from	PlasmoDB	[186,	309].	The	following	procedure	was	used	to	
calculate	the	correlations:	
1. Replicate	FPKM	values	were	averaged.	
2. The	average	gene	expression	value	at	a	particular	time	point	was	divided	by	the	
average	expression	for	that	gene	across	all	sample	time	points	and	the	log2	of	the	
value	was	taken.	This	normalization	step	was	required	because	the	reference	data	
are	from	a	microarray	study	that	essentially	measured	the	gene	expression	level	at	a	
particular	time	against	the	life	cycle	average.		
3. The	Spearman	correlation	between	each	sample	time	point	was	calculated	with	
respect	to	each	3D7	reference	IDC	time	point	individually.	
4. Sample	time	point	and	strain	clustering	as	well	as	heatmap	creation	were	
performed	using	the	heatmap.2	function	in	gplots	version	3.0.1.	
	
	
	
Description	of	the	dephaser	identifier	algorithm	
As	previously	described	mitochondrial	and	apicoplastic	genes	and	genes	with	counts	per	
million	less	than	3	in	more	than	half	the	samples	were	removed.	Further	filtering	was	
performed,	so	that	only	genes	present	in	our	dataset	and	in	the	Derisi	3D7	reference	
transcriptome	were	used.			
The	steps	of	the	dephaser	identifier	(DI)	algorithm	are:	
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1. Calculate	the	relative	gene	expression	level	vectors	for	the	control	and	mutant	
strains:	
log!
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑔𝑒𝑛𝑒 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑎𝑡 𝑎 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑡𝑖𝑚𝑒 𝑝𝑜𝑖𝑛𝑡
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑔𝑒𝑛𝑒 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑎𝑐𝑟𝑜𝑠𝑠 𝑎𝑙𝑙 𝑡𝑖𝑚𝑒 𝑝𝑜𝑖𝑛𝑡𝑠 	
2. Define	a	minimum	acceptable	correlation	between	the	mutant	and	control	strains.	
For	this	experiment,	the	minimum	acceptable	correlation	was	the	highest	spearman	
correlation	that	either	the	wild-type	or	mutant	strain	had	with	a	specific	time	point	
from	the	Derisi	3D7	reference	transcriptome.	
3. Rank	the	relative	gene	expression	levels	for	both	the	mutant	and	the	control	strains.	
4. For	a	pair	of	sample	time	points	calculate	the	difference	in	gene	rank	between	the	
control	and	mutant	strains.	
5. Calculate	the	absolute	value	of	the	rank	difference	of	each	gene.	
6. Group	the	rank	differences	in	gene	expression	into	quantiles.	1%	quantiles	were	
used	and	were	calculated	using	the	type	7	procedure	in	R	version	3.4.1.	
7. Remove	the	highest	unfiltered	quantile	of	genes	from	the	relative	gene	expression	
vectors	for	the	wild-type	and	mutant	strains	and	re-calculate	the	Spearman	
correlation.	
Repeat	step	7	until	the	Spearman	correlation	is	at	least	as	high	as	the	minimum	
acceptable	correlation	or	there	are	no	more	genes	left	to	filter.	
	
Assessment	of	the	biological	consistency	of	the	DI	algorithm		
To	determine	if	the	DI	algorithm	identifies	functionally	related	groups	of	genes	better	than	
chance	a	simulation	was	run	100	times,	where	random	sets	of	genes	equal	in	size	to	the	
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number	of	6	hour	dephasing	genes	(n=546)	were	checked	for	biological	process	
enrichment	using	the	gene	ontology	enrichment	program	topGO	[310].	The	minimum	gene	
ontology	set	size	(the	node_size	parameter	in	the	run_enrichment_tests	function)	was	set	to	
10	and	a	classic	Fisher	test	performed.	A	p-value	of	less	than	or	equal	to	0.05	was	
considered	significant.	The	gene	ontology	annotations	were	obtained	from	the	
Bioconductor	library	org.Pf.plasmodb	[311].	The	6-hour	dephasing	genes	were	checked	for	
biological	process	enrichment	using	the	same	parameters	and	the	results	compared	to	the	
simulation.	
	
Assessment	of	consistent	changes	in	expression	of	the	dephasing	set	
Statistical	tests	were	performed	to	measure	if	the	6-hour	dephasing	genes	showed	
consistent	expression	changes	at	24	hours.		
	
To	verify	that	down-regulated	dephasing	genes	are	more	likely	to	be	up-regulated	at	24	
hours,	a	Wilcoxon	rank	sum	test	using	R	version	3.4.1	on	the	log2	fold	changes	of	the	FPKM	
values	between	the	mutant	and	wild-type	strains	was	performed.	As	a	control	the	same	test	
was	also	performed	on	random	samples	of	genes	that	showed	an	increase	in	relative	rank	
at	6	hours	(n=1,704)	1,000	times	to	get	a	p-value	distribution.	The	set	size	of	the	random	
samples	was	set	equal	to	the	size	of	the	experimental	set.	
	
The	same	test	was	performed	for	the	up-regulated	6	hour	dephasing	genes,	but	the	random	
samples	were	drawn	from	genes	that	had	a	decrease	in	relative	rank	at	6	hours	(n=1,951).		
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Assessment	of	consistent	changes	in	relative	rank	of	the	dephasing	set	
Statistical	tests	were	performed	to	see	if	the	6-hour	dephasing	genes	show	consistent	
changes	in	relative	ranks	at	24	hours.	
	
The	testing	procedure	is	the	same	as	that	described	in	the	“Assessment	of	consistent	
changes	in	expression	of	the	dephasing	set”	section	except	the	input	to	the	Wilcoxon	rank	
sum	test	was	the	differences	in	the	gene	expression	relative	rank	of	the	mutant	and	wild-
type	strains	at	24	hours.	
	
Results	
DI	algorithm	can	make	curves	with	a	periodic	structure	as	similar	as	required	
The	DI	algorithm	identifies	the	genes	most	responsible	for	disrupting	the	sinusoidal	
structure	of	cell-cycle	correlation	curves	(Fig.	2.4)	by	iteratively	removing	the	genes	that	
show	the	largest	rank	changes	in	expression.	In	this	experiment	the	genes	were	removed	in	
one	quantile	batches	and	the	correlations	re-calculated	until	the	stop	criteria	was	fulfilled.	
The	stop	criterion	was	when	the	mutant	and	wild-type	transcriptome	were	at	least	as	well	
correlated	with	each	other	as	the	highest	correlation	either	of	them	had	to	the	reference	
transcriptome.	At	6-hours,	546	genes	were	identified	as	most	disruptive,	and	at	24-hours,	
127	genes	were	identified	as	most	disruptive.	No	major	disruptors	were	identified	at	38	or	
48	hours.		The	movement	in	the	curves	seen	in	Fig.	2.4	results	because	the	algorithm	can	
make	the	samples	as	well	correlated	as	required.	
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Figure	2.4.	The	DI	Algorithm	identifies	genes	responsible	for	IDC	correlation	shifts.	The	DI	
algorithm	identifies	the	genes	responsible	for	decreasing	the	correlations	of	the	mutant	
and	wild-type	transcriptomes	by	iteratively	removing	genes	that	show	the	largest	changes	
in	rank	expression	between	them.	The	genes	are	removed	in	one	quantile	batches	and	the	
correlations	between	the	transcriptomes	are	re-computed.	The	filtering	process	ends	when	
the	correlation	between	the	mutant	and	wild-type	transcriptomes	is	at	least	as	good	as	the	
highest	correlation	either	has	with	the	Derisi	3D7	IDC	transcriptome.	The	correlation	to	
Derisi	3D7	IDC	transcriptome	was	chosen	as	an	unbiased	cut-off	since	2	samples	from	the	
same	lab	should	be	at	least	as	well	correlated	with	each	other	as	a	sample	from	a	different	
lab.	For	the	6	h	samples	the	DI	algorithm	identified	546	genes	as	most	disruptive	to	the	
transcriptome	correlations	and	for	the	24	h	samples	127	genes	were	identified	as	being	de-	
phasing	genes.	The	overlap	between	the	dephasing	sets	was	small	(23	genes),	but	the	genes	
identified	as	dephasing	at	6	h	showed	consistent	regulatory	changes	at	24	h	(See	figures	2.8	
and	2.9).	The	DI	algorithm	did	not	identify	any	genes	as	major	disruptors	in	either	the	38	h	
or	48	h	samples.	The	shift	in	the	38	and	48	h	curves	results	because	the	DI	algorithm	can	
make	correlation	curves	as	precise	as	required,	however	the	genes	removed	did	not	qualify	
as	dephasing	because	the	mutant	and	wild-type	samples	were	already	better	correlated	
with	each	other	than	with	the	Derisi	reference	set.	Originally	published	in	Gibbons	et	al	
[303].  
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DI	algorithm	identifies	biologically	consistent	groups	of	genes	
The	DI	algorithm	identifies	more	functionally	related	groups	of	genes	compared	to	
randomly	sampling	genes	than	expected	by	chance	(Fig.	2.5AB).	Given	that	functionally	
related	groups	of	genes	tend	to	be	regulated	together,	this	suggests	that	the	DI	algorithm	
identifies	genes	that	are	differentially	expressed.	Among	the	6-hour	down-regulated	
dephasing	genes	red	blood	cell	invasion	and	exported	proteins	are	over-represented	and	
among	the	6-hour	up-regulated	dephasing	genes	DNA	replication	and	immune	system	
process	genes	are	over-represented.		
	
	
Figure	2.5	(A)	The	DI	algorithm	identifies	more	functionally	related	groups	of	genes	than	a	
random	sampling	of	genes.(p-value=0.03	see	(B)).	Since	functionally	related	genes	tend	to	
be	regulated	together	this	suggests	that	the	DI	algorithm	is	identifying	genes	that	are	
differentially	regulated	between	the	wild-type	and	K13	mutant	strains.	At	6	hours	red	
blood	cell	invasion	and	exported	proteins	are	over-represented	amongst	the	down-
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regulated	dephasing	genes	(GO:0098602--single	organism	cell	adhesion,	GO:0016337--
single	organismal	cell-cell	adhesion,	GO:0007155--cell	adhesion,	GO:0048518--positive	
regulation	of	biological	process,)	and	DNA	replication	and	immune	system	processes	are	
over-represented	amongst	the	up-regulated	dephasing	genes	(GO:0006260--DNA	
replication,	GO:0006270--DNA	replication	initiation,	GO:0006261--DNA-dependent	DNA	
replication,	GO:0002376--immune	system	process,	GO:0002440--production	of	molecular	
mediator	of	immune	response,	GO:0002377--immunoglobulin	production,	GO:0006259--
DNA	metabolic	process,		GO:0044699--single-organism	process).	(B)	Probability	density	
curve	of	the	number	of	statistically	significant	gene	ontology	biological	function	terms	
returned	from	random	sampling	the	P.	falciparum	genome.	The	area	under	the	curve	is	the	
probability	of	randomly	drawing	a	group	of	genes	that	will	form	a	number	of	statistically	
significant	gene	ontology	groups	by	chance.	The	probability	of	the	DI	algorithm	randomly	
identifying	the	number	of	statistically	significant	gene	ontology	groups	that	it	did	is	p=0.03.	
Originally	published	in	Gibbons	et	al	[303].	
	
	
	
	
DI	algorithm	consistently	improves	the	correlations	between	samples		
The	DI	algorithm	improves	the	correlation	between	the	wild-type	and	mutant	samples	with	
each	iteration	while	randomly	removing	genes	does	not	(Fig.	2.6A).	To	demonstrate	that	
this	trend	is	statistically	significant	1,000	simulations	were	performed	on	randomly	
generated	data	(Fig.	2.6B).	The	simulation	shows	that	the	algorithm	consistently	identifies	
the	factors	responsible	for	decreasing	the	correlation	between	two	datasets,	and	randomly	
removing	genes	does	not	(p-value=0).		
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Figure	2.6	(A)	The	DI	algorithm	consistently	improves	the	correlations	between	the	wild-
type	and	mutant	strains,	while	randomly	removing	genes	does	not.	(B)	The	DI	algorithm	
and	random	removal	were	performed	on	100	simulated	datasets,	and	the	DI	algorithm	
consistently	improved	the	correlations	between	the	simulated	data,	while	random	removal	
did	not	(p-value=0).	Originally	published	in	Gibbons	et	al	[303].	
	
DI	algorithm	is	not	biased	by	gene	expression	level	
The	DI	algorithm	shows	no	bias	in	the	expression	level	of	the	genes	removed	(Fig.	2.7A).	
This	is	aided	by	filtering	out	lowly	expressed	genes	to	prevent	the	identification	of	high	
variance-low	confidence	genes	as	dephasing.	Removing	genes	with	low	expression	levels	
(counts	per	million	less	than	3)	results	in	genes	with	lower	levels	of	variation	being	
preferred	compared	to	using	an	unfiltered	input	(Fig.	2.7B;	p-value=6.21e-05	by	Wilcox	
rank	sum	test).	
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Figure	2.7	(A)	The	DI	algorithm	shows	no	bias	in	the	expression	level	of	genes	labeled	as	
dephasing.	More	traditional	methods	of	identifying	differentially	expressed	genes	have	a	
bias	towards	identifying	genes	with	higher	expression	levels	as	differentially	expressed.	
The	DI	algorithm	identifies	genes	uniformly	along	the	expression	gradient.	(B)	Filtering	out	
lowly	expressed	genes	prior	to	applying	the	DI	algorithm	prevents	the	algorithm	from	
identifying	genes	with	high	variation	as	dephasing.	Originally	published	in	Gibbons	et	al	
[303].	
	
	
Genes	identified	by	the	DI	algorithm	have	consistent	changes	in	gene	expression	
The	DI	algorithm	identifies	groups	of	genes	that	are	regulated	together.	The	6	hour	down-
regulated	dephasing	genes	have	higher	expression	at	24	hours	than	expected	by	chance	
and	the	6	hour	up-regulated	dephasing	genes	have	lower	expression	at	24	hours	than	
expected	by	chance	(Fig.	2.8A).	The	p-values	were	calculated	using	a	Wilcoxon	rank	sum	
test	on	the	log2	fold	change	compared	to	random	samples	(n=1000)	of	genes	that	have	the	
same	rank	difference	as	the	dephasing	set	(Fig.	2.8B).	The	6	hour	dephasing	genes	also	
show	consistent	changes	in	their	relative	expression	level	(Fig.	2.9AB).	The	6	hour	down-
regulated	dephasing	genes	show	a	trend	toward	increased	relative	rank	expression	at	24	
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hours	and	the	6	hour	up-regulated	dephasing	genes	show	a	greater	decrease	in	relative	
rank	expression	than	expected	by	chance.	These	results	suggest	that	the	DI	algorithm	has	
identified	a	group	of	genes	that	experience	co-regulation	in	their	transcript	regulation.	
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Figure	2.8	The	DI	algorithm	identifies	genes	that	show	consistent	changes	in	expression.	
The	6	hour	dephasing	genes	show	consistent	changes	in	expression	at	24	hours.		(A,B)	The	
decreased	relative	rank	dephasing	genes	are	more	likely	to	be	up-regulated	at	24	hours	
than	random	samples	of	genes	that	were	down-regulated	at	6	hours.	(C,D)	Similarly	the	6	
hour	increased	relative	rank	dephasing	genes	are	more	likely	to	be	down-regulated	at	24	
hours	than	random	samples	of	genes	that	were	up-regulated	at	6	hours.	(B,D) The p-value	
distributions	are	for	changes	in	expression	of	the	dephasing	genes	versus	random	samples.	
The	p-values	were	calculated	using	a	Wilcoxon	rank	sum	test	on	the	log2	fold	changes	
compared	to	random	samples	of	genes	that	have	the	same	rank	difference	direction	(up	or	
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down	regulation)	as	the	dephasing	set.	FPKM	is	Fragments	Per	Kilobase	of	transcript	per	
Million	mapped	reads.	Originally	published	in	Gibbons	et	al	[303]. 
	
	
	
	
83	
	
	
Figure	2.9	The	DI	algorithm	identifies	genes	that	undergo	consistent	changes	in	relative	
rank.	Rank	refers	to	the	ranking	of	the	relative	expression	level	of	a	gene	which	is	defined	
in	the	methods	section.	(A,B)	The	6	hour	decreased	relative	rank	dephasing	genes	are	more	
likely	to	show	increases	in	relative	rank	at	24	hours	compared	to	random	samples	of	
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p-value	=	1.263e-05		
p-value	=	0.08868		
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A.	S4	
Dephasing	genes	show	consistent	changes	in	rela?ve	rank:	
The	6	hour	dephasing	genes	have	consistent	changes	in	the	rela4ve	rank	of	their	expression	in	rela4on	to	K13.	The	
decreased	rela4ve	rank	dephasing	genes	are	more	likely	to	show	an	increase	in	the	rela4ve	rank	of	their	expression	at	24	
hours	,	when	K13	is	up-regulated	compared	to	randomly	sampled	down-regulated	6	hour	genes.	Likewise,	genes	that	are	
increased	rela4ve	rank	6	hour	dephasing	genes	are	more	likely	to	show	a	decrease	in	rela4ve	rank	at	24	hours	in	the	
mutant	compared	to	randomly	sampled	6	hour	up-regulated	genes.	(S4)	The	actual	rela4ve	rank	distribu4ons	and	example	
random	samples.	(S5)	The	p-value	distribu4ons	that	result	from	1000	random	samplings.		
4000	
3000	
1000	
200 	
0
M
ut
an
t	R
an
k	
0	 1000	 2000	 3000	 4000	
WT	Rank	
400 	
3000	
1000	
200 	
0
M
ut
an
t	R
an
k	
0	 1000	 2000	 3000	 4000	
WT	Rank	
0	
0.4	
0
50
100
150
200
0.0 0.2 0.4 0.6
p_values
co
un
t
P−value Distribution Rank Differences
 of 6hr downregulated genes at 24hr
0
250
500
750
1000
0.00 0.02 0.04 0.06 0.08
p_values
co
un
t
P−value Distribution Rank Differences
 of 6hr Upregulated genes at 24hr
B.	
S5	
p-value	distribu?ons	of	dephasing	gene	rela?ve	rank	differences	of	6	hour	dephasing	genes	at	24	hours	vs.	random	
samples:	
The	p-values	were	calculated	using	a	Wilcoxon	rank	sum	test	of	the	rank	differences	of	transcript	expression	between	the	
wild-type	and	mutant	strains	for	the	6	hour	dephasing	genes	and	randomly	sampled	genes.	To	test	the	down-regulated	
dephasing	gene	sets	the	random	samples	were	selected	from	genes	that	also	had	nega4ve	rank	differences	at	6	hours	and	
to	test	the	up-regulated	dephasing	gene	sets	the	random	samples	were	selected	from	genes	that	also	had	posi4ve	rank	
differences	at	6	hours.			
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6	Hour	De-phasing	Driver	Genes	Have	Larger	Rela6ve	Rank	Expression	
Differences	Than	Expected	by	Chance		
p-value	=	1.263e-05		
p-value	=	0.08868		
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A.	S4	
Dephasing	genes	show	consistent	changes	in	rela?ve	rank:	
The	6	hour	dephasing	genes	have	consistent	changes	in	the	rela4ve	rank	of	their	expression	in	rela4on	to	K13.	The	
decreased	rela4ve	rank	dephasing	genes	are	more	likely	to	show	an	increase	in	the	rela4ve	rank	of	their	expression	at	24	
hours	,	when	K13	is	up-regulated	compared	to	randomly	sampled	down-regulated	6	hour	genes.	Likewise,	genes	that	are	
increased	rela4ve	rank	6	hour	dephasing	genes	are	more	likely	to	show	a	decrease	in	rela4ve	rank	at	24	hours	in	the	
mutant	compared	to	randomly	sampled	6	hour	up-regulated	genes.	(S4)	The	actual	rela4ve	rank	distribu4ons	and	example	
random	samples.	(S5)	The	p-value	distribu4ons	that	result	from	1000	random	sampli gs.		
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B.	
S5	
p-value	distribu?ons	of	dephasing	gene	rela?ve	rank	differences	of	6	hour	dephasing	genes	at	24	hours	vs.	random	
samples:	
The	p-values	were	calculated	using	a	Wilcoxon	rank	sum	test	of	the	rank	differences	of	transcript	expression	between	the	
wild-type	and	mutant	strains	for	the	6	hour	dephasing	genes	and	randomly	sampled	genes.	To	test	the	down-regulated	
dephasing	gene	sets	the	random	samples	were	selected	from	genes	that	al o	had	nega4ve	rank	differences	at	6	hours	and	
to	test	the	up-regulated	dephasing	gene	sets	the	random	samples	were	selected	from	genes	that	also	had	posi4ve	rank	
differences	at	6	hours.			
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decreased	relative	rank	genes.	(C,D)	The	6	hour	increased	relative	rank	dephasing	genes	
are	more	likely	to	show	a	decrease	in	relative	rank	at	24	hours	compared	to	random	
samples	of	increased	relative	rank	genes.	(B,D)	The	p-value	distributions	are	of	the	
changes	in	relative	rank	of	the	dephasing	genes	versus	random	samples.		The	p-values	
were	calculated	using	a	Wilcoxon	rank	sum	test	of	the	rank	differences	of	transcript	
expression	between	the	wild-type	and	mutant	strains	for	the	6	hour	dephasing	genes	and	
randomly	sampled	genes.	Originally	published	in	Gibbons	et	al	[303].	
	
Discussion	
	
Detection	of	differentially	expressed	transcripts	is	known	to	be	difficult	in	P.	falciparum	
[185].	The	main	cause	of	this	difficulty	is	that	P.	falciparum	transcripts	tend	to	not	undergo	
large	fold	changes	in	expression	level	[186].	However,	small	coordinated	changes	in	
transcript	expression	can	have	large	phenotypic	effects	[286].	The	power	of	small	but	
coordinated	transcript	expression	level	changes	is	evident	in	the	k13	mutant	reported	here.		
	
This	k13	mutant	had	small	but	coordinated	changes	in	stage	specific	gene	transcript	
expression	that	resulted	in	an	acceleration	of	the	transcriptome	towards	later	life	cycle	
stages.	However,	the	changes	in	expression	level	associated	with	this	shift	only	had	an	
average	fold	change	of	1.4.	Normally,	to	confidently	measure	differential	expression	a	fold	
change	of	at	least	2	is	required	[312].	Given	the	drug	sensitivity	phenotypes	of	the	K13	
mutant	studied	here	it	is	likely	that	these	small	but	coordinated	changes	in	relative	
expression	have	a	significant	effect	on	the	parasites	response	to	drugs.	
	
A	weakness	of	the	DI	algorithm	is	the	requirement	for	the	user	to	define	a	correlation	
coefficient	value	to	use	as	a	criterion	to	control	the	filtering	process.	At	the	moment	there	is	
no	obvious	way	to	set	a	cut-off	criteria	without	an	outside	reference	dataset.	When	an	
outside	reference	dataset	is	available	the	recommendation	is	to	use	the	highest	correlation	
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calculated	between	the	experimental	samples	and	the	references	samples	as	the	
correlation	cut-off.	The	logic	underlying	this	cut-off	is	that	samples	from	the	same	lab	
should	be	at	least	as	well	correlated	with	each	other	as	with	a	sample	from	another	lab.	
Finding	an	outside	reference	is	not	an	issue	when	studying	P.	falciparum	as	there	are	
several	reference	transcriptomes	available,	but	this	may	become	an	issue	when	applying	
the	DI	algorithm	to	another	organism.		
	
There	are	two	established	approaches	to	identifying	differentially	expressed	genes	from	
transcriptome	data,	individual	gene	analysis	and	gene	set	analysis.	Individual	gene	analysis	
calculates	the	significance	of	changes	in	transcript	expression	for	each	gene	one	at	a	time.	
Gene	set	analysis	calculates	the	significance	in	transcript	expression	changes	occurring	in	a	
group	of	genes.	The	dephaser	identifier	algorithm	is	a	third	approach.	The	dephaser	
identifier	algorithm	is	similar	to	individual	gene	analysis	since	it	assesses	differences	in	
transcript	expression	one	gene	at	a	time.	However,	the	DI	algorithm	differs	from	individual	
gene	analysis	in	three	ways.		
	
One,	the	DI	algorithm	identifies	genes	as	dysregulated	not	by	changes	in	their	absolute	level	
of	expression	but	by	changes	in	their	relative	expression	level.	This	allows	the	
identification	of	differential	expression	based	upon	changes	in	the	level	of	expression	of	a	
gene	relative	to	all	of	the	other	genes	expressed.		This	is	why	the	DI	algorithm,	unlike	
individual	gene	analysis,	is	not	biased	by	transcript	expression	level.	This	is	important	for	
transcriptomes	such	as	P.	falciparum’s	where	small	but	coordinated	changes	in	transcript	
expression	are	the	norm.			
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Two,	the	DI	algorithm	does	not	require	replicates.	The	DI	algorithm	not	requiring	replicates	
is	both	a	strength	and	a	weakness.	Not	requiring	replicates	is	a	strength	when	there	are	not	
enough	resources	to	produce	replicates	or	replicates	cannot	be	obtained.	However,	it	is	not	
recommended	to	run	the	DI	algorithm	without	replicates.		Assuming	two	samples	are	not	
100%	identical	and	a	non-robust	cutoff	criteria	is	used	the	algorithm	will	identify	some	
genes	as	dysregulated	even	if	there	are	no	significant	differences	between	the	samples.	
Therefore,	replicates	are	recommended	to	allow	statistical	confirmation	of	the	identified	
gene	set.			
		
Three,	the	DI	algorithm	does	not	calculate	a	statistical	significance	value.	Since	the	DI	
algorithm	does	not	provide	a	statistical	significance	value	gene	set	analysis	methods	must	
be	used	to	assess	the	statistical	significance	of	results.	Therefore,	the	DI	algorithm	is	a	
complement	to	gene	set	analysis	by	allowing	gene	groups	to	be	identified	from	within	a	
data	set.	This	allows	novel	relationships	to	be	discovered	using	gene	set	analysis.	Prior	to	
the	development	of	the	DI	algorithm	gene	set	analysis	was	limited	to	studying	the	
relationships	between	predefined	sets	of	genes	[287].	
	
There	are	at	least	two	ways	to	improve	the	DI	algorithm.	One	is	to	develop	a	methodology	
to	calculate	a	filtering	cut-off	value	without	the	need	of	a	reference	dataset.	The	other	is	to	
develop	a	methodology	to	provide	a	statistical	significance	value	for	the	calculated	changes	
in	expression.		The	development	of	these	methodologies	will	be	dependent	on	the	
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availability	of	existing	standards	to	calculate	the	parameters	associated	with	high-quality	
filtering.	
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Chapter	3	
Elucidating	the	biological	function	of	artemisinin	resistance	gene	k13	by	analyzing	
transcriptome	differences		
(Aim	2)	
Rationale	of	study	
K13	is	the	gene	with	the	strongest	link	to	artemisinin	resistance.	Amino	acid	substitutions	
in	the	propeller	region	of	the	K13	protein	are	associated	with	delayed	clearance	and	
treatment	failure	in	patients	[92].		The	most	common	resistance	allele	is	C580Y	[101].	In	
vitro	studies	indicate	that	the	K13	C580Y	resistance	allele	does	mediate	sensitivity	to	
artemisinins	[101-104].	The	K13	mutant		(PB58)	that	inspired	the	DI	algorithm	described	
in	chapter	2	(aim	1)	is	an	isogenic	k13	dysregulation	mutant	[277].	Previous	studies	have	
shown	that	this	K13	mutant	is	more	sensitive	to	artemisinins	and	proteasome	inhibitors	
than	the	parent	strain	[277,	289].	The	increased	sensitivity	to	proteasome	inhibitors	is	
interesting	because	the	resistance	mechanism	has	been	linked	to	changes	in	the	
proteasome	and	ubiquitination	system,	and	proteasome	inhibitors	[105]	have	been	shown	
to	work	synergistically	with	artemisinins	[313].		
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Based	upon	protein	homology	to	known	transcriptional	regulator	Keap1	[105],	we	
hypothesized	that	K13	also	regulates	transcription	and	that	the	observed	drug	sensitivity	
phenotypes	result	from	changes	to	P.	falciparum	transcriptome	regulation.	To	test	this	an	
RNA-seq	experiment	was	performed	taking	samples	from	several	stages	of	the	IDC	to	
measure	differences	associated	with	K13	expression.	
	
Materials	and	methods	
Parasite	culturing	and	sequencing	
The	RNA-seq	and	microarray	samples	used	in	this	chapter	are	the	same	ones	described	in	
chapter	2	under	“Parasite	culturing	and	sequencing”.	
	
Analysis	of	the	transcriptome	differences	identified	by	the	DI	algorithm	
Confirmation	that	DNA	replication	is	dysregulated	in	the	K13	mutant	was	performed	by	
gene	set	analysis.	The	gene	set	analysis	was	performed	using	the	Mann	Whitney	U	test	on	
unpaired	samples	as	implemented	in	Gage	2.26.3	[305].	The	Mann	Whitney	U	test	was	used	
to	measure	all	of	the	P.	falciparum	pathways	annotated	in	KEGG	[254]	on	September	4,	
2017	for	dysregulation.	
	
To	confirm	that	the	alterations	to	the	DNA	replication	and	repair	pathways	are	specific,	
other	housekeeping	pathways	that	undergo	active	transcriptional	regulation	around	6	and	
24	hours	were	also	checked	for	dysregulation.	The	control	housekeeping	pathways	were	
assembled	using	gene	ontology	terms	associated	with:	DNA	replication	and	repair,	the	
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proteasome,	transcription,	and	translation	(Appendix	A).	These	pathways	were	checked	for	
dysregulation	using	GSAR	1.10.0	KStest	[287].		
	
Linking	dephasing	genes	to	a	transcription	factor	
Fisher’s	exact	test	was	used	to	determine	whether	there	is	over-representation	of	genes	in	
the	6-hour	increased	rank	de-phasing	set	among	promoter	sequences	associated	with	
transcription	factors	that	regulate	DNA	replication	genes	[190].	The	genes	associated	with	
each	transcription	factor	were	used	to	partition	the	genome	by	whether	they	have	a	
binding	site	for	the	transcription	factor	or	not	and	whether	they	are	6	hour	increased	rank	
de-phasing	genes	or	not.	The	resulting	contingency	tables	(Appendix	B)	were	used	to	
perform	Fisher’s	exact	test	using	R	version	3.4.1	and	the	p-values	were	corrected	using	the	
Bonferroni	method.		
	
Linking	K13	to	replication	factor	C	
Previous	work	functionally	linked	K13	to	4	of	the	5	components	of	DNA	replication	factor	C	
[314].	To	verify	if	this	association	between	K13	and	replication	factor	C	is	evident	in	the	
present	data,	the	function	Wilcox.test	in	R	version	3.4.1	was	used	to	run	the	Mann-Whitney	
test	on	the	FPKM	values	for	the	separate	components	of	replication	factor	C.	The	6-hour	
samples	were	tested	for	up-regulation	and	the	24-hour	samples	were	tested	for	down-
regulation.	P-values	were	corrected	using	the	false	discovery	rate	(FDR)	method.		
	
Results	
K13	dysregulation	is	specific	
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As	can	be	seen	in	Figure	3.1	a	Piggybac	transposon	was	inserted	in	the	5’	upstream	region	
of	k13.	This	insertion	was	associated	with	a	significant	down-regulation	of	k13	
transcription	at	6-hours	and	a	significant	up-regulation	of	k13	transcription	at	24-hours.		
The	k13	gene	has	two	same	DNA	strand	neighbors	whose	transcript	expression	levels	are	
unaffected	by	the	transposon	insertion,	suggesting	that	the	transposon	only	affects	the	
transcription	of	k13.	
	
Figure	3.1	(a)	Insertion	of	a	PiggyBac	Transposon	in	the	5’	upstream	region	the	gene	k13	
(b)	results	in	the	gene	being	aberrantly	down-regulated	at	the	6	hour	time	point	and	up-
regulated	at	the	24	hour	time	point.	The	expression	of	k13’s	same	strand	neighbors	are	
unaffected	by	the	insertion.	The	changes	in	K13	expression	are	consistent	with	the	known	
regulation	of	the	calmodulin	promoter	in	P.	falciparum.	The	transcript	expression	is	
measured	in	fragments	per	kilobase	per	million	mapped	reads	(FPKM).	The	abbreviations	
for	the	piggybac	transposon	are:	inverted	terminal	repeat	1	(ITR1),	histidine-rich	protein-2	
(hrp2),	human	dihydrofolate	reductase	(hdhfr),	regulatory	elements	of	calmodulin	(cam),	
and	inverted	terminal	repeat	2	(ITR2).	The	insertion	occurs	1034	nucleotides	up-stream	of	
k13.	Originally	published	in	Gibbons	et	al	[303]. 		 
	
Analysis	of	affected	pathways	
The	DI	algorithm	indicated	that	DNA	replication	was	disrupted	in	the	mutant.	To	confirm	
this,	gene	set	analysis	using	the	Mann	U	Whitney	test	in	the	Gage	package	was	used	to	test	
all	of	the	P.	falciparum	pathways	on	KEGG.	This	analysis	confirmed	that	DNA	replication	
A.	Transposon	inser+on	rela+ve	to	K13	
B.	Expression	pa4ern	of	genes	near	transposon	inser+on		
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was	dysregulated	in	the	mutant.	The	analysis	showed	that	DNA	replication	and	repair	are	
dysregulated	(Table	3.1).	The	microarray	results	are	consistent	with	this	interpretation	
(Appendix	C).	
Table	3.1	KEGG	pathways	over-represented	amongst	the	dephasing	genes.		Definitions	of	
terms:	p.geomean:	geometric	mean	of	p-values	from	pairwise	sample	
comparisons.	stat.mean:	Average	Mann	Whitney	U	test	statistic	from	pairwise	sample	
comparisons.	p.val:	p-value	for	the	assumption	of	no	change	in	pathway	
regulation.	q.value:	False	discovery	rate	corrected	p-values.	set.size:	number	of	genes	in	
the	KEGG	Gene	Set.	Originally	published	in	Gibbons	et	al	[303].		
	
	
For	subsequent	analysis	the	DNA	replication	and	repair	pathways	were	combined	since	
they	have	equivalent	expression	profiles	(Appendix	D).	
	
Confirmation	of	the	specificity	of	DNA	replication	and	repair	dysregulation	
When	working	with	data	that	have	a	temporal	sequence	there	is	the	risk	that	the	observed	
differences	are	not	due	to	intrinsic	differences	between	the	samples,	but	instead	result	
from	the	samples	not	being	properly	aligned.	To	check	for	this	possibility	other	biological	
processes	that	are	known	to	undergo	transcriptional	regulation	around	6	and	24	hours	
were	also	checked	for	changes	in	expression.	As	can	be	seen	in	Figure	3.2	the	proteasome,	
transcription,	and	translation	genes	all	experience	similar	rates	of	transcriptional	
regulation	as	DNA	replication	and	repair	genes,	but	only	the	DNA	replication	and	repair	
KEGG	Gene	Set	 p.geomean stat.mean p.val q.val set.size
KEGG	Gene	
Set p.geomean stat.mean p.val q.val set.size
pfa03030	DNA	
replication 2.49E-05 4.50E+00 1.70E-12 7.48E-11 29
pfa03030	
DNA	
replication 5.67E-05 -4.21E+00 2.02E-17 8.90E-16 29
pfa03430	Mismatch	
repair 2.83E-03 2.96E+00 1.18E-06 2.60E-05 19
pfa03430	
Mismatch	
repair 7.03E-03 -2.51E+00 8.72E-08 1.92E-06 19
pfa03440	Homologous	
recombination 2.08E-02 2.17E+00 2.61E-04 2.61E-03 13
pfa03410	
Base	excision	
repair 2.61E-02 -1.86E+00 6.82E-05 7.50E-04 16
pfa03410	Base	
excision	repair 2.31E-02 2.05E+00 4.57E-04 2.87E-03 16
pfa03440	
Homologous	
recombinatio
n 4.08E-02 -1.77E+00 1.08E-04 9.48E-04 13
6	Hour	Up-regulated	KEGG	Pathways 24	Hour	Down-regulated	KEGG	Pathways
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genes	have	dysregulated	expression.	This	suggests	that	the	observed	differences	in	DNA	
replication	and	repair	transcript	levels	result	from	the	transcriptional	dysregulation	of	k13	
	
	
	
	
	
.		
	
Figure	3.2	There	are	clear	shifts	in	the	expression	patterns	of	the	DNA	replication	and	
repair	genes	(A,	B)	that	are	not	apparent	in	other	gene	sets	that	also	undergo	rapid	
transcriptional	regulation	at	the	same	points	of	the	life-cycle.	(C)	As	indicated	by	the	data	
from	Bozdech	et	al	2003,	the	proteasome,	transcriptional	machinery	and	translational	
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machinery	(Additional	File	3)	all	undergo	rapid	changes	in	transcript	expression	levels	
around	6	and	24	hours	of	the	intraerythrocytic	life-cycle,	but	these	gene	sets	show	
consistent	expression	in	the	wild-type	and	mutant	strains	which	supports	the	idea	that	the	
dysregulation	observed	in	the	DNA	replication	and	repair	genes	is	not	due	to	time	point	
sampling	error	but	results	from	the	dysregulation	of	k13.	Grey	dots	represent	absolute	fold	
changes	greater	than	2.5.	The	DNA	replication	and	repair	pathways	were	combined	into	a	
single	plot	because	they	undergo	equivalent	rates	of	transcriptional	regulation	(Appendix	
D).	The	q	statistic	in	(A)	and	(B)	refers	to	the	false	discovery	rate	and	the	*	indicates	
statistical	significance	(q	<	0.05).	Transcript	expression	is	measured	in	fragments	per	
kilobase	per	million	mapped	reads	(FPKM).	Originally	published	in	Gibbons	et	al	[303].		
	
Further	evidence	that	the	observed	changes	are	not	due	to	sample	time	point	misalignment	
comes	from	close	examination	of	the	expression	levels	of	the	DNA	replication	and	repair	
genes.	DNA	replication	and	repair	gene	transcript	levels	are	normally	higher	at	24	hours	
than	6	hours,	but	this	is	reversed	in	the	mutant	with	DNA	replication	and	repair	actually	
having	higher	transcript	levels	at	6-hours	than	24-hours	(Fig.	3.3).	The	odds	of	the	sample	
time	points	being	misaligned	enough	to	cause	such	a	large	change	in	expression	are	very	
low.	
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Figure	3.3	(A)	DNA	replication	and	repair	genes	are	normally	expressed	at	higher	levels	at	
24	hours	than	at	6	hours	[186].	(B)	This	pattern	holds	for	the	wild-type	strain,	but	is	
reversed	in	the	K13	mutant	strain	with	DNA	replication	and	repair	genes	expressed	at	
higher	levels	at	6	hours	than	at	24	hours.	This	result	supports	the	conclusion	that	the	
differences	in	the	expression	of	the	DNA	replication	and	repair	genes	do	not	result	from	
sample	time	point	misalignment	since	the	samples	would	have	to	be	misaligned	by	at	least	
20	hours	for	such	a	result	to	be	expected.	Transcript	expression	is	measured	in	fragments	
per	kilobase	per	million	mapped	reads	(FPKM).	Originally	published	in	Gibbons	et	al	[303].	
	
	
Dephasing	genes	are	regulated	by	a	transcription	factor	predicted	to	regulate	DNA	
replication	
Given	the	strong	link	observed	between	k13	transcript	expression	and	DNA	replication	and	
repair	genes,	the	6-hour	up-regulated	dephasing	genes	were	tested	for	evidence	of	binding	
sites	for	transcription	factors	linked	to	DNA	replication	[190].	Fisher’s	exact	test	was	used	
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to	determine	if	any	of	the	transcription	factor	binding	sites	was	over-represented	in	the	
promoter	regions	of	the	up-regulated	6-hour	dephasing	genes.	Promoter	sequences	
associated	with	AP2	domain	transcription	factor,	putative	(PF3D7_0802100)	were	over-
represented	amongst	the	up-regulated	6-hour	dephasing	genes	(Bonferroni	adjusted	p-
value	7.2e-6).	
	
Linking	K13	to	replication	factor	C	
Previous	studies	have	linked	k13	to	DNA	replication	and	repair	[99,	314].	In	particular	a	
study	that	used	Bayesian	network	analysis	to	integrate	transcriptional	profiling	data,	
phylogenetic	profiles,	and	Rosetta	stone	fusion	protein	data	predicted	a	functional	
interaction	between	k13	and	4	of	the	5	components	of	replication	factor	C	[314].	To	test	if	
this	prediction	is	consistent	with	our	data	set	the	nonparametric	Mann-Whitney	test	was	
used	to	see	if	replication	factor	C	dysregulation	was	associated	with	k13	transcription	
dysregulation.	The	results	confirmed	that	replication	factor	C	is	up-regulated	at	6	hours	
and	down-regulated	at	24	hours	providing	further	evidence	of	a	functional	interaction	
between	k13	and	replication	factor	C	(Fig.	3.4).	This	result	is	consistent	with	the	microarray	
data	(Appendix	C).	
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	Figure	3.4	Network	analysis	links	K13	to	DNA	replication	in	general	and	replication	factor	
C	in	particular	[314].	(a,	b)	The	replication	factor	C	subunits	show	consistent	changes	in	
expression	at	6	and	24	hours	consistent	with	K13	being	a	negative	regulator	of	DNA	
replication.	Microarray	measurements	from	theses	sample	time	points	are	also	consistent	
with	the	RNA-seq	data	presented	here.	The	false	discovery	rate	(q)	was	less	than	or	equal	
to	0.1	for	all	comparisons	made.		Transcript	expression	is	measured	in	fragments	per	
kilobase	per	million	mapped	reads	(FPKM).	Originally	published	in	Gibbons	et	al	[303]. 
	
	
Discussion	
The	k13	mutant	in	this	study	has	increased	sensitivity	to	arteminsins	and	proteasome	
inhibitors.	The	position	of	the	transposon	in	the	5’	upstream	region	of	k13	suggested	that	
this	drug	sensitivity	phenotype	results	from	dysregulation	of	k13	transcription.	This	study	
was	able	to	confirm	that	k13	is	dysregulated	at	2	different	stages	of	the	IDC.	Since	the	
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dysregulation	involves	both	up	and	down-regulation	of	k13	it	was	possible	to	directly	test	
the	effect	of	K13	expression	on	the	transcriptome.	The	results	described	in	chapter	2	led	
me	to	propose	that	DNA	replication	was	dysregulated	in	the	mutant.	I	was	able	to	confirm	
that	DNA	replication	and	repair	dysregulation	occurred	and	that	the	observed	differences	
did	not	result	from	sample	time	point	misalignment.		
	
The	inverse	relationship	between	the	expression	of	K13	and	the	expression	of	DNA	
replication	and	repair	pathways	coupled	with	the	homology	between	K13	and	known	
transcriptional	regulator	Keap1	[315]	suggests	a	model	for	the	function	of	K13,	where	K13	
inhibits	progression	through	the	cell	cycle	via	down-regulation	of	a	transcription	factor	
(Fig.	3.5).		
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Figure	3.5	The	crystal	structure	of	K13	resembles	the	E3	ubiquitin	substrate	ligase	adapter	
Keap1,	which	is	known	as	a	stress	response	regulator	in	humans.	The	structural	similarity	
coupled	with	the	data	presented	here	suggest	that	K13	functions	similarly	to	Keap1.	We	
propose	that	K13	promotes	the	inhibition	of	a	pro-growth	regulatory	unit	via	
ubiquitination	of	a	regulatory	element	that	is	subsequently	degraded	by	the	proteasome.	In	
this	model	down-regulation	of	K13	at	6	hours	would	result	in	an	increased	number	of	
functional	regulatory	units	promoting	the	transcription	of	pro-growth	genes,	which	would	
explain	the	transcriptome	shift	at	6	hours	towards	latter	life-cycle	transcriptomes.	
Originally	published	in	Gibbons	et	al	[303].		
	
	
In	this	model	k13	regulates	progression	through	the	cell	cycle	via	the	direct	regulation	of	
genes	involved	in	DNA	replication	and	repair.	The	up-regulation	of	DNA	replication	and	
repair	genes	results	in	the	acceleration	of	the	P.	falciparum	transcriptome	from	earlier	time	
stages	to	later	time	stages.		
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This	model	is	consistent	with	previous	studies	of	artemisinin	resistance	that		found	
alterations	to	life-cycle	length	are	features	of	artemisinin	resistance	[93-96,	304].		
However,	it	is	not	clear	at	what	point	of	the	life-cycle	the	K13	mutant	becomes	more	
susceptible	to	artemisinins	or	proteasome	inhibitors.		One	possible	explanation	is	that	the	
parasite	has	increased	susceptibility	during	the	ring	stage,	the	stage	where	k13	is	down-
regulated,	due	to	a	decreased	ability	to	slow	or	halt	development	in	the	presence	of	drugs.	
However,	evidence	from	another	study	suggests	that	the	proteins	encoded	by	k13	
resistance	alleles	have	decreased	binding	affinity	[105]	.	Assuming	it	is	true	that	the	
resistance	associated	K13	proteins	have	decreased	binding	affinity	than	down-regulation	of	
K13	would	be	expected	to	be	associated	with	increased	resistance	to	artemisinins,	not	
decreased	resistance.		This	suggests	that	the	increased	sensitivity	of	the	k13	mutant	to	
artemisinins	occurs	during	the	early	trophozoite	stage	when	K13	is	up-regulated	and	there	
is	down-regulation	of	DNA	replication	and	repair	genes.		
	
This	study	sheds	more	light	on	the	function	of	K13,	but	its	role	in	artemisinin	resistance	is	
not	fully	resolved.	The	results	are	consistent	with	previous	studies	that	have	shown	that	
DNA	replication	genes	are	down-regulated	in	artemisinin	resistant	field	isolates	[99,	304].		
Given	that	resistance	and	recrudescence	following	artemisinin	treatment	is	associated	with	
entry	into	a	dormant	state	[93-96,	304]	our	results	suggest	that	K13	may	be	involved	in	
either	entry	or	exit	from	this	dormant	state	via	regulation	of	DNA	replication	and	repair	
genes.	
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However,	recent	studies	have	raised	questions	about	K13’s	centrality	to	the	evolution	of	
artemisinin	resistance	[100,	316-318].	An	in	vivo	study	of	the	artemisinin	artesunate	in	an	
Aotus	monkey	model	found	that	the	k13	resistance	allele	C580Y	is	not	predictive	of	
clearance	half-life	or	recrudescence	[318].		There	is	also	evidence	of	delayed	clearance	and	
resistance	associated	RSA	measurements	from	strains	with	wild-type	K13	[317].	
Additionally,	in	vitro	evolution	studies	have	evolved	artemisinin	resistance	strains	without	
mutations	in	k13	[100,	316].			
	
The	artemisinin	resistant	trains	reported	in	Rocamora	et	al	[100]	do	not	enter	a	dormant	
state,	which	was	previously	thought	to	be	a	requirement	of	artemisinin	resistance	[93-96,	
304].		Similar	to	the	k13	mutant	PB58		the	artemisinin	resistant	strains	reported	by	
Rocamora	et	al	undergo	a	transcriptome	acceleration	during	the	ring	stage	towards	later	
time	points.	The	fact	that	an	accelerated	transcriptome	is	a	key	feature	of	both	a	k13	
dysregulation	mutant	and	two	different	k13	artemisinin	resistance	strains	suggests	that	the	
ability	to	accelerate	the	transcriptome	towards	later	stages	is	a	key	component	of	
artemisinin	resistance.	Given	that	entry	into	a	dormant	state	is	not	a	unique	response	to	
treatment	with	artemisinins	[301,	302]	what	may	be	important	to	artemisinin	resistance	is	
not	the	ability	to	enter	a	dormant	state	but	the	efficiency	with	which	the	parasite	can	exit	
the	dormant	state.		
	
The	parasites	may	enter	a	dormant	state	that	is	protective	against	artemisinin	but	with	
elimination	lives	of	only	1	to	3	hours	in	vivo,	artemisinin	concentrations	are	likely	to	fall	
below	therapeutically	relevant	concentrations	before	parasite	elimination	is	achieved	
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[319].		Indeed,	when	used	as	a	single	therapy	artemisinin	has	a	treatment	failure	rate	of	
40%	[318]	implying	having	enough	parasites	survive	to	cause	recrudescence	is	not	
uncommon.	Once	the	concentration	of	artemisinin	has	fallen	below	a	therapeutically	
relevant	concentration	there	is	no	survival	advantage	to	being	in	a	dormant	state	and	so	
the	ability	to	quickly	exit	the	dormant	state	would	be	adaptive.		
	
If	this	hypothesis	is	correct	it	suggests	that	the	assay	used	to	assess	artemisinin	resistance	
(the	ring	stage	survival	assay)	[320]	is	not	measuring	the	ability	of	the	parasite	to	survive	
artemisinin	treatment,	but	the	ability	to	quickly	exit	a	dormant	state.	This	suggests	that	
what	may	occur	in	the	field	is	not	resistance	to	artemisinin	in	the	traditional	sense,	but	an	
improved	ability	to	recover	from	dormancy	coupled	with	partner	drug	resistance.		The	
ability	to	accelerate	out	of	the	dormant	state	may	help	the	parasite	evade	immune	
responses	or	splenic	clearance	via	pitting,	the	main	mechanism	for	ring	stage	removal	
[321].		
	
	
The	ACT	that	currently	has	spreading	treatment	failures	is	DHA-piperaquine	[90-92].	The	
piperaquine	component	of	this	combination	therapy	was	previously	used	as	a	
monotherapy	with	reported	resistance	in	the	1980s	[58].		This	suggests	the	treatment	
failures	seen	today	may	be	the	result	of	an	accelerated	ability	to	exit	the	dormant	state	
occurring	on	genetic	backgrounds	that	already	have	a	degree	of	resistance	to	the	partner	
drug.			
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The	down-regulation	of	DNA	replication	genes	is	a	frequently	noted,	but	rarely	explored	
feature	of	artemisinin	resistance	[99,	304].	Given	artemisinins	are	assumed	to	work	by	
causing	proteins	to	unfold	[89]	it	is	understandable	that	most	of	the	research	around	the	
mechanism	of	artemisinin	resistance	has	focused	around	the	unfolded	protein	response	
and	the	proteasome	[89,	99,	100,	304,	313].	The	work	presented	here	suggests	that	more	
research	should	be	done	to	understand	how	the	regulation	of	DNA	replication	and	repair	
genes	affects	the	parasites	response	to	artemisinins.	Since	k13	alleles	are	currently	the	best	
predictor	of	artemisinin	resistance	in	the	field,	the	results	of	this	study	suggest	that	
changes	in	the	regulation	of	DNA	replication	and	repair	genes	are	directly	related	to	the	
mechanism	of	resistance	and	are	not	just	the	result	of	cross-talk	with	the	unfolded	protein	
response	or	proteasome.		
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Chapter	4	
Whole	genome	sequencing	to	understand	the	genotypic	changes	associated	with	
atovaquone	resistance	
(Aim	3)	
Rationale	
Drug	resistance	is	evolving	against	ACT	[90-92],	the	current	front	line	anti-malarial	
treatment.	Atovaquone	is	a	safe	and	effective	antimalarial	when	combined	with	proguanil	
[79].	However,	resistance	to	atovaquone	evolves	rapidly	when	it	is	used	as	a	single	therapy	
[64].	Resistance	to	atovaquone	is	associated	with	mutations	in	the	atovaquone	binding	site	
of	Cyt	b	[82].	This	resistance	mechanism	comes	with	a	fitness	disadvantage	[80,	81],	and	it	
is	likely	that	compensatory	mutations	will	occur.	Identifying	these	compensatory	
mutations	before	they	occur	in	the	field	will	guide	treatment	strategies	to	keep	atovaquone	
an	effective	antimalarial.		
	
Materials	and	methods	
In	vitro	evolution	of	an	atovaquone	resistant	strain			
The	creation	of	in	vitro	atovaquone	resistant	strains	was	described	in	a	previously	
published	study	[212].	The	parent	sample	was	obtained	pre-treatment	from	a	patient	that	
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failed	atovaquone	treatment.	Cultures	of	single	parasite	clones	were	created	from	this	
patient	sample	using	limiting	dilution.		From	one	of	these	clones	an	inoculum	of	108	
parasites	were	seeded	in	25	mL	flasks	(n=5)	that	contained	~10	x	EC50	of	atovaquone	(10	
nM).	The	media	was	changed	twice	per	week	and	split	1:2	with	fresh	erythrocytes	every	10	
days.	The	parasites	were	considered	“recovered”	if	they	reached	2%	parasitemia	and	
continued	to	grow	while	under	drug	pressure	[212].			
	
DNA	extraction	and	sequencing	protocols	
The	DNA	extraction	and	sequencing	protocols	are	described	in	Siegel,	2016		[212].	Briefly,	
samples	were	harvested	from	infected	erythrocytes	at	8-10%	parasitemia	of	mostly	
trophozoite	and	schizont	stage	parasites.	First	the	samples	were	centrifuged	to	remove	the	
media.	The	parasites	were	then	removed	from	the	erythrocytes	using	0.1%	saponin	in	1	x	
PBS	for	10	minutes	then	centrifuged	for	10	minutes	and	washed	with	0.1%	saponin	in	1	x	
PBS.	After	lysis	the	parasites	were	washed	twice	in	1	x	PBS	then	resuspended	in	10X	
original	erythrocyte	pellet	of	1	x	PBS	and	incubated	with	20	uL	RNase	A	(20	mg/mL)	at	
37oC	for	10	minutes.	Following	incubation	the	genomic	DNA	was	extracted	using	the	
Qiagen	DNeasy	Kit	following	the	manufacturer’s	protocols.		
	
The	DNA	samples	were	sent	to	the	Genomics	Core	at	the	Oklahoma	Medical	Research	
Foundation	where	paired-end	sequencing	was	performed	on	an	Illumina	HiSeq	3000	for	
150	cycles.	
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Sequence	alignment	
The	sample	reads	were	aligned	to	the	3D7	P.	falciparum	reference	genome	version	27	using	
bowtie2-2.1.0.	[322]	as	described	in	Siegel	2016	[212].		
	
Identification	of	SNPs	and	indels	
Detection	of	SNPs	and	indels	was	done	using	HaplotypeCaller	from	GATK	version	3.7	[273].	
The	calls	were	made	with	respect	to	the	3D7	P.	falciparum	reference	genome	27	and	the	
ploidy	number	was	set	to	one.	HaplotypeCaller	does	not	use	stringent	cutoffs	when	making	
variant	calls	but	provides	a	number	of	metrics	that	can	be	used	to	assess	read	quality.	
Before	filtering	out	low	quality	calls	the	SNP	and	indel	calls	were	separated	using	the	
SelectVariants	tool	from	GATK	version	3.7.	The	VariantRecalibrator	tool	in	GATK	version	
3.7	was	used	to	filter	out	low	confidence	variant	calls.	VariantRecalibrator	uses	a	machine-
learning	algorithm	trained	to	distinguish	between	high	and	low	quality	calls.	The	training	
data	supplied	to	VariantRecalibrator	was	a	set	of	high	quality	SNP	and	indel	calls	from	a	
genetic	cross	experiment	[323].	The	machine	learning	algorithm	trained	for	each	sample	
was	applied	to	each	sample	using	the	GATK	version	3.7	tool	VariantRecalibration	with	a	
tranche	score	of	100	used	as	a	cutoff,	meaning	the	cutoffs	were	chosen	to	find	100%	of	
known	variant	sites.	Calls	that	did	not	pass	the	initial	quality	control	were	filtered	out	using	
VCFtools	v0.1.12a		[324].		
	
The	impact	of	the	mutations	on	genes	was	assessed	using	snpEff	version	4.3	[275].	The	
options	–no-downstream,	-no-upstream	–no-intergenic	were	used	to	limit	the	annotations	
to	only	changes	with	a	direct	impact	on	coding	regions.		
107	
	
	
The	data	were	transformed	from	vcf	format	to	table	format	using	VariantsToTable	from	
GATK	version	3.7.	This	change	in	formatting	facilitated	the	subsequent	analysis	using	
custom	scripts.		
	
The	reference	strain	used	for	the	sequence	alignments	was	not	the	same	as	the	parent	
strain	used	to	create	the	drug	pressured	strains.	This	means	that	there	were	4	types	of	
differences	from	the	alignment	reference	strain	that	had	to	be	identified	to	understand	the	
differences	between	the	parent	and	drug	pressured	strains	(Table	4.1):	
	
1. The	differences	from	the	reference	genome	were	shared	between	the	parent	and	
drug	pressured	strains.	These	differences	were	detected	by	HaplotypeCaller,	but	
they	did	not	result	from	drug	pressure.		Since	these	differences	were	not	relevant	to	
the	drug	resistance	phenotype,	no	code	was	written	to	detect	them.	
2. The	parent	strain	was	the	same	as	the	reference	genome,	but	the	drug	pressured-
strain	was	different	from	the	reference	genome.	This	type	of	change	may	have	
resulted	from	the	drug	pressure	and	custom	code	was	written	to	identify	these	
changes.	
3. The	drug	pressure	strain	was	the	same	as	the	reference	genome,	but	the	parent	
stain	differed	from	the	reference	genome.	This	type	of	change	may	have	resulted	
from	the	drug	pressure	and	custom	code	was	written	to	identify	these	changes.	
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4. Both	the	parent	strain	and	the	drug	pressured	stain	differed	from	the	reference	
genome,	but	in	different	ways.	This	type	of	change	may	have	resulted	from	the	drug	
pressure	and	custom	code	was	written	to	identify	these	changes.	
	
Table	4.1	Summary	of	the	4	ways	the	parent	and	drug	treated	strain	can	differ	from	the	
reference	genome	used	for	alignment.		
	
Many	of	the	identified	differences	were	associated	with	antigenic	variation	genes	and	these	
were	removed	from	further	consideration	since	they	were	known	to	undergo	rapid	
evolution	[323].	The	results	were	further	filtered	so	that	only	positions	modified	in	all	five	
replicates	remained.	These	differences	were	visually	examined	for	consistency	of	the	
alternate	allele	and	possible	strand	bias	and	using	Integrative	Genomics	Viewer	[325].		
	
Detection	of	copy	number	variants	
DepthOfCoverage	from	GATK	version	3.7	was	used	to	calculate	coverage	rates	over	the	
genome,	and	a	custom	script	was	used	to	calculate	the	average	coverage	over	genes.	Genes	
belonging	to	the	antigenic	variation	families	were	removed	from	consideration,	since	it	is	
difficult	to	determine	copy	number	changes	for	these	[84].	Since	regions	with	low	coverage	
have	large	variations	in	fold	changes,	genes	with	coverage	rates	below	the	first	quartile	
were	filtered	out.		If	a	gene	had	a	fold	change	of	greater	than	or	equal	to	two	with	respect	to	
the	parent	strain,	it	was	considered	a	possible	copy	number	variant	and	visually	inspected	
in	IGV	for	confirmation.		
	
Same Different
Same Same/Same Same/Different
Different Different/Same Different/Different
Treated	
Strain
Parent	Strain
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The	custom	code	for	aim	3	can	be	found	in	the	Appendixes	E	(SNPs	and	indels)	and	F	(CNV	
detection).		
	
Results	
SNPs		
A	total	of	9	SNPs	(Table	4.2)	were	common	between	all	five	of	the	drug	pressure	replicates.		
One	of	the	identified	SNPs	results	in	the	Y268S	mutation	in	cytochrome	b	(mal_mito_3),	
which	is	known	to	be	the	primary	mechanism	of	atovaquone	resistance.	The	cytochrome	b	
mutation	in	this	variant	was	previously	confirmed	[212].		
	
Table	4.2	SNP	changes	that	occurred	in	all	5	atovaquone-treated	replicates.	3D7	reference	
refers	to	the	P.	falciparum	strain	that	was	used	to	perform	the	sequence	alignments.	
	
Cowell	et	al.	found	an	indel	in	the	promoter	region	(483	bp	upstream	of	TSS)	of	the	
PF3D7_0519500	gene,	which	encodes	the	putative	carbon	catabolite	repressor	protein	4,	
previously	shown	to	be	associated	with	resistance	to	MMV019662	[84].	An	Ile1276Thr	
substitution	in	this	protein	was	identified	in	all	5	of	the	atovaquone	treated	replicates.	This	
change	does	not	occur	in	a	recognizable	domain,	but	replacement	of	a	branched-chain	
amino	acid	with	a	polar	amino	acid	is	likely	to	result	in	protein	structural	changes.	The	
MalariaGEN	dataset	does	not	include	changes	at	this	position	in	P.	falciparum	[326].	While	
the	putative	carbon	catabolite	repressor	protein	4	is	not	predicted	to	be	essential	[289],	
Gene_ID Product	Description CHROM POS Parent	Allele Drug	Pressure	Allele 3D7	Reference	Allele Annotation Protein	Change
PF3D7_0305200
conserved	Plasmodium	protein,	
unknown	function Pf3D7_03_v3 251748 G C G missense	variant Met169Ile
PF3D7_0507800
conserved	Plasmodium	protein,	
unknown	function Pf3D7_05_v3 323247 C T C missense	variant Pro337Ser
PF3D7_0519500
carbon	catabolite	repressor	protein	
4,	putative Pf3D7_05_v3 805301 A G A missense	variant Ile1276Thr
PF3D7_0704300
conserved	Plasmodium	membrane	
protein,	unknown	function Pf3D7_07_v3 202279 G A G missense	variant Gly1530Asp
PF3D7_0730300
AP2	domain	transcription	factor	
AP2-L,	putative Pf3D7_07_v3 1E+06 C A C missense	variant Pro1024Thr
PF3D7_0812000
conserved	Plasmodium	protein,	
unknown	function Pf3D7_08_v3 602105 T C T missense	variant Lys48Arg
PF3D7_1010400
conserved	Plasmodium	protein,	
unknown	function Pf3D7_10_v3 416903 A C A missense	variant Tyr144Asp
PF3D7_1208800 zinc	finger	protein,	putative Pf3D7_12_v3 408020 G T G missense	variant Asp377Glu
mal_mito_3 cytochrome	b Pf_M76611 4294 A C A missense	variant Tyr268Ser
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protein	homology-based	analyses	lead	me	to	suggest	that	it	plays	a	role	in	regulating	mRNA	
half-life	by	acting	as	the	catalytic	subunit	of	the	ccr4/Pop2	deadenylase	complex	[327].		
	
The	transcription	factor	AP2	domain	transcription	factor-L,	putative	(PF3D7_0730300)	has	
a	consistent	Pro1024Thr	mutation	in	the	AP2	domain	in	all	5	of	the	atovaquone	treated	
replicates.	The	AP2	domain	is	the	DNA-binding	domain	of	the	transcription	factors,	and	no	
changes	at	this	site	in	P.	falciparum	have	been	reported	in	the	MalariaGEN	dataset.	Given	
that	this	site	shows	no	variation	in	P.	falciparum	field	isolates,	but	this	change	occurs	
consistently	under	atovaquone	drug	pressure	and	an	inflexible	aliphatic	amino	acid	is	
replaced	by	a	more	flexible	polar	amino	acid	changes	in	DNA-binding	efficiency	are	likely	to	
occur.	This	transcription	factor	is	not	essential	for	growth	of	the	parasite	in	the	blood	stage	
[289,	328]	and	is	primarily	required	for	completion	of	the	liver	stage	[328].	However,	its	
transcript	level	changes	throughout	the	blood	stage	[194,	329]	suggesting	it	regulates	
transcription	during	the	blood	stage.		
	
There	are	two	conserved	Plasmodium	proteins	of	unknown	function	with	mutations	in	
recognizable	domains	that	provide	hints	about	their	function.	The	gene	PF3D7_0507800	
contains	a	DnaJ-class	molecular	chaperone	with	C-terminal	Zn	finger	domain,	which	is	
associated	with	posttranslational	modifications,	turnover	and	chaperone	functions	[330-
332].	The	mutation	in	PF3D7_0507800	is	Pro337Ser.	Sequencing	of	field	isolates	indicated	
that	this	site	is	invariable,	and	given	the	major	structural	and	chemical	differences	between	
proline	and	serine	this	mutation	is	likely	to	impact	protein	function.		
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The	other	conserved	Plasmodium	protein	of	unknown	function	identified	with	known	
domains	is	PF3D7_1010400-encoded.	This	gene	encodes	a	Tyr144Asp	mutation	in	a	Nop14	
super	protein	family	domain.	This	domain	is	associated	with	rRNA	processing	[333],	and	
no	variants	at	this	position	have	been	found	in	P.	falciparum,	suggesting	that	this	change	
impacts	function.	The	protein	also	contains	two	repeats	of	the	domain	COG4642	
superfamily,	but	no	function	has	yet	been	associated	with	this	domain.		
	
Consistent	changes	occurred	in	a	putative	zinc	finger	protein	(encoded	by	
PF3D7_1208800).	The	Asp377Glu	change	occurred	outside	of	any	recognizable	domain,	
thus	it	is	not	clear	whether	this	change	impacts	the	function	of	the	protein.	No	mutations	
have	been	reported	at	this	position,	so	it	is	possible	this	change	does	impact	function.	The	
zinc	finger	domain	is	a	C3HC4	type,	which	is	frequently	associated	with	the	ubiquitination	
pathway	[334].		
	
The	conserved	Plasmodium	PF3D7_0305200-encoded	protein	of	unknown	function	
harbors	a	consistent	Met169Ille	mutation	in	response	to	atovaquone	selection.	This	
mutation	is	not	within	a	recognizable	domain,	but	this	position	has	no	known	mutations	in	
P.	falciparum.	As	the	name	implies	this	protein	has	no	well-established	function,	but	
contains	a	SMC	N-terminal	domain	which	is	often	involved	in	regulating	the	chromatin	
state	of	DNA	[330-332].		
	
The	conserved	Plasmodium	membrane	protein	of	unknown	function	PF3D7_0704300-
encoded	is	mutated	with	a	Gly1530Asp	substitution	in	response	to	atovaquone	selection	
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pressure.	This	membrane	protein	is	predicted	to	have	an	ABC2_membrane_3	domain,	
which	is	associated	with	drug	efflux	[335].	
	
Indels	
Two	indels	appear	consistently	in	the	five	atovaquone	treated	replicates	(Table	4.3).	The	
first	indel	produces	a	conserved	Plasmodium	protein	of	unknown	function	
(PF3D7_1248700-encoded)	with	a	disruptive	inframe	deletion.		This	protein	has	no	
identifiable	domains	but,	based	on	sequence	similarity,	is	predicted	to	localize	to	the	
nucleus	[336].		
	
Table	4.3	Indel	changes	that	occurred	in	all	5	atovaquone	treated	replicates.	3D7	refers	to	
the	P.	falciparum	strain	used	to	perform	the	sequence	alignments.		
	
	
The	other	indel	(PF3D7_1126800)	is	for	an	insertion	in	a	putative	RNA-binding	protein.	
The	insertion	is	after	any	recognizable	domain	and	corrects	a	deletion	that	occurred	in	the	
parent	strain.	Deletions	in	this	region	are	not	uncommon	[309],	and	since	the	gene	is	
predicted	to	be	dispensable	their	impact	on	the	protein’s	function	is	unclear.	The	protein	is	
predicted	to	have	strong	3D	structural	similarity	(40%	percent	identity	and	p-value	2	x	10-
14)	to	splicing	proteins	[309].	
	
	
	
Gene_ID Product_Description CHROM POS Parent	Allele Drug	Pressure	Allele 3D7	Reference	Allele Annotation Protein	Change
PF3D7_1248700
conserved	Plasmodium	
protein,	unknown	
function Pf3D7_12_v3 1996498 GTATTGATGAAGAAGA G GTATTGATGAAGAAGA disruptive	inframe	deletion Asp582_Ile586del
PF3D7_1126800
RNA-binding	protein,	
putative Pf3D7_11_v3 1050894 T TTAA TTAA disruptive	inframe	deletion Asn331insertion
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Copy	number	variation	
Three	of	the	five	atovaquone	treated	replicates	have	a	duplication	of	plasmepsin	II	and	
plasmepsin	III	(Figure	4.1).	These	are	neighboring	genes	on	the	chromosome	so	it	is	likely	
that	the	duplication	of	both	genes	results	from	a	single	duplication	events.		There	are	ten	
plasmepsins	in	the	P.	falciparum	genome	leading	to	the	possibility	that	the	observed	copy	
number	variation	could	be	the	result	of	mismapping.	However,	the	plasmepsins	without	a	
putative	increase	in	copy	number	all	show	fold	change	distributions	around	one		(Figure	
4.2)	suggesting	that	reads	were	not	being	inappropriately	mapped.	
	
The	plasmepsins	are	aspartic	proteases	and	plasmepsin	II	and	III	are	both	involved	in	
hemoglobin	degradation	in	the	food	vacuole	[24,	337].	Increased	copy	numbers	of	
plasmepsin	II	and	plasmepsin	III	have	not	been	previously	linked	to	atovaquone	resistance	
[60],	but	have	been	linked	to	piperaquine	resistance.	Piperaquine	is	thought	to	work	by	
inferring	with	hemoglobin	digestion	[338],	so	the	amplification	of	the	plasmepsins	as	a	
resistance	mechanism	is	consistent	with	the	hypothesized	mechanism	of	action.	The	
connection	between	the	plasmepsins	and	atovaquone	resistance	is	less	clear,	since	
atovaquone	targets	cytochrome	b	in	the	mitochondria.	Piperaquine	resistance	has	also	
been	associated	with	a	nonsynonymous	SNP	in	a	putative	mitochondrial	carrier	protein	1	
[339]	suggesting	that	there	may	be	a	connection	between	a	target	of	piperaquine	and	the	
mitochondria.	The	mitochondria	and	the	food	vacuole	co-localize	during	the	trophozoite	
stage	of	Plasmodium	chabaudi	[340]	and	hemoglobin	catabolism	is	a	source	of	heme	for	the	
mitochondrial	cytochromes	[341,	342],	suggesting	that	increased	degradation	of	
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hemoglobin	may	lead	to	more	functional	cytochrome	b	in	mitochondria	to	compensate	for	
inhibition	by	atovaquone.		
	
Figure	4.1	The	density	of	the	average	coverage	fold	changes	with	respect	to	the	
parent	strain.	Samples	12,	13,	and	16	have	a	duplication	of	Plasmepsin	II	and	Plasmepsin	
III.	As	expected	the	majority	of	genes	have	fold	changes	around	one	consistent	with	most	
genes	not	undergoing	copy	number	changes.		
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Figure	4.2	Fold	change	distribution	of	the	Plasmepsins.	Plasmepsins	are	a	gene	family	in	P.	
falciparum	raising	concerns	that	the	observed	copy	number	variation	results	from	
mismapping	given	that	the	genes	have	very	similar	sequences.	The	plasmepsins	not	
associated	with	copy	number	variation	have	fold	changes	around	one,	suggesting	that	
reads	were	not	inappropriately	mapped	to	the	plasmepsin	II	or	plasmepsin	III.	[CNV,	copy	
number	variation].	Density	refers	to	the	proportion		of	the	genes	with	the	fold	change	
specified	on	the	x-axis.		
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However,	when	atovaquone	is	used	as	a	single	agent	P.	falciparum	rapidly	acquires	
resistance	to	atovaquone,	and	atovaquone	resistance	has	been	attributed	to	prophylaxis	
failures	in	travelers	[343].	The	atovaquone	resistance	Y268S	mutation	in	cytochrome	b	
comes	with	a	fitness	cost	[80,	81],	and	so	compensatory	changes	in	the	genetic	background	
will	likely	occur	for	atovaquone	resistance	to	spread.	Whole	genome	sequencing	of	P.	
falciparum	parasites	cultured	under	atovaquone	pressure	resulted	in	the	canonical	
atovaquone	resistance	mutation	Y268S	in	cytochrome	b.	The	additional	changes	occurred	
in	genes	either	known	to	be	involved	in	gene	regulation	or	that	have	protein	domains	that	
strongly	hint	at	involvement	in	gene	regulation.	
	
Four	of	the	eleven	mutated	genes	are	for	proteins	involved	in	transcriptional	regulation.	
One	of	these	genes	(PF3D7_0519500)	encodes	carbon	catabolite	repressor	4,	which	has	
previously	been	implicated	in	drug	resistance	[84]	and	regulation	of	mRNA	half-life	[327].		
Another	gene	(PF3D7_1126800)	encodes	for	a	protein	bearing	strong	homology	to	known	
alternative	splicing	proteins	[309].	Two	of	the	mutations	are	likely	to	affect	the	rates	of	
transcription	for	certain	genes,	since	one	(PF3D7_0730300)	encodes	a	transcription	factor	
with	changes	to	its	DNA	binding	domain,	and	the	other	protein	(PF3D7_0305200-encoded)	
contains	a	domain	associated	with	regulation	of	chromatin	[330-332].	These	four	changes	
are	likely	to	result	in	changes	in	the	transcription	profile	of	resistant	strains	via	changes	in	
the	amount	of	transcription	occurring	for	certain	genes	and	how	genes	are	being	post-
transcriptionally	regulated.	
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Three	of	the	eleven	mutated	genes	are	involved	in	regulating	translation	or	post-
translational	modifications.	The	protein	encoded	by	PF3D7_1010400	contains	a	Nop14	
super	family	domain	which	has	been	linked	to	regulating	rRNA	processing	in	response	to	
stress	[333].	The	other	two	proteins		(encoded	by	PF3D7_0507800	and	PF3D7_128800)	
contain	domains	associated	with	post-translation	regulation	either	via	post-translation	
modification,	aiding	folding,	or	promoting	degradation	[330-332].	Not	enough	is	known	
about	these	particular	genes	to	make	firm	predictions	about	how	these	genetic	changes	will		
effect	the	proteome,	nevertheless,		coupled	with	the	changes	in	transcriptional	regulatory	
genes,	our	results	suggests	that	modifications	to	the	wider	proteome	occurred	as	a	result	of	
atovaquone	evolutionary	pressure.			
	
Copy	number	variation	of	plasmepsin	II	and	plasmepsin	III	are	known	antimalarial	drug	
resistance	mechanisms	[90,	339,	344],	but	until	now	they	have	not	been	associated	with	
atovaquone	resistance.	Since	the	plasmepsins	are	involved	in	hemoglobin	digestion,	and	
degradation	of	hemoglobin	can	yield	heme	to	mitochondrial	cytochromes	[80,	81]	the	
increased	production	of	plasmepsins	may	increase	the	number	of	functional	cytochrome	
b’s	in	the	presence	of	atovaquone.		
	
It	is	striking	that	most	of	the	genes	identified	to	vary	consistently	among	the	drug	resistant	
strains	and	the	parent	strain	are	linked	to	regulation	either	at	the	transcript	or	protein	
levels.	This	suggests	that	compensatory	changes	have	occurred	to	increase	the	fitness	of	
the	atovaquone	resistant	parasites.	Further	studies	examining	how	these	genes	affect	the	
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parasites	response	to	atovaquone	will	shed	light	on	the	resistance	mechanisms	likely	to	be	
used	by	P.	falciparum	to	survive	atovaquone	treatment	in	the	field.	
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Summary	
	
As	long	as	drugs	are	used	to	treat	and	control	malaria,	the	threat	of	drug	resistance	will	be	
present.	It	is	estimated	that	should	artemisinin	resistance	become	wide-spread,	an	
additional	116,000	humans	will	be	killed	by	malaria	annually	[345].		Artemisinins	have	
helped	decrease	the	prevalence	of	P.	falciparum	[346]	and	this	decreased	prevalence	has	
led	to	reduced	immunity	[28]	in	the	human	populations.	Therefore,	should	artemisinins	
fail,	malaria	deaths	will	likely	spike	higher	than	the	current	estimates.		
	
Containing	drug	resistance	requires	field	monitoring	and	understanding	of	resistance	
mechanisms.	Next	generation	sequencing	technology	allows	the	rapid	identification	and	
confirmation	of	drug	resistance	mechanisms.	It	took	over	40	years	to	identify	the	gene	
involved	in	chloroquine	resistance.	In	contrast,	due	to	next	generation	sequencing	it	took	
just	5	years	from	the	first	hints	of	arteminsin	resistance	to	the	identification	of	K13	as	the	
major	predictor	of	resistance.	
	
Genome	sequencing	allows	the	identification	of	drug	resistance	markers,	while	
transcriptomics	allows	the	inference	of	the	pathways	involved	in	drug	resistance.	The	work	
described	here	aimed	at	identifying	the	function	of	artemisinin	resistance	gene	k13	and	
identifying	the	mechanisms	of	resistance	to	a	possible	arteminsin	alternative	atovaquone.		
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The	first	aim	of	the	thesis	was	developed	to	address	a	need	for	a	new	methodology.	The	
transcriptomes	of	an	isogenic	k13	dysregulation	mutant	and	the	parent	strain	were	
sequenced	to	identify	the	processes	regulated	by	K13.	Despite	the	k13	mutant	having	
increased	sensitivity	to	both	artemisinins	and	proteasome	inhibitors	and	harboring	major	
alterations	in	its	transcriptome,	these	changes	could	not	be	linked	to	any	particular	gene	or	
genes.	This	is	a	well-known	problem	in	the	malaria	field	that	stems	from	low	statistical	
power	caused	by	low	fold	changes	and	large	fluctuations	among	the	members	of	antigenic	
variation	gene	families.	Gene	set	analysis	can	be	used	to	increase	statistical	power,	but	it	is	
unlikely	to	find	novel	relationships	between	genes	and	presently	there	are	no	reliable	
methods	to	link	the	dysregulated	gene	sets	to	the	observed	transcriptome	shifts.		
	
To	solve	these	problems	described	above,	I	developed,	what	is	to	my	knowledge,	a	novel	
algorithm	to	identify	the	genes	responsible	for	transcriptome	cycle	shifts.		The	DI	algorithm	
identified	a	group	of	genes	that	contained	more	functionally	related	groups	of	genes	and	
experienced	greater	co-regulation	than	expected	by	chance.	The	DI	algorithm	is	not	limited	
to	studying	transcriptomes	and	can	be	applied	to	any	data	set	with	a	periodic	structure.		
	
	
The	studies	described	in	chapter	2	allowed	the	identification	of	DNA	replication	as	a	
dysregulated	pathway	in	the	k13	mutant.	With	the	studies	reported	in	chapter	3,	I	aimed	to	
establish	if	there	was	a	link	between	K13	and	the	observed	dysregulation	in	DNA	
replication.	Statistical	analysis	of	currently	annotated	P.	falciparum	pathways	confirmed	
that	DNA	replication	and	DNA	repair	are	dysregulated	in	the	k13	mutant.	I	further	
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confirmed	that	the	observed	dysregulation	did	not	result	from	sample	time	point	
misalignment	by	checking	for	dysregulation	in	other	pathways	that	undergo	similar	rates	
of	transcriptional	regulation	and	demonstrated	that	DNA	replication	and	repair	genes	were	
expressed	at	higher	levels	at	6	hours	in	the	mutant	than	at	24	hours.		
	
Given	K13’s	homology	to	known	transcriptional	regulator	Keap1	and	the	fact	that	specific	
pathways	were	dysregulated	in	response	to	K13	dysregulation	the	up-regulated	6-hour	
dephasing	genes	were	cross-referenced	with	genes	containing	transcription	factor	binding	
sites	in	their	promoter	regions	linked	to	DNA	replication.	This	cross-referencing	
demonstrated	that	the	up-regulated	6-hour	dephasing	genes	are	more	likely	to	have	a	
binding	site	for	a	putative	AP2	domain	transcription	factor	(PF3D7_0802100-encoded)	
than	expected	by	chance.	Further	a	previous	computational	analysis	predicted	K13	has	a	
functional	relationship	with	replication	factor	C,	which	is	consistent	with	my	results.	These	
results	suggest	a	model	where	K13	negatively	regulates	a	pro-growth	regulatory	unit.		
	
Given	K13’s	essentiality,	a	dose	response	study	would	be	the	best	way	to	further	validate	
K13’s	link	to	DNA	replication	and	repair.	Given	the	difficulty	of	genetically	editing	P.	
falciparum	a	k13	episome	with	an	inducible	promoter	maybe	the	best	approach.	There	are	
keap1	inhibitors	[347]	and	if	they	are	active	against	K13	these	can	also	be	used	in	a	dose	
response	study.	Single	cell	sequencing	offers	another	avenue	for	validation.	Traditional	
RNA-sequencing	approaches	provide	a	population	average	for	a	genes	transcription.	By	
sequencing	the	RNA	from	individual	parasites	the	inherent	variability	of	a	biological	system	
may	be	used	to	see	if	there	is	co-variation	between	K13	and	DNA	replication	and	repair	
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genes	on	a	single	cell	level.	The	single	cell	sequencing	approach	could	also	be	used	to	
confirm	the	observed	transcriptome	shift	since	the	population	structure	of	the	k13	mutant	
should	show	a	shift	relative	to	the	parent	strain.		
	
The	major	aim	described	in	chapter	4	was	to	identify	the	resistance	mechanisms	of	the	
potential	arteminsin	replacement	atovaquone.	Understanding	the	evolution	of	atovaquone	
resistance	will	allow	the	development	of	treatment	strategies	to	prolong	the	life	of	
atovaquone	as	a	treatment.	This	aim	was	accomplished	by	analyzing	the	whole	genome	
sequences	of	a	P.	falciparum	strain	taken	from	a	patient	that	subsequently	failed	treatment	
with	atovaquone	and	that	had	its	resistance	to	atovaquone	enhanced	by	subjecting	the	
strain	to	further	atovaquone	pressure	in	vitro.	The	subsequent	changes	from	the	continued	
drug	pressure	are	likely	to	represent	compensatory	that	decrease	the	cost	of	the	primary	
drug	resistance	mechanism.	Most	of	the	identified	genes	have	evidence	of	being	involved	in	
regulation	with	4	of	the	11	altered	genes	regulating	transcripts	and	3	being	involved	in	
regulating	translation	or	post-translational	modifications.	Three	of	the	five	replicate	strains	
have	copy	number	increases	in	the	genes	for	plasmepsin	II	and	plasmepsin	III	which	may	
be	involved	in	ultimately	increasing	heme	production	to	create	more	functional	
cytochrome	b	subunits.		
	
The	results	of	the	studies	described	in	chapter	4	provide	a	list	of	candidate	genes	that	are	
likely	to	be	involved	in	modulating	atovaquone	resistance.	Genetic	engineering	studies	may	
be	conducted	to	confirm	that	these	genes	are	associated	with	atovaquone	resistance.	It	may	
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also	be	possible	to	chemically	inhibit	some	of	the	genes	to	measure	the	effect	on	
susceptibility	to	atovaquone.	
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DNA	Replication	and	Repair	
[Gene	ID] [Product	Description]
PF3D7_0107800 double-strand	break	repair	protein	MRE11
PF3D7_0203300 ERCC1	nucleotide	excision	repair	protein,	putative
PF3D7_0206000 DNA	repair	protein	RAD2,	putative
PF3D7_0217400 conserved	Plasmodium	protein,	unknown	function
PF3D7_0219600 replication	factor	C	subunit	1,	putative
PF3D7_0305600 AP	endonuclease	(DNA-[apurinic	or	apyrimidinic	site]	lyase),	putative
PF3D7_0408500 flap	endonuclease	1
PF3D7_0416400 histone	acetyltransferase,	putative
PF3D7_0505500 DNA	mismatch	repair	protein	MSH6,	putative
PF3D7_0509500 ERCC4	domain-containing	protein,	putative
PF3D7_0513600 deoxyribodipyrimidine	photo-lyase,	putative
PF3D7_0605800 DNA	repair	protein	RAD50,	putative
PF3D7_0614800 endonuclease	III	homologue,	putative
PF3D7_0619100 conserved	Plasmodium	protein,	unknown	function
PF3D7_0628500 conserved	Plasmodium	protein,	unknown	function
PF3D7_0706700 DNA	mismatch	repair	protein	MSH2,	putative
PF3D7_0709500 conserved	Plasmodium	protein,	unknown	function
PF3D7_0710100 conserved	Plasmodium	protein,	unknown	function
PF3D7_0710400 DNA	repair	protein	RAD14,	putative
PF3D7_0725000 exonuclease	I,	putative
PF3D7_0726300 DNA	mismatch	repair	protein	PMS1,	putative
PF3D7_0803400 DNA	repair	and	recombination	protein	RAD54,	putative
PF3D7_0816800 meiotic	recombination	protein	DMC1,	putative
PF3D7_0910500 DNA	repair	protein	REV1,	putative
PF3D7_0917100 N-glycosylase/DNA	lyase,	putative
PF3D7_1003700 MKT1	domain-containing	protein,	putative
PF3D7_1008200 endonuclease,	putative
PF3D7_1011700 DNA	repair	protein	RAD23,	putative
PF3D7_1031300 conserved	Plasmodium	protein,	unknown	function
PF3D7_1037600 DNA	repair	helicase	RAD25,	putative
PF3D7_1106000 RuvB-like	helicase	2
PF3D7_1107400 DNA	repair	protein	RAD51
PF3D7_1112600 DNA	helicase,	putative
PF3D7_1117800 DNA	mismatch	repair	protein	MLH
PF3D7_1129500 A/G-specific	adenine	glycosylase,	putative
PF3D7_1140300 P-loop	containing	nucleoside	triphosphate	hydrolase,	putative
PF3D7_1215700 conserved	Plasmodium	protein,	unknown	function
PF3D7_1244200 RNA	polymerase	II	transcription	factor	B	subunit	2,	putative
PF3D7_1250800 DNA	repair	protein	rhp16,	putative
PF3D7_1303800 conserved	Plasmodium	protein,	unknown	function
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	 	PF3D7_1304100 DNA	ligase	I
PF3D7_1314900 general	transcription	factor	IIH	subunit	2
PF3D7_1316900 conserved	Plasmodium	protein,	unknown	function
PF3D7_1328200 conserved	Plasmodium	protein,	unknown	function
PF3D7_1332100 conserved	Plasmodium	membrane	protein,	unknown	function
PF3D7_1332600 apurinic/apyrimidinic	endonuclease	Apn1,	putative
PF3D7_1338400 SprT-like	domain-containing	protein,	putative
PF3D7_1353500 RNA	polymerase	II	transcription	factor	B	subunit	4,	putative
PF3D7_1368300 conserved	Plasmodium	protein,	unknown	function
PF3D7_1368800 DNA	repair	endonuclease,	putative
PF3D7_1405400 DNA	mismatch	repair	protein,	putative
PF3D7_1415000 uracil-DNA	glycosylase
PF3D7_1427500 DNA	mismatch	repair	protein	MSH2,	putative
PF3D7_1429900 ADP-dependent	DNA	helicase	RecQ
PF3D7_1441900 RNA	polymerase	II	transcription	factor	B	subunit	5,	putative
PF3D7_1442100 replication	factor	A	protein	3,	putative
PF3D7_1455300 conserved	Plasmodium	protein,	unknown	function
PF3D7_1461000 conserved	Plasmodium	protein,	unknown	function
PF3D7_1467100 DNA-3-methyladenine	glycosylase,	putative
PF3D7_1471600 conserved	Plasmodium	protein,	unknown	function
PF3D7_0108600 conserved	Plasmodium	protein,	unknown	function
PF3D7_0111300 replication	factor	c	protein,	putative
PF3D7_0215800 origin	recognition	complex	subunit	5
PF3D7_0217400 conserved	Plasmodium	protein,	unknown	function
PF3D7_0218000 replication	factor	C	subunit	2,	putative
PF3D7_0219600 replication	factor	C	subunit	1,	putative
PF3D7_0308000 DNA	polymerase	delta	small	subunit,	putative
PF3D7_0317200 cdc2-related	protein	kinase	4
PF3D7_0409600 replication	protein	A1,	large	subunit
PF3D7_0411900 DNA	polymerase	alpha	catalytic	subunit	A
PF3D7_0416300 DNA	helicase	MCM9,	putative
PF3D7_0503200 conserved	Plasmodium	protein,	unknown	function
PF3D7_0508800 single-stranded	DNA-binding	protein
PF3D7_0527000 DNA	replication	licensing	factor	MCM3,	putative
PF3D7_0625300 DNA	polymerase	1,	putative
PF3D7_0630300 DNA	polymerase	epsilon	catalytic	subunit	A,	putative
PF3D7_0705300 origin	recognition	complex	subunit	2,	putative
PF3D7_0705400 DNA	replication	licensing	factor	MCM7
PF3D7_0709500 conserved	Plasmodium	protein,	unknown	function
PF3D7_0910500 DNA	repair	protein	REV1,	putative
PF3D7_0910900 DNA	primase	large	subunit,	putative
PF3D7_0917500 conserved	Plasmodium	protein,	unknown	function
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	 	PF3D7_1015800 ribonucleoside-diphosphate	reductase	small	chain,	putative
PF3D7_1017000 DNA	polymerase	delta	catalytic	subunit
PF3D7_1029900 conserved	Plasmodium	protein,	unknown	function
PF3D7_1037000 DNA	polymerase	zeta	catalytic	subunit,	putative
PF3D7_1106700 DNA	replication	ATP-dependent	helicase/nuclease	DNA2,	putative
PF3D7_1107400 DNA	repair	protein	RAD51
PF3D7_1111100 replication	factor	C	subunit	5,	putative
PF3D7_1112600 DNA	helicase,	putative
PF3D7_1127100 deoxyuridine	5'-triphosphate	nucleotidohydrolase
PF3D7_1203000 origin	recognition	complex	subunit	1
PF3D7_1211300 DNA	helicase	MCM8,	putative
PF3D7_1211700 DNA	replication	licensing	factor	MCM5,	putative
PF3D7_1217100.2 meiotic	recombination	protein	SPO11,	putative
PF3D7_1234300 DNA	polymerase	epsilon	subunit	B,	putative
PF3D7_1241700 replication	factor	C	subunit	4,	putative
PF3D7_1304100 DNA	ligase	I
PF3D7_1314200 telomerase	reverse	transcriptase
PF3D7_1317100 DNA	replication	licensing	factor	MCM4
PF3D7_1334100 conserved	Plasmodium	protein,	unknown	function
PF3D7_1343300 conserved	Plasmodium	protein,	unknown	function
PF3D7_1347100 DNA	topoisomerase	3,	putative
PF3D7_1355100 DNA	replication	licensing	factor	MCM6
PF3D7_1359200 high	mobility	group	protein	B4,	putative
PF3D7_1405300 conserved	Plasmodium	protein,	unknown	function
PF3D7_1411300 conserved	Plasmodium	protein,	unknown	function
PF3D7_1411400 plastid	replication-repair	enzyme
PF3D7_1417800 DNA	replication	licensing	factor	MCM2
PF3D7_1425900 conserved	Plasmodium	protein,	unknown	function
PF3D7_1429900 ADP-dependent	DNA	helicase	RecQ
PF3D7_1437200 ribonucleoside-diphosphate	reductase	large	subunit,	putative
PF3D7_1438700 DNA	primase	small	subunit
PF3D7_1442100 replication	factor	A	protein	3,	putative
PF3D7_1463200 replication	factor	C	subunit	3,	putative
PF3D7_1463300 DNA	polymerase	alpha	subunit	B,	putative
Translation
[Gene	ID] [Product	Description]
PF3D7_0102900 aspartate--tRNA	ligase
PF3D7_0106600 conserved	Plasmodium	protein,	unknown	function
PF3D7_0107400 conserved	Apicomplexan	protein,	unknown	function
PF3D7_0109800 phenylalanine--tRNA	ligase	alpha	subunit
PF3D7_0110100 selenocysteine-specific	elongation	factor	selB	homologue,	putative
PF3D7_0111700 conserved	Plasmodium	protein,	unknown	function
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	 	PF3D7_0111800 eukaryotic	translation	initiation	factor	4E,	putative
PF3D7_0209500 conserved	Plasmodium	protein,	unknown	function
PF3D7_0210100 60S	ribosomal	protein	L37ae,	putative
PF3D7_0210100 60S	ribosomal	protein	L37ae,	putative
PF3D7_0210400 50S	ribosomal	protein	L33,	putative
PF3D7_0211800 asparagine--tRNA	ligase
PF3D7_0212200 mitochondrial	ribosomal	protein	L12	precursor,	putative
PF3D7_0212300 peptide	chain	release	factor	subunit	1,	putative
PF3D7_0212500 conserved	Plasmodium	protein,	unknown	function
PF3D7_0214200 mitochondrial	ribosomal	protein	L13	precursor,	putative
PF3D7_0217800 40S	ribosomal	protein	S26
PF3D7_0219200 40S	ribosomal	protein	S30
PF3D7_0304400 60S	ribosomal	protein	L44
PF3D7_0305000 elongation	factor	Ts
PF3D7_0305400 conserved	Plasmodium	protein,	unknown	function
PF3D7_0306900 40S	ribosomal	protein	S23,	putative
PF3D7_0307100 40S	ribosomal	protein	S12,	putative
PF3D7_0307200 60S	ribosomal	protein	L7,	putative
PF3D7_0309600 60S	acidic	ribosomal	protein	P2
PF3D7_0310000 50S	ribosomal	protein	L9,	apicoplast,	putative
PF3D7_0310300 phosphoglycerate	mutase,	putative
PF3D7_0311200 valine--tRNA	ligase,	putative
PF3D7_0312800 60S	ribosomal	protein	L26,	putative
PF3D7_0315100 eukaryotic	translation	initiation	factor	4E
PF3D7_0315500 mitochondrial	ribosomal	protein	L29/L47	precursor,	putative
PF3D7_0316100 mitochondrial	ribosomal	protein	L27	precursor,	putative
PF3D7_0316800 40S	ribosomal	protein	S15A,	putative
PF3D7_0317100 6-cysteine	protein
PF3D7_0317600 40S	ribosomal	protein	S11,	putative
PF3D7_0319600 elongation	factor	1-delta,	putative
PF3D7_0322900 40S	ribosomal	protein	S3A,	putative
PF3D7_0406800 ribosomal	protein	L25,	putative
PF3D7_0409700 peptide	chain	release	factor	2
PF3D7_0411200 conserved	Plasmodium	protein,	unknown	function
PF3D7_0412100 mitochondrial	ribosomal	protein	S12	precursor,	putative
PF3D7_0415900 60S	ribosomal	protein	L15,	putative
PF3D7_0418000 conserved	Plasmodium	protein,	unknown	function
PF3D7_0419800 60S	ribosomal	protein	L7ae/L30e,	putative
PF3D7_0422400 40S	ribosomal	protein	S19
PF3D7_0423300 conserved	Plasmodium	protein,	unknown	function
PF3D7_0425300 Plasmodium	exported	protein	(PHISTa),	unknown	function,	pseudogene
PF3D7_0503000 50S	ribosomal	protein	L28,	apicoplast,	putative
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	 	PF3D7_0503800 60S	ribosomal	protein	L31
PF3D7_0506100 60S	ribosomal	subunit	protein	L24,	putative
PF3D7_0507100 60S	ribosomal	protein	L4
PF3D7_0509600 asparagine--tRNA	ligase
PF3D7_0514300 aspartate--tRNA	ligase,	putative
PF3D7_0516200 40S	ribosomal	protein	S11
PF3D7_0516600 sporozoite	surface	antigen	MB2
PF3D7_0516900 60S	ribosomal	protein	L2
PF3D7_0517000 60S	ribosomal	protein	L12,	putative
PF3D7_0517700 eukaryotic	translation	initiation	factor	3	subunit	B,	putative
PF3D7_0519100 mitochondrial	ribosomal	protein	L14	precursor,	putative
PF3D7_0519400 40S	ribosomal	protein	S24
PF3D7_0520000 40S	ribosomal	protein	S9,	putative
PF3D7_0522500 50S	ribosomal	protein	L17,	apicoplast,	putative
PF3D7_0524600 50S	ribosomal	protein	L12,	apicoplast,	putative
PF3D7_0528900 conserved	Plasmodium	protein,	unknown	function
PF3D7_0531200 mitochondrial	ribosomal	protein	S16	precursor,	putative
PF3D7_0602000 conserved	Plasmodium	protein,	unknown	function
PF3D7_0602400 elongation	factor	G
PF3D7_0603700 phenylalanine--tRNA	ligase
PF3D7_0605000 50S	ribosomal	protein	L24,	putative
PF3D7_0607000 translation	initiation	factor	IF-2,	putative
PF3D7_0610000 mitochondrial	ribosomal	protein	L19	precursor,	putative
PF3D7_0610900 transcription	elongation	factor	SPT5,	putative
PF3D7_0611700 60S	ribosomal	protein	L39
PF3D7_0613400 apicoplast	ribosomal	protein	L18	precursor,	putative
PF3D7_0614500 60S	ribosomal	protein	L19
PF3D7_0614600 conserved	Plasmodium	protein,	unknown	function
PF3D7_0618300 60S	ribosomal	protein	L27a,	putative
PF3D7_0619200 conserved	Plasmodium	protein,	unknown	function
PF3D7_0620200 conserved	Plasmodium	protein,	unknown	function
PF3D7_0622800 leucine--tRNA	ligase,	putative
PF3D7_0704100 conserved	Plasmodium	membrane	protein,	unknown	function
PF3D7_0704900 peptide	chain	release	factor	2
PF3D7_0705700 40S	ribosomal	protein	S29,	putative
PF3D7_0706400 60S	ribosomal	protein	L37
PF3D7_0706500 conserved	Plasmodium	protein,	unknown	function
PF3D7_0710600 60S	ribosomal	protein	L34
PF3D7_0713600 mitochondrial	ribosomal	protein	S5	precursor,	putative
PF3D7_0715600 GTP-binding	translation	elongation	factor	tu	family	protein,	putative
PF3D7_0716800 eukaryotic	translation	initiation	factor	3	subunit	I,	putative
PF3D7_0717700 serine--tRNA	ligase,	putative
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	 	PF3D7_0718400 mitochondrial	ribosomal	protein	S8	precursor,	putative
PF3D7_0719600 60S	ribosomal	protein	L11a,	putative
PF3D7_0719700 40S	ribosomal	protein	S10,	putative
PF3D7_0721600 40S	ribosomal	protein	S5,	putative
PF3D7_0728000 eukaryotic	translation	initiation	factor	2	subunit	alpha,	putative
PF3D7_0807900 tyrosine--tRNA	ligase
PF3D7_0810100 apicoplast	ribosomal	protein	L33	precursor,	putative
PF3D7_0813600 translation	initiation	factor	SUI1,	putative
PF3D7_0813900 40S	ribosomal	protein	S16,	putative
PF3D7_0814000 60S	ribosomal	protein	L13-2,	putative
PF3D7_0815600 eukaryotic	translation	initiation	factor	3	subunit	G,	putative
PF3D7_0820800 conserved	Plasmodium	protein,	unknown	function
PF3D7_0821700 60S	ribosomal	protein	L22,	putative
PF3D7_0822000 mitochondrial	ribosomal	protein	L4	precursor,	putative
PF3D7_0825200 translation	initiation	factor	IF-3
PF3D7_0827100 translation	initiation	factor	IF-2,	putative
PF3D7_0827500 apicoplast	ribosomal	protein	L21	precursor,	putative
PF3D7_0828200 leucine--tRNA	ligase,	putative
PF3D7_0829000 conserved	Plasmodium	membrane	protein,	unknown	function
PF3D7_0903300 conserved	Plasmodium	membrane	protein,	unknown	function
PF3D7_0903900 60S	ribosomal	protein	L32
PF3D7_0907600 translation	initiation	factor	SUI1,	putative
PF3D7_0907800 apicoplast	ribosomal	protein	L35	precursor,	putative
PF3D7_0911100 conserved	Plasmodium	protein,	unknown	function
PF3D7_0912800 tRNA	(adenine(58)-N(1))-methyltransferase	non-catalytic	subunit	TRM6,	putative
PF3D7_0913200 elongation	factor	1-beta
PF3D7_0913400 conserved	Plasmodium	protein,	unknown	function
PF3D7_0913900 arginine--tRNA	ligase,	putative
PF3D7_0918200 50S	ribosomal	protein	L3,	apicoplast,	putative
PF3D7_0918300 eukaryotic	translation	initiation	factor	3	subunit	F,	putative
PF3D7_0922800 conserved	Plasmodium	protein,	unknown	function
PF3D7_0923500 cyclin-dependent	kinases	regulatory	subunit,	putative
PF3D7_0925300 proline--tRNA	ligase,	putative
PF3D7_0932400 peptide	chain	release	factor	1
PF3D7_0932600 apicoplast	ribosomal	protein	S6,	putative
PF3D7_0934000 histidine--tRNA	ligase,	putative
PF3D7_0934200 conserved	Plasmodium	protein,	unknown	function
PF3D7_0934600 conserved	Plasmodium	protein,	unknown	function
PF3D7_0935700 Plasmodium	exported	protein,	unknown	function
PF3D7_1003500 40S	ribosomal	protein	S20e,	putative
PF3D7_1004000 60S	ribosomal	protein	L13,	putative
PF3D7_1005000 methionine--tRNA	ligase,	putative
150	
	
	 	PF3D7_1007900 eukaryotic	translation	initiation	factor	3	subunit	D,	putative
PF3D7_1010600 eukaryotic	translation	initiation	factor	2	subunit	beta
PF3D7_1010800 50S	ribosomal	protein	L22,	mitochondrial,	putative
PF3D7_1015200 cysteine--tRNA	ligase
PF3D7_1015200 cysteine--tRNA	ligase
PF3D7_1015200 cysteine--tRNA	ligase
PF3D7_1016500 Plasmodium	exported	protein	(PHISTc),	unknown	function
PF3D7_1017700 conserved	Plasmodium	protein,	unknown	function
PF3D7_1019400 60S	ribosomal	protein	L30e,	putative
PF3D7_1026800 40S	ribosomal	protein	S2
PF3D7_1027200 mitochondrial	ribosomal	protein	S22	precursor,	putative
PF3D7_1027800 60S	ribosomal	protein	L3
PF3D7_1030300 conserved	Plasmodium	protein,	unknown	function
PF3D7_1034200 apicoplast	ribosomal	protein	L27	precursor,	putative
PF3D7_1034600 translation	initiation	factor	IF-3,	putative
PF3D7_1034900 methionine--tRNA	ligase
PF3D7_1103100 60S	acidic	ribosomal	protein	P1,	putative
PF3D7_1104000 phenylalanine--tRNA	ligase	beta	subunit
PF3D7_1105400 40S	ribosomal	protein	S4,	putative
PF3D7_1106100 apicoplast	ribosomal	protein	S15	precursor,	putative
PF3D7_1109900 60S	ribosomal	protein	L36
PF3D7_1110600 mitochondrial	ribosomal	protein	L11	precursor,	putative
PF3D7_1117500 tyrosine--tRNA	ligase
PF3D7_1117600 peptidyl-tRNA	hydrolase	ICT1,	peptidyl-tRNA	hydrolase	ICT1,	putative
PF3D7_1117600 peptidyl-tRNA	hydrolase	ICT1,	peptidyl-tRNA	hydrolase	ICT1,	putative
PF3D7_1123400 translation	elongation	factor	EF-1,	subunit	alpha,	putative
PF3D7_1124900 60S	ribosomal	protein	L35,	putative
PF3D7_1126000 threonine--tRNA	ligase
PF3D7_1126200 40S	ribosomal	protein	S18,	putative
PF3D7_1130100 60S	ribosomal	protein	L38
PF3D7_1130200 60S	ribosomal	protein	P0
PF3D7_1132700 50S	ribosomal	protein	L2,	putative
PF3D7_1137100 mitochondrial	ribosomal	protein	S9	precursor,	putative
PF3D7_1137500 apicoplast	ribosomal	protein	S14p/S29e	precursor,	putative
PF3D7_1142600 60S	ribosomal	protein	L35ae,	putative
PF3D7_1143400 translation	initiation	factor	eIF-1A,	putative
PF3D7_1144000 40S	ribosomal	protein	S21
PF3D7_1144100 mitochondrial	large	subunit	ribosomal	protein,	putative
PF3D7_1144300 60S	ribosomal	protein	L41
PF3D7_1145800 conserved	Plasmodium	protein,	unknown	function
PF3D7_1147000 sporozoite	and	liver	stage	asparagine-rich	protein
PF3D7_1204300 eukaryotic	translation	initiation	factor	5A
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	 	PF3D7_1206200 eukaryotic	translation	initiation	factor	3	subunit	C,	putative
PF3D7_1206700 eukaryotic	translation	initiation	factor	5,	putative
PF3D7_1208000 apicoplast	ribosomal	protein	L29	precursor,	putative
PF3D7_1210000 50S	ribosomal	protein	L1,	apicoplast,	putative
PF3D7_1211500 mitochondrial	ribosomal	protein	S18	precursor,	putative
PF3D7_1212700 eukaryotic	translation	initiation	factor	3	subunit	A,	putative
PF3D7_1213800 proline--tRNA	ligase
PF3D7_1216000 serine--tRNA	ligase,	putative
PF3D7_1218600 arginine--tRNA	ligase
PF3D7_1223900 50S	ribosomal	protein	L24,	putative
PF3D7_1225100 isoleucine--tRNA	ligase,	putative
PF3D7_1232000 phenylalanine--tRNA	ligase
PF3D7_1233000 elongation	factor	G
PF3D7_1235400 tetQ	family	GTPase,	putative
PF3D7_1239100 mitochondrial	ribosomal	protein	L23	precursor,	putative
PF3D7_1239400 conserved	Plasmodium	protein,	unknown	function
PF3D7_1242700 40S	ribosomal	protein	S17,	putative
PF3D7_1243600 translation	initiation	factor	SUI1,	putative
PF3D7_1245400 mitochondrial	ribosomal	protein	L3	precursor,	putative
PF3D7_1246700 conserved	Plasmodium	protein,	unknown	function
PF3D7_1251700 tryptophan--tRNA	ligase
PF3D7_1302800 40S	ribosomal	protein	S7,	putative
PF3D7_1308300 40S	ribosomal	protein	S27
PF3D7_1309100 60S	ribosomal	protein	L24,	putative
PF3D7_1310900 mitochondrial	ribosomal	protein	S15	precursor,	putative
PF3D7_1312400 translation	initiation	factor	IF-2,	putative
PF3D7_1313200 methionyl-tRNA	formyltransferase,	putative
PF3D7_1317800 40S	ribosomal	protein	S19
PF3D7_1322800 conserved	Plasmodium	protein,	unknown	function
PF3D7_1323100 60S	ribosomal	protein	L6,	putative
PF3D7_1323400 60S	ribosomal	protein	L23
PF3D7_1324600 conserved	Plasmodium	protein,	unknown	function
PF3D7_1326400 translation	initiation	factor	eIF-2B	subunit	gamma,	putative
PF3D7_1330600 elongation	factor	Tu,	putative
PF3D7_1331700 glutamine--tRNA	ligase,	putative
PF3D7_1331800 60S	ribosomal	protein	L23,	putative
PF3D7_1332200 conserved	Plasmodium	protein,	unknown	function
PF3D7_1332900 isoleucine--tRNA	ligase,	putative
PF3D7_1336200 conserved	Plasmodium	protein,	unknown	function
PF3D7_1336900 tryptophan--tRNA	ligase
PF3D7_1337900 conserved	Plasmodium	protein,	unknown	function
PF3D7_1338200 60S	ribosomal	protein	L6-2,	putative
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	 	PF3D7_1338300 elongation	factor	1-gamma,	putative
PF3D7_1339500 mitochondrial	ribosomal	protein	L49	precursor,	putative
PF3D7_1341200 60S	ribosomal	protein	L18,	putative
PF3D7_1341300 60S	ribosomal	protein	L18-2,	putative
PF3D7_1342000 40S	ribosomal	protein	S6
PF3D7_1348300 elongation	factor	Tu,	putative
PF3D7_1349200 glutamate--tRNA	ligase,	putative
PF3D7_1349900 conserved	Plasmodium	protein,	unknown	function
PF3D7_1350100 lysine--tRNA	ligase
PF3D7_1351400 60S	ribosomal	protein	L17,	putative
PF3D7_1354700 conserved	Plasmodium	protein,	unknown	function
PF3D7_1357000 elongation	factor	1-alpha
PF3D7_1357100 elongation	factor	1-alpha
PF3D7_1357200 glutamate--tRNA	ligase
PF3D7_1358800 40S	ribosomal	protein	S15
PF3D7_1365100 mitochondrial	ribosomal	protein	S17	precursor,	putative
PF3D7_1365900 ubiquitin-60S	ribosomal	protein	L40
PF3D7_1366900 conserved	Plasmodium	protein,	unknown	function
PF3D7_1367700 alanine--tRNA	ligase
PF3D7_1402200 conserved	Plasmodium	protein,	unknown	function
PF3D7_1402500 ubiquitin-40S	ribosomal	protein	S27a,	putative
PF3D7_1404400 mitochondrial	ribosomal	protein	L16	precursor,	putative
PF3D7_1408600 40S	ribosomal	protein	S8e,	putative
PF3D7_1409600 conserved	Plasmodium	protein,	unknown	function
PF3D7_1410600 eukaryotic	translation	initiation	factor	2	subunit	gamma,	putative
PF3D7_1413400 30S	ribosomal	protein	S9,	putative
PF3D7_1414300 60S	ribosomal	protein	L10,	putative
PF3D7_1416800 lysine--tRNA	ligase,	putative
PF3D7_1420400 glycine--tRNA	ligase
PF3D7_1421200 40S	ribosomal	protein	S25
PF3D7_1424100 60S	ribosomal	protein	L5,	putative
PF3D7_1424400 60S	ribosomal	protein	L7-3,	putative
PF3D7_1426000 60S	ribosomal	protein	L21
PF3D7_1428600 peptide	chain	release	factor	1
PF3D7_1429100 apicoplast	ribosomal	protein	L15	precursor,	putative
PF3D7_1429700 mitochondrial	ribosomal	protein	L15	precursor,	putative
PF3D7_1431000 mitochondrial	ribosomal	protein	L17-2	precursor,	putative
PF3D7_1431700 60S	ribosomal	protein	L14,	putative
PF3D7_1434600 methionine	aminopeptidase	2
PF3D7_1441200 60S	ribosomal	protein	L1,	putative
PF3D7_1442800 conserved	Plasmodium	protein,	unknown	function
PF3D7_1445000 conserved	Plasmodium	protein,	unknown	function
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	 	PF3D7_1445100 histidine--tRNA	ligase,	putative
PF3D7_1447000 40S	ribosomal	protein	S5
PF3D7_1447300 mitochondrial	ribosomal	protein	S14	precursor,	putative
PF3D7_1451100 elongation	factor	2
PF3D7_1454600 mitochondrial	ribosomal	protein	S11	precursor,	putative
PF3D7_1456400 conserved	Plasmodium	protein,	unknown	function
PF3D7_1456600 mitochondrial	ribosomal	protein	L28	precursor,	putative
PF3D7_1457300 conserved	Plasmodium	protein,	unknown	function
PF3D7_1460300 60S	ribosomal	protein	L29,	putative
PF3D7_1460700 60S	ribosomal	protein	L27
PF3D7_1460900 apicoplast	ribosomal	protein	S10,	putative
PF3D7_1461300 40S	ribosomal	protein	S28e,	putative
PF3D7_1461900 valine--tRNA	ligase,	putative
PF3D7_1463800 mitochondrial	ribosomal	protein	S6-2	precursor,	putative
PF3D7_1465900 40S	ribosomal	protein	S3
PF3D7_1467400 50S	ribosomal	protein	L22,	apicoplast,	putative
PF3D7_1469000 translation	initiation	factor	IF-1
PF3D7_1474100 mitochondrial	ribosomal	protein	L20	precursor,	putative
PF3D7_API01300 50S	ribosomal	protein	L4,	putative
PF3D7_API01500 apicoplast	ribosomal	protein	L2
PF3D7_API01600 apicoplast	ribosomal	protein	S19
PF3D7_API01700 ribosomal	protein	S3,	putative
PF3D7_API01800 apicoplast	ribosomal	protein	L16
PF3D7_API02000 apicoplast	ribosomal	protein	L14
PF3D7_API02100 apicoplast	ribosomal	protein	S8
PF3D7_API02200 apicoplast	ribosomal	protein	L6
PF3D7_API02300 apicoplast	ribosomal	protein	S5
PF3D7_API02500 apicoplast	ribosomal	protein	L36
PF3D7_API02600 apicoplast	ribosomal	protein	S11
PF3D7_API02700 apicoplast	ribosomal	protein	S12
PF3D7_API02800 apicoplast	ribosomal	protein	S7
PF3D7_API04100 30S	ribosomal	protein	S2,	putative
Transcription
[Gene	ID] [Product	Description]
PF3D7_0110400 DNA-directed	RNA	polymerase	II	subunit	RPB9,	putative
PF3D7_0110800 transcription	initiation	factor	TFIIB,	putative
PF3D7_0205500 DNA-directed	RNA	polymerase	II	16	kDa	subunit,	putative
PF3D7_0206600 DNA-directed	RNA	polymerase	III	subunit	RPC10,	putative
PF3D7_0208700 conserved	Plasmodium	protein,	unknown	function,	unspecified	product
PF3D7_0208700 conserved	Plasmodium	protein,	unknown	function,	unspecified	product
PF3D7_0209700 RING	zinc	finger	protein,	putative
PF3D7_0215700 DNA-directed	RNA	polymerase	II	subunit	RPB2,	putative
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PF3D7_0303300 DNA-directed	RNA	polymerases	I,	II,	and	III	subunit	RPABC2,	putative
PF3D7_0305100 conserved	Plasmodium	protein,	unknown	function
PF3D7_0313000 conserved	Plasmodium	protein,	unknown	function
PF3D7_0318200 DNA-directed	RNA	polymerase	II	subunit	RPB1
PF3D7_0406600 conserved	Plasmodium	protein,	unknown	function
PF3D7_0407300 transcription	factor,	putative
PF3D7_0407700 conserved	Plasmodium	protein,	unknown	function
PF3D7_0410800 conserved	Plasmodium	protein,	unknown	function
PF3D7_0416500 repressor	of	RNA	polymerase	III	transcription	MAF1,	putative
PF3D7_0505600 conserved	Plasmodium	protein,	unknown	function
PF3D7_0506200 TATA-box-binding	protein
PF3D7_0506800 transcription	factor	25,	putative
PF3D7_0509400 RNA	polymerase	I
PF3D7_0517200 conserved	Plasmodium	protein,	unknown	function
PF3D7_0517400 FACT	complex	subunit	SPT16,	putative
PF3D7_0521400 conserved	Plasmodium	protein,	unknown	function
PF3D7_0522000 conserved	Plasmodium	protein,	unknown	function
PF3D7_0522200 transcription	initiation	factor	TFIID	subunit	10,	putative
PF3D7_0603600 conserved	Plasmodium	protein,	unknown	function
PF3D7_0610900 transcription	elongation	factor	SPT5,	putative
PF3D7_0621000 conserved	Plasmodium	protein,	unknown	function
PF3D7_0625200 conserved	Plasmodium	protein,	unknown	function
PF3D7_0703200 conserved	Plasmodium	protein,	unknown	function
PF3D7_0708100 DNA-directed	RNA	polymerases	I,	II,	and	III	subunit	RPABC5,	putative
PF3D7_0714500 transcription	elongation	factor	s-II,	putative
PF3D7_0716400 transcription	initiation	factor	IIA	subunit	1,	putative
PF3D7_0717300 transcription	initiation	factor	IIE	subunit	alpha,	putative
PF3D7_0723300 conserved	Plasmodium	protein,	unknown	function
PF3D7_0824000 conserved	Plasmodium	protein,	unknown	function
PF3D7_0905800 conserved	Plasmodium	protein,	unknown	function
PF3D7_0912800 tRNA	(adenine(58)-N(1))-methyltransferase	non-catalytic	subunit	TRM6,	putative
PF3D7_0914600 transcription	elongation	factor	1,	putative
PF3D7_0923000 DNA-directed	RNA	polymerase	II	subunit	RPB3,	putative
PF3D7_0924400 conserved	Plasmodium	protein,	unknown	function
PF3D7_0929000 transcription	initiation	factor	TFIID	subunit	7,	putative
PF3D7_0933700 conserved	Plasmodium	protein,	unknown	function
PF3D7_1010200 DNA2/NAM7	helicase,	putative
PF3D7_1015900 enolase
PF3D7_1027400 DNA-directed	RNA	polymerase	II	subunit	RPB7,	putative
PF3D7_1032900 RNA	polymerase	II-associated	protein	1,	putative
PF3D7_1036500 probable	protein,	unknown	function
PF3D7_1037600 DNA	repair	helicase	RAD25,	putative
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	 	PF3D7_1104700 DNA-directed	RNA	polymerase	III	subunit	RPC8,	putative
PF3D7_1104700 DNA-directed	RNA	polymerase	III	subunit	RPC8,	putative
PF3D7_1105000 histone	H4
PF3D7_1108000 IWS1-like	protein,	putative
PF3D7_1111900 conserved	Plasmodium	protein,	unknown	function
PF3D7_1119700 conserved	Plasmodium	protein,	unknown	function
PF3D7_1125300 DNA-directed	RNA	polymerase
PF3D7_1127800 conserved	Plasmodium	protein,	unknown	function
PF3D7_1134700 DNA-directed	RNA	polymerase	I	subunit	RPA2,	putative
PF3D7_1143300 DNA-directed	RNA	polymerases	I	and	III	subunit	RPAC1,	putative
PF3D7_1144600 transcription	initiation	factor	IIF	subunit	beta,	putative
PF3D7_1145800 conserved	Plasmodium	protein,	unknown	function
PF3D7_1206600 DNA-directed	RNA	polymerase	III	subunit	RPC2,	putative
PF3D7_1213700 DNA-directed	RNA	polymerases	I,	II,	and	III	subunit	RPABC3,	putative
PF3D7_1224700 conserved	Plasmodium	protein,	unknown	function
PF3D7_1225200 conserved	Plasmodium	protein,	unknown	function
PF3D7_1225400 conserved	Plasmodium	protein,	unknown	function
PF3D7_1226800 ataxin-3,	putative
PF3D7_1227400 conserved	Plasmodium	protein,	unknown	function
PF3D7_1231300 conserved	Plasmodium	protein,	unknown	function
PF3D7_1241400 RNA-binding	protein,	putative
PF3D7_1244200 RNA	polymerase	II	transcription	factor	B	subunit	2,	putative
PF3D7_1250700 conserved	Plasmodium	protein,	unknown	function
PF3D7_1301500 Plasmodium	exported	protein	(PHISTa),	unknown	function
PF3D7_1302500 conserved	Plasmodium	protein,	unknown	function
PF3D7_1304900 DNA-directed	RNA	polymerase	II	subunit	RPB11,	putative
PF3D7_1307600 DNA-directed	RNA	polymerase	alpha	chain,	putative
PF3D7_1314900 general	transcription	factor	IIH	subunit	2
PF3D7_1316900 conserved	Plasmodium	protein,	unknown	function
PF3D7_1329000 DNA-directed	RNA	polymerase	III	subunit	RPC1,	putative
PF3D7_1337400 conserved	Plasmodium	protein,	unknown	function
PF3D7_1342700 DNA-directed	RNA	polymerases	I,	II,	and	III	subunit	RPABC4,	putative
PF3D7_1363500 DNase	I-like	protein,	putative
PF3D7_1364800 DNA-directed	RNA	polymerases	I,	II,	and	III	subunit	RPABC1,	putative
PF3D7_1404000 DNA-directed	RNA	polymerase	II	subunit	RPB4,	putative
PF3D7_1406200 conserved	Plasmodium	protein,	unknown	function
PF3D7_1415200 DNA-directed	RNA	polymerases	I	and	III	subunit	RPAC2,	putative
PF3D7_1421400 DNA-directed	RNA	polymerase	III	subunit	RPC6,	putative
PF3D7_1428800 transcription	initiation	TFIID-like,	putative
PF3D7_1428800 transcription	initiation	TFIID-like,	putative
PF3D7_1441100 conserved	Plasmodium	protein,	unknown	function
PF3D7_1448900 conserved	Plasmodium	protein,	unknown	function
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	 	PF3D7_1449300 transcription	factor	IIIb	subunit,	putative
PF3D7_1450400 zinc	finger	protein,	putative
PF3D7_1457700 large	ribosomal	subunit	nuclear	export	factor,	putative
PF3D7_1457900 conserved	Plasmodium	protein,	unknown	function
PF3D7_1458800 DNA-directed	RNA	polymerase	III	subunit	RPC5,	putative
PF3D7_1460800 snRNA-activating	protein	complex	subunit	3,	putative
PF3D7_1463400 DNA-directed	RNA	polymerase	III	subunit	RPC4,	putative
PF3D7_1464400 zinc	finger	protein,	putative
PF3D7_1469700 mediator	of	RNA	polymerase	II	transcription	subunit	6,	putative
PF3D7_1472700 DNA-directed	RNA	polymerase,	alpha	subunit,	putative
PF3D7_1475000 mediator	of	RNA	polymerase	II	transcription	subunit	31,	putative
PF3D7_API04200 RNA	polymerase	D
PF3D7_API04300 RNA	polymerase	beta	subunit,	putative
PF3D7_API04400 DNA-directed	RNA	polymerase	subunit	beta,	putative
Proteasome
[Gene	ID] [Product	Description]
PF3D7_0104300 ubiquitin	carboxyl-terminal	hydrolase	1,	putative
PF3D7_0108000 proteasome	subunit	beta	type-3,	putative
PF3D7_0205900 26S	proteasome	regulatory	subunit	RPN1,	putative
PF3D7_0312300 26S	proteasome	regulatory	subunit	RPN12,	putative
PF3D7_0313100 ubiquitin-protein	ligase,	putative
PF3D7_0314200 conserved	Plasmodium	protein,	unknown	function
PF3D7_0314300 DER1-like	protein
PF3D7_0317000 proteasome	subunit	alpha	type-3,	putative
PF3D7_0317800 26S	proteasome	non-ATPase	regulatory	subunit	9,	putative
PF3D7_0403500 ubiquitin	specific	protease,	putative
PF3D7_0413600 26S	protease	regulatory	subunit	6B,	putative
PF3D7_0413900 ubiquitin	carboxyl-terminal	hydrolase	13,	putative
PF3D7_0507700 nuclear	protein	localization	protein	4,	putative
PF3D7_0518300 proteasome	subunit	beta	type-1,	putative
PF3D7_0527200 ubiquitin	carboxyl-terminal	hydrolase	14
PF3D7_0528000 proteasome	maturation	factor	UMP1,	putative
PF3D7_0608500 proteasome	subunit	alpha	type-2,	putative
PF3D7_0619400 cell	division	cycle	protein	48	homologue,	putative
PF3D7_0711000 AAA	family	ATPase,	CDC48	subfamily
PF3D7_0723600 proteasome	assembly	chaperone	4,	putative
PF3D7_0727400 proteasome	subunit	alpha	type-5,	putative
PF3D7_0803800 proteasome	subunit	beta	type-4
PF3D7_0807500 proteasome	subunit	alpha	type-6,	putative
PF3D7_0811000 cullin-1,	putative
PF3D7_0814300 AAA	family	ATPase,	putative
PF3D7_0815700 ubiquitin
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	 	PF3D7_0907400 ATP-dependent	protease	ATPase	subunit	ClpY
PF3D7_0907700 proteasome	activator	28	subunit	beta,	putative
PF3D7_0912900 26S	proteasome	regulatory	subunit	RPN8,	putative
PF3D7_0916500 ubiquitin	fusion	degradation	protein	1
PF3D7_0931800 proteasome	subunit	beta	type-6,	putative
PF3D7_1008400 26S	protease	regulatory	subunit	4,	putative
PF3D7_1011400 proteasome	subunit	beta	type-5
PF3D7_1011700 DNA	repair	protein	RAD23,	putative
PF3D7_1017900 26S	proteasome	regulatory	subunit	p55,	putative
PF3D7_1030500 26S	proteasome	regulatory	subunit	RPN9,	putative
PF3D7_1032500 DER1-like	protein,	putative
PF3D7_1113400 ubiquitin	domain-containing	protein	DSK2,	putative
PF3D7_1129200 26S	proteasome	regulatory	subunit	RPN7,	putative
PF3D7_1130400 26S	protease	regulatory	subunit	6A,	putative
PF3D7_1130800 armadillo	repeat	protein	PF16,	putative
PF3D7_1203900 ubiquitin-conjugating	enzyme	E2
PF3D7_1211800 polyubiquitin
PF3D7_1230400 ATP-dependent	protease	subunit	ClpQ
PF3D7_1237000 SUMO-activating	enzyme	subunit	2
PF3D7_1248900 26S	protease	regulatory	subunit	8,	putative
PF3D7_1306400 26S	protease	regulatory	subunit	10B,	putative
PF3D7_1311500 26S	protease	regulatory	subunit	7,	putative
PF3D7_1328100 proteasome	subunit	beta	type-7,	putative
PF3D7_1333200 ubiquitin-activating	enzyme
PF3D7_1338100 26S	proteasome	regulatory	subunit	RPN3,	putative
PF3D7_1345500 ubiquitin-conjugating	enzyme	E2
PF3D7_1353800 proteasome	subunit	alpha	type-4,	putative
PF3D7_1353900 proteasome	subunit	alpha	type-7,	putative
PF3D7_1365400 ubiquitin-activating	enzyme
PF3D7_1368100 26S	proteasome	regulatory	subunit	RPN11,	putative
PF3D7_1402300 26S	proteasome	regulatory	subunit	RPN6
PF3D7_1414000 26S	proteasome	regulatory	subunit	RPN13,	putative
PF3D7_1418000 ubiquitin	fusion	degradation	protein	UFD1,	putative
PF3D7_1422500 ERAD-associated	E3	ubiquitin-protein	ligase	HRD1
PF3D7_1448400 ubiquitin-protein	ligase,	putative
PF3D7_1452300 DER1-like	protein
PF3D7_1466300 26S	proteasome	regulatory	subunit	RPN2,	putative
PF3D7_1468500 derlin-1
PF3D7_1470900 proteasome	subunit	beta	type-2,	putative
PF3D7_1474800 proteasome	subunit	alpha	type-1,	putative
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P-value Bonferroni	Corrected
No	Binding	Site Total 0.00000143 0.00000715
Up-regulated	Dephasing 63 242 305
Not	up-regulated	Dephasing 483 4005 4488
Total	 546 4247 4793
PF3D7_1007700 Binding	Site No	Binding	Site Total 0.7507 1
Up-regulated	Dephasing 53 252 305
Not	up-regulated	Dephasing 746 3742 4488
Total 799 3994 4793
PF3D7_1143100 Binding	Site No	Binding	Site Total 0.395 1
Up-regulated	Dephasing 30 275 305
Not	up-regulated	Dephasing 377 4111 4488
Total 407 4386 4793
PF3D7_1456000 Binding	Site No	Binding	Site Total 0.000354 0.00177
Up-regulated	Dephasing 48 257 305
Not	up-regulated	Dephasing 406 4082 4488
Total 454 4339 4793
PF3D7_0420300 Binding	Site No	Binding	Site Total 0.0002795 0.0013975
Up-regulated	Dephasing 67 238 305
Not	up-regulated	Dephasing 628 3860 4488
Total 695 4098 4793
PF3D7_0802100
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up-regulated	in	the	mutant	at	24	hours.	
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Microarray	array	measurements	are	consistent	with	RNA-seq	measurements	showing	an	up-regula&on	of	the	
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Appendix	D:	Justification	for	combining	DNA	replication	and	repair	pathways	
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DNA	replica4on	and	repair	expression	profiles:	
The	DNA	replica&on	and	the	DNA	repair	expression	profiles	have	the	same	rates	of	transcrip&onal	regula&on	
throughout	the	cell	cycle.	This	is	the	ra&onale	for	combining	the	DNA	replica&on	and	repair	genes	for	analysis.	
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import pandas as pd
def 
columns_from_snpEff_generator(column,annotation_fields=["Allele","Annotation","Puta
tive_impact","Gene_Name","Gene_ID","Feature_type","Featue_ID","Transcript_biotype",
"Rank/total","HGVS.c","HGVS.p","cDNA_position/cDNA_len","CDS_position/CDS_len",
"Protein_position/
Protein_len","Distance_to_feature","Errors_Warnings_or_Information_messages"]):
 """This maybe more trouble than it's worth"""
 ##Multple predicted affects seperated by a comma. I'm not 100% sure multiple 
effects will always be written out in the same order.
 
 #df_out=df["ANN"].apply(lambda x: pd.Series( filter(lambda x: x != "" ,
[i.strip() for i in  x.split("|")] )))
 num_effects=[]
 for row in column:
  new_columns=[]
  effects=row.split(",")
  effects_dic_list=[]
  for effect in effects:
   effects_dic_list.append(dict(zip(annotation_fields,effect.split("|"))))
  for column in annotation_fields:
   new_column_values=[]
   for effects_dic in effects_dic_list:
    new_column_values.append(effects_dic[column].strip())
   new_columns.append("&".join(new_column_values).strip("&")) #There seems 
to be a lot of excess & being added to the ends of at least the warning 
messages
  yield new_columns
def 
columns_from_snpEff_ANN(row,annotation_fields=["Allele","Annotation","Putative_impa
ct","Gene_Name","Gene_ID","Feature_type","Featue_ID","Transcript_biotype","Rank/
total","HGVS.c","HGVS.p","cDNA_position/cDNA_len","CDS_position/CDS_len",
"Protein_position/
Protein_len","Distance_to_feature","Errors_Warnings_or_Information_messages"]):
        """This maybe more trouble than it's worth"""
        ##Multple predicted affects seperated by a comma. I'm not 100% sure multiple 
effects will always be written out in the same order.
        
       #df_out=df["ANN"].apply(lambda x: pd.Series( filter(lambda x: x != "" ,
[i.strip() for i in  x.split("|")] )))
 effects=row.split(",")
        effects_dic_list=[]
 new_columns=[]
        for effect in effects:
   effects_dic_list.append(dict(zip(annotation_fields,effect.split("|"))))
 for column in annotation_fields:
  new_column_values=[]
                for effects_dic in effects_dic_list:
                        new_column_values.append(effects_dic[column].strip())
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                new_columns.append("&".join(new_column_values).strip("&")) #There 
seems to be a lot of excess & being added to the ends of at least 
the warning messages
                
 return new_columns
def 
create_snpEff_columns(df,annotation_fields=["Allele","Annotation","Putative_impact"
,"Gene_Name","Gene_ID","Feature_type","Featue_ID","Transcript_biotype","Rank/
total","HGVS.c","HGVS.p","cDNA_position/cDNA_len","CDS_position/CDS_len",
"Protein_position/
Protein_len","Distance_to_feature","Errors_Warnings_or_Information_messages"]):
 df_ann=df["ANN"].apply(lambda x: pd.Series(columns_from_snpEff_ANN(x)))
 
 column_mappings=dict(zip(range(0,len(annotation_fields)), annotation_fields))
 df_ann.rename(columns=column_mappings,inplace=True)
 
 df_out=df.merge(df_ann,left_index=True,right_index=True)
 return df_out
def 
remove_common_rows(df_ref,df_exp,relevant_columns=["CHROM","POS","ID","REF","ALT","
ANN"],columns_to_sort_on=["CHROM","POS"]):
 df_ref_rel_cols=df_ref[relevant_columns]
        df_exp_rel_cols=df_exp[relevant_columns]
        ref_tuples=[tuple(line) for line in df_ref_rel_cols.values.tolist()]
        exp_tuples=[tuple(line) for line in df_exp_rel_cols.values.tolist()]
 ref_set=set(ref_tuples)
 exp_set=set(exp_tuples)
 
        intersection_exp_ref_set=exp_set & ref_set #This is the differences they 
have in common to the reference
        ##Remove the differences that they have in common with the reference; these 
are of no interest
        ##This step may not be neccessary, it depends on what I end up doing 
downstream
 ##With snpEff it will also only work if the annotations are written out in the 
same order and I'm not 100% sure that they are
        ref_set_intersect_removed=ref_set-intersection_exp_ref_set
        exp_set_intersect_removed=exp_set-intersection_exp_ref_set
        
df_ref_intersect_removed=pd.DataFrame(list(ref_set_intersect_removed),colum
ns=df_ref_rel_cols.columns).sort_values(columns_to_sort_on,ascending=[True,
True])
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df_exp_intersect_removed=pd.DataFrame(list(exp_set_intersect_removed),colum
ns=df_exp_rel_cols.columns).sort_values(columns_to_sort_on,ascending=[True,
True])
 return (df_ref_intersect_removed,df_exp_intersect_removed)
def remove_common_CHROM_POS_REF_ALT(df_ref,df_exp):
 relevant_columns=["CHROM","POS","REF","ALT"]
 
 df_ref_rel_cols=df_ref[relevant_columns]
        df_exp_rel_cols=df_exp[relevant_columns]
 
 ref_tuples=[tuple(line) for line in df_ref_rel_cols.values.tolist()]
        exp_tuples=[tuple(line) for line in df_exp_rel_cols.values.tolist()]
 
 ref_index=pd.MultiIndex.from_tuples(ref_tuples,names=relevant_columns)
 df_ref.index=ref_index
 exp_index=pd.MultiIndex.from_tuples(exp_tuples,names=relevant_columns)
 df_exp.index=exp_index
        ref_set=set(ref_tuples)
        exp_set=set(exp_tuples)
        intersection_exp_ref_set=exp_set & ref_set #This is the differences they 
have in common to the reference
 ref_rows_to_keep=list(ref_set-intersection_exp_ref_set)
 exp_rows_to_keep=list(exp_set-intersection_exp_ref_set)
 
df_ref=df_ref.filter(items=ref_rows_to_keep,axis=0).sort_values(relevant_column
s,ascending=[True,True,True,True])
 
df_exp=df_exp.filter(items=exp_rows_to_keep,axis=0).sort_values(relevant_column
s,ascending=[True,True,True,True])
 return (df_ref,df_exp)
def remove_common_CHROM_POS_REF_ALT_from_exp(df_ref,df_exp):
        relevant_columns=["CHROM","POS","REF","ALT"]
        df_ref_rel_cols=df_ref[relevant_columns]
        df_exp_rel_cols=df_exp[relevant_columns]
        ref_tuples=[tuple(line) for line in df_ref_rel_cols.values.tolist()]
        exp_tuples=[tuple(line) for line in df_exp_rel_cols.values.tolist()]
        ref_index=pd.MultiIndex.from_tuples(ref_tuples,names=relevant_columns)
        df_ref.index=ref_index
        exp_index=pd.MultiIndex.from_tuples(exp_tuples,names=relevant_columns)
        df_exp.index=exp_index
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 """Find Positions where the reference strain differs from the reference genome, 
but the experimental strain does not"""
 relevant_columns=["CHROM","POS"]
 df_ref_rel_cols=df_ref[relevant_columns]
        df_exp_rel_cols=df_exp[relevant_columns]
        ref_tuples=[tuple(line) for line in df_ref_rel_cols.values.tolist()]
        exp_tuples=[tuple(line) for line in df_exp_rel_cols.values.tolist()]
 ref_index=pd.MultiIndex.from_tuples(ref_tuples,names=relevant_columns)
        df_ref.index=ref_index
        exp_index=pd.MultiIndex.from_tuples(exp_tuples,names=relevant_columns)
        df_exp.index=exp_index
        ref_set=set(ref_tuples)
        exp_set=set(exp_tuples)
        in_ref_not_exp_set=list(ref_set - exp_set) #Positions where ref strain 
differs from reference genome, but the experimental set does not
        
df_in_ref_not_exp=df_ref.filter(items=in_ref_not_exp_set,axis=0).sort_value
s(relevant_columns,ascending=[True,True])
   
        return df_in_ref_not_exp 
def return_chrom_pos_intersection_dataframes(df_ref,df_exp):
 relevant_columns=["CHROM","POS"]
        df_ref_rel_cols=df_ref[relevant_columns]
        df_exp_rel_cols=df_exp[relevant_columns]
        ref_tuples=[tuple(line) for line in df_ref_rel_cols.values.tolist()]
        exp_tuples=[tuple(line) for line in df_exp_rel_cols.values.tolist()]
       
 ref_index=pd.MultiIndex.from_tuples(ref_tuples,names=relevant_columns)
        df_ref.index=ref_index
        exp_index=pd.MultiIndex.from_tuples(exp_tuples,names=relevant_columns)
        df_exp.index=exp_index
        ref_set=set(ref_tuples)
        exp_set=set(exp_tuples)
 
 intersect_list=list(ref_set & exp_set)
 
 
df_ref_intersect=df_ref.filter(items=intersect_list,axis=0).sort_values(relevan
t_columns,ascending=[True,True])
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df_exp_intersect=df_exp.filter(items=intersect_list,axis=0).sort_values(relevan
t_columns,ascending=[True,True])
 return (df_ref_intersect,df_exp_intersect)
def check_chrom_pos_intersection(df_ref,df_exp):
 relevant_columns=["CHROM","POS"]
        df_ref_rel_cols=df_ref[relevant_columns]
        df_exp_rel_cols=df_exp[relevant_columns]
        ref_tuples=[tuple(line) for line in df_ref_rel_cols.values.tolist()]
        exp_tuples=[tuple(line) for line in df_exp_rel_cols.values.tolist()]
 ref_set=set(ref_tuples)
        exp_set=set(exp_tuples)
 return ref_set & exp_set
def find_positions_where_diff_from_ref_strain_and_ref_genome(df_ref,df_exp):
        """This is the intersection of the CHORM and POS for the reference and 
experimental VCFs,
but the ALT value will be different. Return the rows from df_ref where this is 
true"""
 ##Find where the same positions are altered in the reference and experimental 
strains
 
df_ref_intersect,df_exp_intersect=return_chrom_pos_intersection_dataframes(df_r
ef,df_exp)
 ##Find positions were the ALT values are different
 ALT="ALT"
 mask=df_ref_intersect[ALT]==df_exp_intersect[ALT]
 df_exp_diff_from_ref_strain_ref_genome=df_ref_intersect[~mask] #The tilde is 
inverting the booleans
 
df_exp_diff_from_ref_strain_ref_genome=df_exp_diff_from_ref_strain_ref_genome.m
erge(df_exp,how="inner",on=["CHROM","POS"],suffixes=("_ref","_exp"))
 return df_exp_diff_from_ref_strain_ref_genome
def combine_experimental_groups_into_single_dataframe(experimental_groups):
 """Creates a sample column for each sample to specify the sample and then 
combines the dataframes"""
 ###In the long-run this will probably make the analysis faster and easier to 
code if all of the experimental groups are in
 ###one dataframe. Consequences: removing the intersection will remove a effect 
even if it's not shared by all of the samples,
 ###can identify differences even if they are not shared by all of the 
experimental groups
 pass
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def find_gene_differences_in_snpEff_annotations(df_ref,df_exp):
 """Input is table generated using gatk VariantsToTable (any properly formated 
table will work though) that has been run through snpEFF 
and reports on the differences in snpEFF annotation."""
 
 ##The QUAL and AC columns are probably not relevant and hindering the 
identification of unique differences.
 ##I either need too not include them in the input or exclude them from the set 
comparisions
 
 relevant_columns=["CHROM","POS","ID","REF","ALT","ANN"] 
 columns_to_sort_on=["CHROM","POS"]
 
 #print "Ref Pre-filter "+str(df_ref.shape)
 #print "Exp Pre-filter "+str(df_exp.shape)
 
 
#df_ref,df_exp=remove_common_rows(df_ref,df_exp,relevant_columns=relevant_colum
ns,columns_to_sort_on=columns_to_sort_on)
 df_ref,df_exp=remove_common_CHROM_POS_REF_ALT(df_ref,df_exp)
 #print "Exp After-filter "+str(df_exp.shape)
 
 df_ref=create_snpEff_columns(df_ref)
 df_exp=create_snpEff_columns(df_exp)
 #print "Ref snpEff Cols "+str(df_ref.shape)
 df_ref.to_csv("test_data/ref_retain_common_rows.txt",sep="\t")
 #print "Exp snpEff Cols "+str(df_exp.shape)
 df_exp.to_csv("test_data/exp_retain_common_rows.txt",sep="\t")
 
df_genes_modified_in_exp_not_ref=identify_genes_modified_in_exp_not_ref(df_ref,
df_exp)
 #print "Modified in Exp not ref: "+str(df_genes_modified_in_exp_not_ref.shape)
 
 return df_genes_modified_in_exp_not_ref
 ##The VCF only reports differences from the reference (3D7). If want to have the 
actual parent nucleotide in the table need
 ##to get that seperatly.
 ##May need to filter out Antigenic variation genes. I think I only did that for 
the copy number variants so far (Not part of this workflow)
def update_experimental_results_with_ref_strain_allele(df_ref,df_exp):
 """Addeds a column to df_exp called Ref_Strain_ALT"""
 pass
def filter_and_combine_samples(dic_samples,ref_sample_name="23_dec"):
 #Might not need ref_sample_name
 sample_type_col="Sample_Type"
 sample_name_col="Sample_Name"
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 experimental_key="Experimental"
 sep="\t"
 df_ref=pd.read_table(dic_samples["Reference"],sep=sep)
 df_ref.dropna(subset=["ANN"],inplace=True) ##Remove row if ANN empty
 df_ref=create_snpEff_columns(df_ref)
 
 ##The differences with the reference genome not shared with the reference strain
 experimental_dataframes_common_diffs_removed_list=[]
 ##Experimental strain is the same as the reference genome, but the reference 
strain is different from the reference genome
 ##For these REF is equivalent to ALT and ALT is equivelent ot REF with respect 
to the reference strain (Column values swap)
 ref_dataframes_exp_same_as_ref_genome_ref_strain_diff_from_ref_genome_list=[]
 ##Experimental strain different from the reference genome and the reference 
stain is the same as the reference genome
 
exp_datafames_exp_different_from_ref_genome_ref_strain_same_as_ref_genome_list=
[]
 
 ##Experimental strain and the reference strain are both different from the 
reference genome
 ##The positions is modified in both the ref strain and the exp strain but the 
differences are not the same. These should be in the common removed as well
 exp_stain_and_ref_strain_diff_from_ref_genome_in_diff_ways_list=[]
 for sample in dic_samples[experimental_key]:
  df_exp=pd.read_table(dic_samples[experimental_key][sample],sep=sep)
  df_exp.dropna(subset=["ANN"],inplace=True) ##Remove row if ANN empty
  df_exp[sample_type_col]=experimental_key
  df_exp[sample_name_col]=sample
 
  ##Seperate the snpEff data into seperate columns for easier analysis
                df_exp=create_snpEff_columns(df_exp)
              
  ##1. Remove differences that the experimental group shares with the 
reference sample. This probably doesn't need to be done
  
df_exp_common_removed=remove_common_CHROM_POS_REF_ALT_from_exp(df_ref,df_ex
p)
  
experimental_dataframes_common_diffs_removed_list.append(df_exp_common_remo
ved)
  ##2.Experimental strain is the same as the reference genone, but the 
reference strain is different from the reference genome
  
df_exp_strain_same_as_ref_genome_ref_strain_diff_from_genome=find_positions
_exp_same_as_ref_genome(df_ref,df_exp)
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df_exp_strain_same_as_ref_genome_ref_strain_diff_from_genome["Sample_Name"]
=sample 
  
ref_dataframes_exp_same_as_ref_genome_ref_strain_diff_from_ref_genome_list.
append(df_exp_strain_same_as_ref_genome_ref_strain_diff_from_genome)
  
  
  ##3.Experimental strain is different from the reference genome, but the 
reference strain is the same as the reference genome
  
df_exp_strain_diff_from_ref_genome_ref_strain_same_as_ref_genome=find_posit
ions_exp_same_as_ref_genome(df_exp,df_ref)
  
exp_datafames_exp_different_from_ref_genome_ref_strain_same_as_ref_genome_l
ist.append(df_exp_strain_diff_from_ref_genome_ref_strain_same_as_ref_genome
)
  ##4. Experimental stain and reference strain are both different from the 
reference genome in different ways
  
df_exp_stain_and_ref_strain_diff_from_ref_genome_in_diff_ways=find_position
s_where_diff_from_ref_strain_and_ref_genome(df_ref,df_exp)
  
df_exp_stain_and_ref_strain_diff_from_ref_genome_in_diff_ways["Sample_Name"
]=sample 
  
exp_stain_and_ref_strain_diff_from_ref_genome_in_diff_ways_list.append(df_e
xp_stain_and_ref_strain_diff_from_ref_genome_in_diff_ways)
 ##Combine each list of dataframes into a single dataframe
 df_common_removed=pd.concat(experimental_dataframes_common_diffs_removed_list)
 
df_exp_strain_same_as_ref_genome_ref_strain_diff_from_genome=pd.concat(ref_data
frames_exp_same_as_ref_genome_ref_strain_diff_from_ref_genome_list)
 
df_exp_strain_diff_from_ref_genome_ref_strain_same_as_ref_genome=pd.concat(exp_
datafames_exp_different_from_ref_genome_ref_strain_same_as_ref_genome_list)
 
df_exp_stain_and_ref_strain_diff_from_ref_genome_in_diff_ways=pd.concat(exp_sta
in_and_ref_strain_diff_from_ref_genome_in_diff_ways_list)
 return {"Common_Removed":df_common_removed,
"Exp_Same_As_Ref_Genome_Ref_Strain_Diff_From_Ref_Genome":df_exp_strain_same_as_ref_g
enome_ref_strain_diff_from_genome,
"Exp_Strain_Diff_From_Ref_Genome_Ref_Strain_Same_As_Ref_Genome":df_exp_strain_diff_f
rom_ref_genome_ref_strain_same_as_ref_genome,
"Exp_Strain_And_Ref_Strain_Diff_From_Ref_Genome_in_Diff_Ways":df_exp_stain_and_ref_s
train_diff_from_ref_genome_in_diff_ways}
  
def get_CHORM_POS_REF_ALT_counts(df,groupby_columns=["CHROM","POS","REF","ALT"]):
 return 
df.groupby(groupby_columns).size().reset_index().rename(columns={0:'count'})
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def 
get_changes_that_occur_in_all_samples(df,annotation_fields=["CHROM","POS","REF","AL
T","Allele","Annotation","Putative_impact","Gene_Name","Gene_ID","Feature_type","Fe
atue_ID","Transcript_biotype","Rank/total","HGVS.c","HGVS.p","cDNA_position/
cDNA_len","CDS_position/CDS_len",
"Protein_position/
Protein_len","Distance_to_feature","Errors_Warnings_or_Information_messages"],group
by_columns=["CHROM","POS","REF","ALT"]):
 sample_name_col="Sample_Name"
 ##Get the number of samples
 number_of_samples=len(df[sample_name_col].unique())
 
 ##Get the counts for each change
 
df_changes_counts=get_CHORM_POS_REF_ALT_counts(df,groupby_columns=groupby_colum
ns)
 
 ##Get the changes that occur in all the samples
 
df_changes_all_samples=df_changes_counts[df_changes_counts["count"]==number_of_
samples]
 ##Get the annotations associated with these changes
 
df_annotations=df_changes_all_samples.merge(right=df,how="inner",on=groupby_col
umns)[annotation_fields]
 df_annotations=df_annotations.drop_duplicates()
 return df_annotations 
def 
get_reference_strain_allele(df_common_removed,df_same_as_ref_genome,df_diff_from_re
f_genome_strain):
 print df_ref[:3]
 print df_exp[:3]
 
df_ref_strain_allele=df_ref.merge(right=df_exp,how="inner",on=["CHROM","POS"],s
uffixes=("_Ref","_Exp"))
 print df_ref_strain_allele
def identify_three_kinds_of_diffs(sample_dic,outdir="/shares/biocomputing/Bitbucket/
misc_bin/
test_data/",create_gene_subset=False,gene_subset_suffix="gene_subset",ref_sample_na
me="23_dec"):
 """If want to create reports on a subset of genes set create_gene_subset to a 
file path pointing to a file with gene ids under a Gene_ID header"""
 ##used to be called main
 print sample_dic 
 
results_filtered_and_combined=filter_and_combine_samples(dic_samples=sample_dic
,ref_sample_name=ref_sample_name)
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key_Exp_Same_As_Ref_Genome_Ref_Strain_Diff_From_Ref_Genome="Exp_Same_As_Ref_Gen
ome_Ref_Strain_Diff_From_Ref_Genome"
 
key_Exp_Strain_Diff_From_Ref_Genome_Ref_Strain_Same_As_Ref_Genome="Exp_Strain_D
iff_From_Ref_Genome_Ref_Strain_Same_As_Ref_Genome"
 
key_Exp_Strain_And_Ref_Strain_Diff_From_Ref_Genome_in_Diff_Ways="Exp_Strain_And
_Ref_Strain_Diff_From_Ref_Genome_in_Diff_Ways"
 unfiltered_suffix="_unfiltered.txt"
 all_samples_suffix="_all_samples.txt"
 
 df_common_removed=results_filtered_and_combined["Common_Removed"]
 
df_exp_strain_same_as_ref_genome_ref_strain_diff_from_genome=results_filtered_a
nd_combined[key_Exp_Same_As_Ref_Genome_Ref_Strain_Diff_From_Ref_Genome]
 
df_exp_strain_diff_from_ref_genome_ref_strain_same_as_ref_genome=results_filter
ed_and_combined[key_Exp_Strain_Diff_From_Ref_Genome_Ref_Strain_Same_As_Ref_Geno
me]
 
df_exp_stain_and_ref_strain_diff_from_ref_genome_in_diff_ways=results_filtered_
and_combined[key_Exp_Strain_And_Ref_Strain_Diff_From_Ref_Genome_in_Diff_Ways]
 
 print "1. Differences not shared between the exp and ref strains"
        print df_common_removed.shape #[["CHROM","POS","REF","ALT","Sample_Name"]]
        print "2. Exp strain same as reference genome, but the reference strain is 
different from the reference genome"
        print df_exp_strain_same_as_ref_genome_ref_strain_diff_from_genome.shape # 
[["CHROM","POS","REF","ALT","Sample_Name"]]
        print "3. Exp strain is different from the reference genome, but the 
reference strain is the same as the reference genome"
        print df_exp_strain_diff_from_ref_genome_ref_strain_same_as_ref_genome.shape 
#[["CHROM","POS","REF","ALT","Sample_Name"]]
        print "4. Experimental and reference strain both different from the 
reference genome in different ways" 
 print df_exp_stain_and_ref_strain_diff_from_ref_genome_in_diff_ways.shape 
#[["CHROM","POS","REF_ref","ALT_ref","REF_exp","ALT_exp","Sample_Name"]]
 
 
outfile_Exp_Same_As_Ref_Genome_Ref_Strain_Diff_From_Ref_Genome_unfiltered=outdi
r+key_Exp_Same_As_Ref_Genome_Ref_Strain_Diff_From_Ref_Genome+unfiltered_suffix
 
outfile_Exp_Strain_Diff_From_Ref_Genome_Ref_Strain_Same_As_Ref_Genome_unfiltere
d=outdir+key_Exp_Strain_Diff_From_Ref_Genome_Ref_Strain_Same_As_Ref_Genome+unfi
ltered_suffix
 
outfile_Exp_Strain_And_Ref_Strain_Diff_From_Ref_Genome_in_Diff_Ways_unfiltered=
outdir+key_Exp_Strain_And_Ref_Strain_Diff_From_Ref_Genome_in_Diff_Ways+unfilter
ed_suffix
 
df_exp_strain_same_as_ref_genome_ref_strain_diff_from_genome.to_csv(outfile_Exp
_Same_As_Ref_Genome_Ref_Strain_Diff_From_Ref_Genome_unfiltered,sep="\t")
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df_exp_strain_diff_from_ref_genome_ref_strain_same_as_ref_genome.to_csv(outfile
_Exp_Strain_Diff_From_Ref_Genome_Ref_Strain_Same_As_Ref_Genome_unfiltered,sep="
\t")
 
df_exp_stain_and_ref_strain_diff_from_ref_genome_in_diff_ways.to_csv(outfile_Ex
p_Strain_And_Ref_Strain_Diff_From_Ref_Genome_in_Diff_Ways_unfiltered,sep="\t")
 if create_gene_subset:
         df_subset_input=pd.read_table(create_gene_subset,sep="\t")
  unfiltered="_unfiltered"
                ##ValueError seems to occur when the input dataframe is empty   
                try:
                        
df_exp_strain_same_as_ref_genome_ref_strain_diff_from_genom
e_all_subset=subset_by_gene_id(df_exp_strain_same_as_ref_ge
nome_ref_strain_diff_from_genome,df_subset_input)
                        
outfile_Exp_Same_As_Ref_Genome_Ref_Strain_Diff_From_Ref_Gen
ome_subset=outdir+key_Exp_Same_As_Ref_Genome_Ref_Strain_Dif
f_From_Ref_Genome+unfiltered+gene_subset_suffix
                        
df_exp_strain_same_as_ref_genome_ref_strain_diff_from_genom
e_all_subset.to_csv(outfile_Exp_Same_As_Ref_Genome_Ref_Stra
in_Diff_From_Ref_Genome_subset,sep="\t")
                except ValueError:
                        pass
                try:
                        
df_exp_strain_diff_from_ref_genome_ref_strain_same_as_ref_g
enome_all_subset=subset_by_gene_id(df_exp_strain_diff_from_
ref_genome_ref_strain_same_as_ref_genome,df_subset_input)
                        
outfile_Exp_Strain_Diff_From_Ref_Genome_Ref_Strain_Same_As_
Ref_Genome_subset=outdir+key_Exp_Strain_Diff_From_Ref_Genom
e_Ref_Strain_Same_As_Ref_Genome+unfiltered+gene_subset_suff
ix
                        
df_exp_strain_diff_from_ref_genome_ref_strain_same_as_ref_g
enome_all_subset.to_csv(outfile_Exp_Strain_Diff_From_Ref_Ge
nome_Ref_Strain_Same_As_Ref_Genome_subset,sep="\t")
                except ValueError:
                        pass
                try:
                        
df_exp_stain_and_ref_strain_diff_from_ref_genome_in_diff_wa
ys_all_subset=subset_by_gene_id(df_exp_stain_and_ref_strain
_diff_from_ref_genome_in_diff_ways,df_subset_input,gene_id_
col_df="Gene_ID_ref")
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outfile_Exp_Strain_And_Ref_Strain_Diff_From_Ref_Genome_in_D
iff_Ways_subset=outdir+key_Exp_Strain_And_Ref_Strain_Diff_F
rom_Ref_Genome_in_Diff_Ways+unfiltered+gene_subset_suffix
                        
df_exp_stain_and_ref_strain_diff_from_ref_genome_in_diff_wa
ys_all_subset.to_csv(outfile_Exp_Strain_And_Ref_Strain_Diff
_From_Ref_Genome_in_Diff_Ways_subset,sep="\t")
                except ValueError:
                        pass
 ##Find the differences common to all the samples
 
 
outfile_Exp_Same_As_Ref_Genome_Ref_Strain_Diff_From_Ref_Genome_all_samples=outd
ir+key_Exp_Same_As_Ref_Genome_Ref_Strain_Diff_From_Ref_Genome+all_samples_suffi
x
 
outfile_Exp_Strain_Diff_From_Ref_Genome_Ref_Strain_Same_As_Ref_Genome_all_sampl
es=outdir+key_Exp_Strain_Diff_From_Ref_Genome_Ref_Strain_Same_As_Ref_Genome+all
_samples_suffix
 
outfile_Exp_Strain_And_Ref_Strain_Diff_From_Ref_Genome_in_Diff_Ways_all_samples
=outdir+key_Exp_Strain_And_Ref_Strain_Diff_From_Ref_Genome_in_Diff_Ways+all_sam
ples_suffix
 
df_exp_strain_same_as_ref_genome_ref_strain_diff_from_genome_all_samples=get_ch
anges_that_occur_in_all_samples(df_exp_strain_same_as_ref_genome_ref_strain_dif
f_from_genome)
 
df_exp_strain_diff_from_ref_genome_ref_strain_same_as_ref_genome_all_samples=ge
t_changes_that_occur_in_all_samples(df_exp_strain_diff_from_ref_genome_ref_stra
in_same_as_ref_genome)
 
df_exp_stain_and_ref_strain_diff_from_ref_genome_in_diff_ways_all_samples=get_c
hanges_that_occur_in_all_samples(df_exp_stain_and_ref_strain_diff_from_ref_geno
me_in_diff_ways,
annotation_fields=["CHROM","POS","REF_ref","ALT_ref","Allele_ref","Annotation_ref","
Putative_impact_ref","Gene_Name_ref","Gene_ID_ref","Feature_type_ref","Featue_ID_re
f","Transcript_biotype_ref","Rank/
total_ref","HGVS.c_ref","HGVS.p_ref","cDNA_position/cDNA_len_ref","CDS_position/
CDS_len_ref","Protein_position/
Protein_len_ref","Distance_to_feature_ref","Errors_Warnings_or_Information_messages
_ref","REF_exp","ALT_exp","Allele_exp","Annotation_exp","Putative_impact_exp","Gene
_Name_exp","Gene_ID_exp","Feature_type_exp","Featue_ID_exp","Transcript_biotype_exp
","Rank/total_exp","HGVS.c_exp","HGVS.p_exp","cDNA_position/
cDNA_len_exp","CDS_position/CDS_len_exp","Protein_position/
Protein_len_exp","Distance_to_feature_exp","Errors_Warnings_or_Information_messages
_exp"],groupby_columns=["CHROM","POS"])
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        print "2. Exp strain same as reference genome, but the reference strain is 
different from the reference genome"
        print 
df_exp_strain_same_as_ref_genome_ref_strain_diff_from_genome_all_samples.sh
ape # [["CHROM","POS","REF","ALT","Sample_Name"]]
        print "3. Exp strain is different from the reference genome, but the 
reference strain is the same as the reference genome"
        print 
df_exp_strain_diff_from_ref_genome_ref_strain_same_as_ref_genome_all_sample
s.shape #[["CHROM","POS","REF","ALT","Sample_Name"]]
        print "4. Experimental and reference strain both different from the 
reference genome in different ways" 
        print 
df_exp_stain_and_ref_strain_diff_from_ref_genome_in_diff_ways_all_samples.s
hape 
#[["CHROM","POS","REF_ref","ALT_ref","REF_exp","ALT_exp","Sample_Name"]]
 
 
df_exp_strain_same_as_ref_genome_ref_strain_diff_from_genome_all_samples.to_csv
(outfile_Exp_Same_As_Ref_Genome_Ref_Strain_Diff_From_Ref_Genome_all_samples,sep
="\t")
 
df_exp_strain_diff_from_ref_genome_ref_strain_same_as_ref_genome_all_samples.to
_csv(outfile_Exp_Strain_Diff_From_Ref_Genome_Ref_Strain_Same_As_Ref_Genome_all_
samples,sep="\t")
 
df_exp_stain_and_ref_strain_diff_from_ref_genome_in_diff_ways_all_samples.to_cs
v(outfile_Exp_Strain_And_Ref_Strain_Diff_From_Ref_Genome_in_Diff_Ways_all_sampl
es,sep="\t")
 if create_gene_subset:
  df_subset_input=pd.read_table(create_gene_subset,sep="\t")
  ##ValueError seems to occur when the input dataframe is empty 
  try:
   
df_exp_strain_same_as_ref_genome_ref_strain_diff_from_genome_all_sample
s_subset=subset_by_gene_id(df_exp_strain_same_as_ref_genome_ref_strain_
diff_from_genome_all_samples,df_subset_input)
   
outfile_Exp_Same_As_Ref_Genome_Ref_Strain_Diff_From_Ref_Genome_subset=o
utdir+key_Exp_Same_As_Ref_Genome_Ref_Strain_Diff_From_Ref_Genome+gene_s
ubset_suffix
   
df_exp_strain_same_as_ref_genome_ref_strain_diff_from_genome_all_sample
s_subset.to_csv(outfile_Exp_Same_As_Ref_Genome_Ref_Strain_Diff_From_Ref
_Genome_subset,sep="\t")
  except ValueError:
   pass
  try:
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df_exp_strain_diff_from_ref_genome_ref_strain_same_as_ref_genome_all_sa
mples_subset=subset_by_gene_id(df_exp_strain_diff_from_ref_genome_ref_s
train_same_as_ref_genome_all_samples,df_subset_input)
   
outfile_Exp_Strain_Diff_From_Ref_Genome_Ref_Strain_Same_As_Ref_Genome_s
ubset=outdir+key_Exp_Strain_Diff_From_Ref_Genome_Ref_Strain_Same_As_Ref
_Genome+gene_subset_suffix
   
df_exp_strain_diff_from_ref_genome_ref_strain_same_as_ref_genome_all_sa
mples_subset.to_csv(outfile_Exp_Strain_Diff_From_Ref_Genome_Ref_Strain_
Same_As_Ref_Genome_subset,sep="\t")
  except ValueError:
   pass
  try:
   
df_exp_stain_and_ref_strain_diff_from_ref_genome_in_diff_ways_all_sampl
es_subset=subset_by_gene_id(df_exp_stain_and_ref_strain_diff_from_ref_g
enome_in_diff_ways_all_samples,df_subset_input,gene_id_col_df="Gene_ID_
ref")
   
outfile_Exp_Strain_And_Ref_Strain_Diff_From_Ref_Genome_in_Diff_Ways_sub
set=outdir+key_Exp_Strain_And_Ref_Strain_Diff_From_Ref_Genome_in_Diff_W
ays+gene_subset_suffix
   
df_exp_stain_and_ref_strain_diff_from_ref_genome_in_diff_ways_all_sampl
es_subset.to_csv(outfile_Exp_Strain_And_Ref_Strain_Diff_From_Ref_Genome
_in_Diff_Ways_subset,sep="\t")
  except ValueError:
   pass
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import csv
def bed_meta_data_to_dic(bed_metadata_col):
 features_list=bed_metadata_col.split(";")
 features_dic=dict()
 for feature in features_list:
  key,value=feature.split("=")
  features_dic[key.strip()]=value.strip()
 return features_dic
  
def get_gene_locations_from_bed_file(bed_file,select_feature="gene"):
 feature_type_col_index=7
 locus_col_index=0
 feature_start_index=1
 feature_end_index=2
 meta_data_col_index=9
 gene_locations=dict()
 with open(bed_file,"r") as in_bed:
  csv_reader=csv.reader(in_bed,delimiter="\t")
  for row in csv_reader:
   if row[7]==select_feature:
    locus=row[locus_col_index]
    feature_start=row[feature_start_index]
    feature_end=row[feature_end_index]
    metadata=row[meta_data_col_index]
    gene_id=bed_meta_data_to_dic(metadata)["ID"]
    
gene_locations[gene_id]={"Locus":locus,"Start":feature_start,"End":
feature_end}
 return gene_locations
def parse_depth_of_coverage_output(depth_of_coverage_output_file):
 
#header=["Locus","Total_Depth","Average_Depth_sample","Depth_for_USF","USF_base
_counts"]
 locus_key="Locus"
 data_dic=dict()
 with open(depth_of_coverage_output_file,"r") as in_doc:
  csv_reader=csv.reader(in_doc,delimiter="\t")
  header=csv_reader.next() #Get the header
  for row in csv_reader:
   row_dict=dict(zip(header,row))
   data_dic[row_dict[locus_key]]=row_dict
 return data_dic
def 
average_depth_of_coverage_per_gene(gene_locations_dic,depth_of_coverage_dic,outfile
=None):
 dic_out=dict()
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	 	 for gene in gene_locations_dic:
  gene_locations=[]
  gene_data=gene_locations_dic[gene]
  start_location=int(gene_data["Start"])+1 #Bed file indexes start at 0 but 
gatk indexes start at 1
  end_location=int(gene_data["End"])+2 #Python ranges stop before the last 
number and the last number needs to be included
  locus=gene_data["Locus"]
  for i in range(start_location,end_location):
   gene_locations.append(locus+":"+str(i))
  sum_of_gene_coverage=0
  for location in gene_locations:
   sum_of_gene_coverage+=int(depth_of_coverage_dic[location]
["Total_Depth"])
  gene_average_coverage=float(sum_of_gene_coverage)/len(gene_locations)
  dic_out[gene]=gene_average_coverage
 if outfile:
  import pandas as pd
  
df=pd.DataFrame(data=list(dic_out.iteritems()),columns=["Gene_ID","Read_Cov
erage"])
  #df.index.name="Gene_ID"
  df.to_csv(outfile,index=False,sep=",")
 return dic_out
def 
apply_average_depth_of_coverae_per_gene_to_dir_commands(indir,outdir,infile_regions
,search_suffix="*_gatk_output",outfile_suffix="_average_gene_coverage.csv"):
 import os
 import glob
 try:
  os.mkdir(outdir)
 except OSError:
  pass
 command_name="python /shares/biocomputing/Bitbucket/CNV_Detection/
average_coverage_over_region.py"
 commands=[]
 ##Make sure the file paths are correct
 indir=indir.rstrip("/")+"/"
 outdir=outdir.rstrip("/")+"/"
 ##Get the locations of the data
 coverage_data=glob.glob(indir+search_suffix)
 ##Itererate through the coverage_data file paths
 for file_path in coverage_data:
  
  sample_name=os.path.basename(file_path).split(search_suffix.lstrip("*"))[0]
  sample_outfile=sample_name+outfile_suffix
  command=[command_name,infile_regions,file_path,sample_outfile]
  commands.append(command)
 return commands
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if __name__=="__main__":
 import sys
 program,infile_regions,infile_doc,outfile=sys.argv
 
 gene_locations=get_gene_locations_from_bed_file(infile_regions)
 doc_data_dic=parse_depth_of_coverage_output(infile_doc)
 
average_gene_coverage=average_depth_of_coverage_per_gene(gene_locations,doc_dat
a_dic,outfile=outfile) 
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read_coverage_summaries<-function(df){
  ref_read_coverage=df["Read_Coverage_Ref"]
  exp_read_coverage=df["Read_Coverage_Exp"]
  print("Read Coverage Reference")
  print(summary(ref_read_coverage))
  print("Experimental Coverage")
  print(summary(exp_read_coverage))
  
  v_combined=unlist(c(ref_read_coverage,exp_read_coverage))
  print("Combined")
  print(summary(v_combined))
}
filter_by_coverage<-function(df,greater_than_or_equal_to_read_coverage){
  
df_filtered=df[which(df["Read_Coverage_Ref"]>=greater_than_or_equal_to_read_cover
age & df["Read_Coverage_Exp"] >= greater_than_or_equal_to_read_coverage),]
  return(df_filtered)
}
fold_change_distribution<-function(df,outfile){
  v_log2_fold_change=df$log2_fold_change
  print(summary(v_fold_change))
  print(typeof(v_fold_change))
  pdf(outfile)
  hist(v_log2_fold_change)
  dev.off()
}
filter_by_fold_change<-function(df,greater_than_or_equal_to){
  df_filtered=df[which(df$fold_change>=greater_than_or_equal_to),]
  return(df_filtered)
}
filter_by_coverage_and_fold_change<-
function(df,greater_than_or_equal_to_coverage,greater_than_or_equal_to_fold_change,
outfile){
  
  df=filter_by_coverage(df,greater_than_or_equal_to_coverage)
  df=filter_by_fold_change(df,greater_than_or_equal_to_fold_change)
  write.csv(df,outfile)
  return(df)
  
}
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From: Cathi Siegel journal@ajtmh.org
Subject: Re: Permission Request
Date: October 1, 2018 at 4:41 PM
To: jgibbon1@health.usf.edu
Hi Justin,
Thanks for asking and yes, you have the journal's permission to use
this figure. We get a lot of requests to use this one. Best of luck
with the dissertation.
Best regards,
Cathi Siegel
Managing editor
On Mon, Oct 1, 2018 at 2:47 PM Gibbons, Justin <jgibbon1@health.usf.edu> wrote:
Hello,
My name is Justin Gibbons.
May I have permission to re-use Figure 2 from “A global index representing the stability of malaria transmission” by Kiszewski et al
2004 in my doctoral dissertation?
I am at the University of South Florida 3720 Spectrum Blvd Suite 404 Tampa, FL 33612.
The expected number of pages is 175 and is expected to be completed in December 2018.
The title of the dissertation will be "Genomics and Transcriptomic approaches to understanding drug resistance mechanisms in the
malaria parasite Plasmodium falciparum”
Please let me know if you require any additional information.
Thank you
Justin Gibbons
-- 
Cathi Siegel
Managing Editor
American Journal of Tropical Medicine and Hygiene
Phone: 216-368-6940
FAX: 216-368-6987
cbs15@case.edu
www.ajtmh.org
US Mail:
AJTMH/CWRU Center for Global Health and Diseases
10900 Euclid Avenue LC:  4983
Cleveland, OH 44106
Visitors & Deliveries (FedEx, UPS):
AJTMH/CWRU Center for Global Health and Diseases
2109 Adelbert Road, Room 429
Cleveland, OH 44106
184	
	
Permission	to	use	the	figures	in	chapters	2	and	3	
	
	
	
	
Figures	in	chapter	4	are	original	to	this	publication.	
